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ABSTRACT 
 
 
MECHANISMS OF NOTCH-MEDIATED INHIBITION 
 
OF SKELETAL MYOGENESIS 
 
 
 
Matthew F. Buas 
 
Tom Kadesch, Ph.D. 
 
 
 
 The Notch pathway is an evolutionarily conserved signaling cascade that 
regulates many cell fate decisions. Recent work has revealed that Notch plays critical 
roles in the control of skeletal muscle development and regeneration. In the embryo, 
Notch maintains a pool of myogenic progenitor cells and prevents their premature 
differentiation. In the adult, after muscle injury, Notch signaling is essential for the initial 
expansion of muscle stem cells, or satellite cells. 
 While it has been known for over a decade that Notch activity represses myogenic 
differentiation, the molecular mechanisms by which this inhibition occurs are poorly 
defined. In this thesis, I sought to identify the key transcriptional effectors of Notch in 
muscle and explore how these proteins repress the myogenic program. Using the mouse 
myoblast cell line C2C12, I identified 82 transcripts upregulated after six hours of ligand-
mediated Notch stimulation. When constitutively expressed in myoblasts, several of these 
genes (Nrarp, HeyL, Trib2) had no apparent impact on differentiation, while at least two 
of them, the canonical effector Hey1 and the novel Notch-responsive gene MyoR, were 
capable of recapitulating the pathway’s inhibitory effects. Interestingly, siRNA 
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knockdown of Hey1 or MyoR, or the two factors in combination, failed to rescue the 
differentiation of myoblasts exposed to Notch ligands. These results support a model in 
which Notch acts through multiple, potentially redundant pathways to repress 
myogenesis. 
 In subsequent work, I focused on the mechanistic question of how the Notch 
effector Hey1 interferes with myogenic transcription. My functional and biochemical 
data revealed that Hey1 does not target the inherent transcriptional activity of the skeletal 
muscle master regulator MyoD. I found that Hey1 repressed only a subset of MyoD 
target genes, and consistently, did not disrupt dimerization of MyoD with its obligate 
binding partner E47. My results indicated that Hey1 is recruited to the promoter regions 
of Myogenin and Mef2C, two genes whose induction is critical for differentiation. 
Expression of Hey1 in C2C12 myoblasts correlated with reduced recruitment of MyoD to 
these promoters, arguing that Hey1 inhibits myogenesis by associating with and 
repressing expression of key myogenic targets. 
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Chapter I. Introduction 
 
Part 1: Skeletal myogenesis 
 
The generation of skeletal muscle tissue is a highly regulated, step-wise process that is 
controlled in vertebrates by a family of four homologous transcription factors, known as 
muscle regulatory factors (MRFs). The founding member of this family, MyoD, was 
discovered over twenty years ago and shown to exhibit the remarkable ability to convert a 
wide range of non-muscle cell lines into the muscle lineage (Davis et al., 1987; 
Weintraub et al., 1989). Since the initial cloning and characterization of this master 
regulator, skeletal muscle has become one of the best studied systems of cellular 
differentiation. The availability of cell culture models, which recapitulate many aspects 
of in vivo myogenesis, has greatly facilitated the molecular and biochemical dissection of 
the myogenic transcriptional program. 
 
Muscle regulatory factors 
 MyoD was discovered by Weintraub and colleagues, who first made the 
intriguing observation that rare colonies of 10T1/2 fibroblasts transfected with DNA from 
5’azacytidine-treated fibroblasts were converted to a muscle phenotype (Lassar et al., 
1986). This finding was interpreted to suggest that a structural change, likely 
demethylation, of a single, normally-silent DNA locus within fibroblasts was capable of 
inducing myogenesis. Subtractive cDNA hybridization was then employed to identify a 
cDNA, MyoD, that exhibited this potential and shared sequence homology to the 
transcription factors myc and achaete-scute (Davis et al., 1987). Consistent with a role as 
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skeletal muscle master regulator, MyoD was found to be expressed exclusively in this 
lineage in vivo, and only in myogenic cell lines in vitro. Soon after the identification of 
MyoD, three other homologous muscle-specific transcription factors—Myf-5, Myogenin, 
and MRF4—were also cloned and shown capable of converting cultured fibroblasts to a 
muscle phenotype (Braun et al., 1990; Braun et al., 1989; Wright et al., 1989). 
 MyoD and the other MRFs belong to a family of transcription factors known as 
basic helix-loop-helix (bHLH) proteins (Figure 1.1). These factors bind to E-box 
elements (CANNTG) within DNA to activate transcription. MyoD requires both its basic 
domain, for DNA binding, and its HLH motif, for dimerization with other bHLH factors 
known as E-proteins, such as E2A, E2-2, and HEB. While MyoD homodimers may 
assemble and function with low efficiency, an important role for heterodimerization was 
suggested by several lines of evidence—MyoD-E protein heterodimers are the 
predominant species in myoblast nuclear extracts, E proteins synergize with MyoD in 
transcriptional reporter assays, and anti-sense E47 impairs MyoD-mediated conversion of 
fibroblasts (Lassar et al., 1991). 
 One of the early puzzles in transcriptional control by MyoD was the fact that its 
DNA recognition element, the E-box, was found not only in myogenic target gene 
promoters, but also in many promoters not activated in muscle. Conversely, non-
myogenic bHLH proteins, such as ubiquitously expressed E proteins, were found to bind 
to myogenic E-boxes but failed to activate these promoters. In vitro DNA binding 
capacity alone did not account for transcriptional activity. The basis for specificity was 
first explored by Weintraub and coworkers, who demonstrated that two residues present 
within the MyoD basic domain but absent from other bHLH proteins, an alanine and 
Acidic H/C bHLH
Helix III
1 318
Figure 1.1. Structure of the MyoD protein. The N-terminal acidic domain 
functions in transcriptional activation, the H/C and Helix III motifs participate 
in chromatin remodeling, and the bHLH (basic helix-loop-helix) domain 
mediates DNA binding and dimerization. Adapted from Berkes et al. (2004).
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threonine, were critical for transcriptional activity on myogenic promoters (Davis and 
Weintraub, 1992; Weintraub et al., 1991). It was proposed, and later demonstrated, that 
these residues are important for collaboration of MyoD with critical cofactors, namely 
members of the Mef2 family of transcription factors (Molkentin et al., 1995). In parallel, 
other work suggested that the inability of MyoD to activate E-box-containing non-muscle 
promoters, such as the immunoglobulin heavy chain (IgH) enhancer, was in part due to 
the presence of negatively acting cis-elements. It was postulated that nucleotides flanking 
the E-box could potentially recruit a repressor acting specifically on MyoD but not E47 
(Weintraub et al., 1994). 
 
Skeletal muscle development 
 During mammalian embryogenesis, skeletal muscle tissue of the body and limbs 
is derived from the somites, regularly patterned blocks of paraxial mesoderm adjacent to 
the neural tube. Somites are subdivided into a ventral compartment, the sclerotome, and a 
dorsal compartment, the dermomyotome. While the sclerotome gives rise to ribs, 
vertebrae, and discs, the dermomyotome gives rise to skin and skeletal muscle. The 
dermomyotome can be further divided into a medial portion, from which epaxial muscles 
of the back and intercostals are derived, and a lateral portion, from which hypaxial 
muscles of the ventral body wall and limbs are derived. Myogenesis is a step-wise 
process whereby proliferating myogenic progenitors give rise to a population of 
myoblasts, which continue to divide before exiting the cell cycle, differentiating, and 
fusing into multinucleated myotubes (Figure 1.2). Bundles of parallel myotubes then 
form a mature myofiber, the basic contractile unit of skeletal muscle. The myotome, a 
4
Myogenic progenitor
Myoblast
Myotube
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sheet of muscle precursors between the sclerotome and dermomyotome, represents the 
first skeletal muscle mass to be formed. Primary myofibers arise from the fusion of 
embryonic myoblasts and are thought to serve as a framework on which myoblasts 
continue to proliferate before fusing into secondary myofibers during fetal development 
(Kelly and Zacks, 1969). 
 Gene knockout studies in the 1990s established critical roles for the MRFs in 
controlling skeletal myogenesis in the embryo. While muscle development proceeded 
normally in MyoD or Myf-5 single knockout animals, MyoD/Myf-5 double knockouts 
died soon after birth with virtually a complete absence of skeletal muscle (Braun et al., 
1992; Rudnicki et al., 1992; Rudnicki et al., 1993). This initial finding implied that 
MyoD and Myf-5 can compensate for each other in myogenic specification. In stark 
contrast to the single knockouts above, deletion of Myogenin resulted in a severe 
reduction of skeletal muscle, and an apparent block in the ability of myoblasts to 
terminally differentiate (Hasty et al., 1993; Nabeshima et al., 1993). The MRF4 knockout 
was viable and fertile, and a significant upregulation of Myogenin was observed, 
suggesting potential compensation by this pro-differentiation factor (Zhang et al., 1995). 
Later studies suggested that MRF4 may also contribute to specification in parallel with 
MyoD and Myf-5 (Kassar-Duchossoy et al., 2004). The picture that emerged from these 
genetic studies was a hierarchical relationship among the MRFs, in which MyoD and 
Myf-5 (and likely MRF4) were involved in the initial specification of myogenic 
precursors, while Myogenin functioned downstream in promoting terminal 
differentiation. 
6
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 One interesting question raised by the MRF knockout studies was whether the 
divergent phenotypes observed were a consequence of inherent functional differences 
among these four proteins, or were merely a reflection of differences in expression 
patterns. For example, it was possible that Myogenin (or MRF4) was unable to rescue 
myogenic specification in the MyoD/Myf-5 double knockout simply because its 
expression in embryogenesis is delayed relative to Myf-5 (Ott et al., 1991; Sassoon et al., 
1989). To address this possibility genetically, the Myogenin coding region was knocked 
in to the Myf-5 locus, and resulting mice were crossed to the MyoD knockout. 
Importantly, in this background, expression of Myogenin in the same spatiotemporal 
pattern as Myf-5 only partially rescued myogenesis and was not sufficient to prevent 
perinatal lethality resulting from compromised muscle formation (Wang and Jaenisch, 
1997). This result indicated that Myogenin was not as intrinsically capable as Myf-5 in 
the process of specifying or maintaining muscle precursors. Consistent with the idea of 
functional divergence, later studies by Tapscott and colleagues in cultured fibroblasts 
further revealed that MyoD and Myf-5 were markedly more efficient than Myogenin in 
remodeling chromatin and inducing transcription at endogenous muscle promoters 
(Gerber et al., 1997). By contrast, the MRFs were equivalent in their ability to activate 
transfected reporters driven by E-boxes. These results suggested that the capacity of 
MyoD and Myf-5 to function efficiently in myogenic specification might derive from an 
ability to activate genes in silent chromatin. Mapping experiments indicated that the 
remodeling activity of MyoD could be localized to a histidine/cysteine (H/C)-rich N-
terminal domain and a C-terminal alpha-helix (Helix III), conserved in the Myf-5 but not 
Myogenin coding sequence (Figure 1.1). Domain swapping confirmed that these motifs 
7
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within MyoD could render Myogenin capable of efficiently inducing silent endogenous 
genes (Bergstrom and Tapscott, 2001). Interestingly, instead of encoding chromatin 
remodeling activity, the Myogenin C-terminus was shown to contain a general 
transcriptional activation domain, further providing a molecular explanation for the 
distinct activity exhibited by this downstream pro-differentiation MRF. 
 Other work revealed the upstream signals responsible for initiating MRF 
expression within the developing somite. Explant studies showed that the inducing 
activities of axial structures such as the floor plate and dorsal neural tube could be 
mimicked by the signaling molecules sonic hedgehog and Wnt1, 3, 4, respectively 
(Munsterberg et al., 1995). Wnts and Shh were further shown to act upstream of two 
paired-box family transcription factors, Pax3 and Pax7. Forced retroviral expression of 
Pax3 in chick somite explants was capable of activating expression of Myf-5 and MyoD 
in the absence of axial tissues (Maroto et al., 1997). Conversely, mice homozygous null 
for both Pax3 and Myf-5 lacked body muscles and MyoD expression, suggesting that 
Pax3 and Myf-5 lie genetically upstream of MyoD activation; consistently, Myf-5 RNA 
is induced approximately two days prior to MyoD during development (Tajbakhsh et al., 
1997). Interestingly, Pax3 single knockout animals lacked limb muscles (Bober et al., 
1994; Goulding et al., 1994), likely a consequence of impaired induction of c-met, a 
receptor critical for the proper migration of muscle precursors from the somite to the limb 
bud (Epstein et al., 1996; Yang et al., 1996). Within the somite, the domain of Pax3 
activity is further restricted to the dorsal medial lip (DML) of the dermomyotome by 
signaling through bone morphogenic proteins (BMPs). Specifically, BMPs inhibit 
8
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MyoD/Myf5 activation in Pax3+ cells, except in the DML, where the BMP antagonist 
noggin relieves this repression and allows for MRF expression (Reshef et al., 1998).  
 
Post-natal myogenesis: satellite cells 
 Skeletal muscle has long been known to possess the ability to regenerate in 
response to injury (Carlson, 1973). This regenerative capacity has been ascribed to the 
presence of a normally quiescent population of mononuclear cells known as satellite cells 
(SCs), situated between the basal lamina and the muscle fiber membrane (Mauro, 1961). 
In response to tissue damage, SCs exit quiescence, become activated, proliferate, and 
either differentiate and fuse to form new myofibers or return to their ground state and 
repopulate the SC niche (Figure 1.3). A number of independent studies provided support 
for the notion that satellite cells possess the hallmark properties of stem cells—the ability 
to self-renew and differentiate to maintain tissue homeostasis (Collins et al., 2005; 
Montarras et al., 2005; Sacco et al., 2008). An emerging theme from this work is that 
despite the original definition of a satellite cell based on anatomic location, all satellite 
cells are not equivalent, and only a subset may exhibit true stem-cell properties. 
 Various markers have been used to identify satellite cells prospectively, but one 
of the first and most commonly employed is the transcription factor Pax7. Initial studies 
demonstrated that mice homozygous null for Pax7 exhibit grossly normal muscle, but 
completely lack satellite cells, fail to thrive, and die after two weeks (Seale et al., 2000). 
The defect was originally postulated to be at the level of SC specification, but later work 
argued instead that Pax7 is required for SC maintenance and survival, potentially acting 
to inhibit SC apoptosis (Oustanina et al., 2004; Relaix et al., 2006). It now appears that 
9
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Pax7 is necessary for satellite cell survival and function only during the first few weeks 
of postnatal life, when SCs are still making the transition to their ultimate state of 
quiescence (Lepper et al., 2009). Recent studies have established that satellite cells and 
embryonic muscle progenitors share a common embryological origin, a proliferating pool 
of Pax3+/Pax7+ cells that arise within the central dermomyotome of the somite (Gros et 
al., 2005; Kassar-Duchossoy et al., 2005; Relaix et al., 2005). Pax7 appears to be 
uniformly retained in SCs after birth, whereas Pax3 expression is only detected in subsets 
of SCs in certain muscles, and apparently cannot compensate for Pax7’s functions in SCs 
maintenance (Relaix et al., 2006). 
 While satellite cells have long been considered a resident stem cell pool and the 
primary source of muscle regenerative potential, conclusive evidence for this notion was 
obtained only in the last five years. Multiple groups have prospectively isolated satellite 
cells from mice and demonstrated their ability to engraft into the endogenous SC 
compartment of injured mice and contribute to repair (Cerletti et al., 2008; Montarras et 
al., 2005). Single myofibers with their associated satellite cells have also been 
transplanted into injured muscles, and SC contributions to regeneration have been 
verified (Collins et al., 2005). In such studies, donor SCs are often isolated from 
transgenic animals such that they are marked, for example with GFP, and can easily be 
tracked in vivo upon engraftment into host animals. Importantly, such work has shown 
that engrafted satellite cells not only contribute to formation of regenerating muscle, but 
also reseed the SC niche and can participate in multiple rounds of repair after repeated 
injury (Cerletti et al., 2008; Collins et al., 2005; Sacco et al., 2008). These findings argue 
strongly that SCs exhibit self-renewal and the ability to maintain an adult tissue. 
11
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Interestingly, other cellular reservoirs—bone marrow-derived cells, “side population” 
muscle cells, and CD45+Sca1+ resident myogenic cells—have also been proposed to 
contribute to the muscle repair process (Ferrari et al., 1998; Gussoni et al., 1999; 
Polesskaya et al., 2003); these populations, however, do not exhibit the equivalent 
properties of satellite cells and are now believed to play only a negligible role in 
regeneration (Sherwood et al., 2004).  
 Studies on cultured myofibers and associated satellite cells in vitro in combination 
with in vivo injury experiments have helped define the sequence of molecular events 
accompanying SC activation. In the quiescent state, SCs are Pax7+ but devoid of MRF 
expression; upon activation, they first upregulate MyoD and/or Myf-5 (Cooper et al., 
1999; Cornelison and Wold, 1997). While most of these cells continue to proliferate, 
downregulate Pax7, and ultimately express Myogenin/MRF4 upon entry into the 
differentiation pathway, some retain Pax7 and lose MRF expression (Cornelison and 
Wold, 1997; Zammit et al., 2004; Zammit et al., 2006). It is these Pax7+/MRF− cells that 
exit the cell cycle and return to a state of quiescence to replenish the stem cell niche. 
Interestingly, as in the embryo, MyoD/Myf-5 and Myogenin/MRF4 appear to play 
divergent roles, with the first two proteins apparently functioning in the 
activation/specification phase of satellite cell-mediated regeneration, and the latter two 
factors operating downstream in promoting differentiation. In contrast to the largely 
redundant functions of MyoD and Myf-5 during embryogenesis, however, MyoD was 
found to play a unique role in postnatal regeneration, as the MyoD knockout mouse 
displayed a significantly impaired response to muscle injury (Megeney et al., 1996). In 
the absence of MyoD, there appeared to be a defect in the proliferative expansion of 
12
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activated, committed satellite cells, suggesting that MyoD is required for SCs to enter the 
proliferative phase and progress down the lineage pathway. 
 A recent study provided compelling evidence that satellite cells as defined 
anatomically are a heterogeneous population, only a small fraction of which may exhibit 
true stem-cell potential (Kuang et al., 2007). By crossing the ROSA26-YFP mouse to a 
Myf-5-Cre line, Rudnicki and colleagues were able to permanently mark cells that at any 
point in their history expressed Myf-5. Strikingly, they found that ~10% of sublaminar 
Pax7+ SCs were YFP−. It was later demonstrated in single fiber cultures that YFP− SCs 
divide asymmetrically to generate a YFP+ daughter cell in apposition to the muscle fiber 
membrane, and a YFP− daughter adjacent to the basal lamina. Upon transplantation, 
purified YFP− SCs expanded rapidly and contributed both to myofiber differentiation and 
to the endogenous SC niche, while YFP+ SCs failed to expand or reseed the niche. These 
results imply that satellite cells comprise at least two populations, one of which never 
expresses Myf-5, remains in continuous contact with the basal lamina during cell 
division, and likely represents the pool of muscle stem cells. Interestingly, follow-up 
studies in the past year have revealed that non-canonical Wnt signaling, initiated by 
Wnt7a, appears to stimulate the symmetric expansion of satellite stem cells (YFP−) and 
thereby enhance the regenerative process (Le Grand et al., 2009). 
 
The myogenic transcriptional program 
 Cell culture-based models of myogenesis have greatly facilitated the investigation 
of how MRFs initiate and drive forward a transcriptional differentiation program on a 
molecular level. Myogenic transcription proceeds in a strict temporal sequence from early 
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to late gene expression (Andres and Walsh, 1996; Bergstrom et al., 2002). This cascade is 
highly regulated by positively acting feedback loops and finely tuned by a variety of 
signaling pathways that ultimately target individual transcription factors and/or bring 
about key chromatin alterations. 
  Much work has been directed at elucidating the transcriptional control of the 
Myogenin locus, as this gene plays an essential role in inducing differentiation, and its 
regulation has illustrated important general concepts about myogenic transcription. In the 
early 1990s, studies in transgenic reporter mice revealed that a 133-bp proximal promoter 
was sufficient to recapitulate the normal temporal and spatial pattern of Myogenin 
expression in the developing embryo (Yee and Rigby, 1993). Two DNA binding 
elements, an E-box (E1) and Mef2 element, were found to be essential for the induction 
of Myogenin transcription (Cheng et al., 1993), while a third element, Mef3, was later 
shown also to be necessary (Spitz et al., 1998) (Figure 1.4). The presence of a paired E-
box and Mef2 element is a common motif present within many myogenic promoters and 
facilitates cooperation between the MRFs and the Mef2 family of transcription factors. In 
mammals, there are four Mef2 factors (Mef2A, B, C, and D), all of which share a 
common MADS box and MEF2 domain which allow for DNA binding and dimerization 
(Black and Olson, 1998). MRFs and Mef2 factors physically interact and can synergize 
with one another (Molkentin et al., 1995). Importantly, Mef2C is itself a direct 
transcriptional target of MyoD (Dodou et al., 2003; Wang et al., 2001). Once expressed, 
Mef2C collaborates with MyoD in the activation of the Myogenin promoter (Figure 1.5) 
(Edmondson et al., 1992), setting up what has been proposed as a “feed forward” model 
underlying the myogenic program (Tapscott, 2005). This concept of MyoD collaborating 
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with downstream mediators to drive forward sequential gene expression represents a 
recurrent theme in myogenic transcription. To add another layer of control, Myogenin 
also feeds back to enhance expression of Mef2C, and MRFs themselves have been shown 
capable of inducing their own transcription (Ridgeway et al., 2000; Thayer et al., 1989). 
The net result is that initial, small expression changes become amplified and self-
reinforced and enable a robust transcriptional output. In addition to the synergistic 
regulation conferred by MRFs and Mef2, members of the Six family of homeodomain 
proteins (Six1, Six4) have also been implicated in the control of Myogenin transcription 
(Spitz et al., 1998). Six factors associate with the essential Mef3 DNA binding element 
located distal to the Mef2 site and are thought to participate in cooperative induction. 
 
Regulation of MyoD 
 A long-studied and still-relevant challenge in the field of myogenesis has been to 
unravel the multiple modes of regulation that control MyoD transcriptional activity. In 
cultured myoblasts, MyoD is expressed, yet the induction of Myogenin and downstream 
targets does not occur until differentiation is triggered either by removing serum or by 
allowing cells to reach confluence, both of which initiate cell cycle exit. This implies that 
the proliferative state of myoblasts may exert negative control over MyoD-mediated 
transcription. Consistent with this idea, forced expression of cyclin D1 inhibits MyoD 
activity and correlates with MyoD phosphorylation, although the functional significance 
of this phosphorylation has yet to be clearly established (Skapek et al., 1995). A basic but 
controversial question has been whether MyoD in myoblasts is regulated at the level of 
DNA binding to its target gene promoters. Some reports employing chromatin 
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immunoprecipitation (chIP) assays have shown that MyoD does indeed occupy the 
Myogenin promoter in myoblasts, but may be kept inactive by its association with 
repressive chromatin modifying enzymes such as histone deacetylases (HDACs) or 
histone methyltransferases (HMTs) (Mal and Harter, 2003; Mal et al., 2001; Mal, 2006). 
Additional work has built on this model by suggesting that upon cell cycle exit, the 
hypophosphorylated form of the tumor suppressor protein Rb may titrate HDAC1 away 
from MyoD to help alleviate repression (Puri et al., 2001). It has not been demonstrated, 
however, that inhibition of HDACs or HMTs results in significant derepression of 
myogenic targets in myoblasts, implying that additional regulatory mechanisms are at 
play (Mal, 2006). Other studies failed even to detect appreciable MyoD recruitment to 
target promoters under proliferative conditions (Caretti et al., 2004; Serra et al., 2007) 
 One early finding that supported an alternative model of restricted MyoD DNA 
binding in myoblasts was the identification of Id proteins. Ids, expressed in growth 
conditions and downregulated upon differentiation, are helix-loop-helix factors which 
lack a basic domain and can sequester MyoD and E-proteins into inactive heterodimers 
(Benezra et al., 1990; Jen et al., 1992). More recent studies have pointed to a role for 
chromatin structure in controlling MyoD’s access to DNA. Multiple reports have 
demonstrated that myogenic promoters undergo chromatin changes at the level of both 
histone acetylation and nucleosome remodeling over the course of gene activation. 
Enzymes involved in both processes, such as p300 and PCAF for acetylation, and the 
SWI/SNF factors BRG1 and BRM for remodeling, are required for transcriptional 
induction (de la Serna et al., 2001; Puri et al., 1997). Importantly, Tapscott and 
colleagues showed that hyperacetylation of histone H4 and recruitment of BRG1 to 
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myogenic loci appeared to precede the detectable binding of MyoD (by chIP) at these 
promoters (de la Serna et al., 2005). The implication was that MyoD could only access 
DNA after such chromatin alterations had already occurred. Additional studies helped 
formulate an interesting model consistent with the “feed-forward” paradigm in 
myogenesis, in which MyoD itself helps bring about the chromatin transition required for 
its own (stable) recruitment. Specifically, it was proposed that MyoD gains access to the 
Myogenin promoter in two stages, first weakly through association with DNA-bound 
protein intermediates, and then later directly via E-box DNA occupancy (Berkes et al., 
2004). MyoD/E47 was found to physically interact with the homeodomain proteins 
Pbx1/Meis, constitutively bound factors just upstream of the Mef3 element (Figure 1.4). 
This interaction requires the same domains within MyoD that are essential for its ability 
to activate genes within silent chromatin in fibroblasts, suggesting that Pbx1/Meis could 
serve as a “molecular beacon” for initial MyoD recruitment. Under this model, declining 
Id protein levels would lead to increased MyoD/E47 association with Pbx1/Meis. Since 
past work had demonstrated that MyoD physically interacts with acetyltransferases and 
BRG1 (Puri et al., 1997; Sartorelli et al., 1997; Simone et al., 2004), recruitment of these 
enzymes would likely accompany association of MyoD and ultimately result in 
alterations necessary for its stable binding to the E-box (detectable by chIP). 
 Chromatin structure likely also plays an important role in determining why MyoD 
activates subsets of target genes in different temporal windows following the initiation of 
myogenesis. A plausible model posits that target promoters induced at later times may 
require more extensive chromatin alterations prior to activation, and/or the activities of 
additional MyoD cofactors. The work of Sartorelli and coworkers, for example, has 
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demonstrated that in myoblasts, the Polycomb methyltransferase Ezh2 deposits the 
repressive histone H3-K27-methyl mark specifically on the promoters of late-phase 
genes, such as myosin heavy chain (MHC) and muscle creatine kinase (MCK) (Caretti et 
al., 2004). Activation of these late-phase genes presumably requires the activity of a 
demethylase enzyme to remove this modification and facilitate gene induction. In other 
work, Tapscott and colleagues have shown that MyoD recruitment to target gene 
promoters generally tracks with the timing of gene expression, supporting the notion that 
MyoD DNA binding is rate-limiting (Bergstrom et al., 2002). These studies have 
suggested that induction of late-phase genes may require the concerted actions of Mef2D 
and the mitogen-activated protein kinase (MAPK) p38, a molecule that promotes 
myogenesis through multiple mechanisms, including chromatin remodeling (Penn et al., 
2004). Given that Mef2D expression and p38 activity increase over the course of 
differentiation, these results again point to a model in which MyoD works in tandem with 
downstream partners to orchestrate a cascade of myogenic gene transcription. 
 
Signaling inputs to the myogenic program 
 A wide range of signaling cascades has been implicated in the control of 
embryonic and post-natal myogenesis. Signaling downstream of the MAPK p38 is one of 
the best characterized. p38 is essential for myogenesis in the embryo and for effective 
satellite cell function in the adult (de Angelis et al., 2005; Jones et al., 2005). This kinase 
can be thought of as a master potentiator of myogenesis that positively influences the 
transcriptional apparatus on multiple, complementary levels. While phospho-p38 (the 
activated form) has been known for some time to increase over the course of myogenesis, 
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the mechanism by which this MAPK becomes activated was only recently explored. 
Work by Krauss and colleagues revealed that the myogenic transmembrane protein CDO, 
a member of the immunoglobulin superfamily, plays a critical role in p38 activation via 
the scaffold proteins JLP and Bnip-2, and the Abl tyrosine kinase (Bae et al., 2009; Kang 
et al., 2008). Initial studies had demonstrated that CDO promotes myogenesis in vitro by 
enhancing MRF:E protein heterodimer formation via the hyperphosphorylation of E 
proteins (Cole et al., 2004). Interestingly, CDO was shown to be a target of MyoD, 
adding yet another layer of positive feedback. Subsequent studies showed that p38 itself 
was responsible for phosphorylating E47 on serine 140 (Lluis et al., 2005). p38 also 
directly phosphorylates Mef2A and Mef2C and thereby promotes their transcriptional 
activity (Wu et al., 2000b). Another important and surprising role for p38 was revealed in 
its ability to associate with myogenic promoters and help recruit the SWI/SNF chromatin 
remodeling complex (Simone et al., 2004). Finally, separate work has demonstrated that 
p38 may also function post-transcriptionally by phosphorylating and inactivating the 
protein KSRP, which binds to selected myogenic transcripts and directs them to 
exosome-mediated degradation (Briata et al., 2005). 
 A second signaling cascade of particular importance in muscle is that initiated by 
the insulin-like growth factors (IGF1/IGF2). IGFs act through multiple pathways to 
promote myoblast proliferation, differentiation, and hypertrophy and have been 
implicated in both muscle development and regeneration (Barton-Davis et al., 1998; Liu 
et al., 1993; Musaro et al., 2001). The use of pharmacological inhibitors on cultured 
myoblasts suggested early on that signaling downstream of IGF1 diverges into at least 
two arms, one of which works through ERK to maintain proliferation, and one of which 
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acts via PI3K to induce differentiation (Coolican et al., 1997). ERK activity was 
postulated to be a transient response that declines to allow for cell cycle exit. Signaling 
downstream of PI3K serves to enhance the transcriptional activities of both MRFs and 
Mef2 proteins. A recent study has provided evidence that an important target of PI3K, 
acting via the downstream kinases Akt1 and Akt2, is the coactivator and histone 
acetyltransferase p300 (Serra et al., 2007). Akt was shown to directly phosphorylate 
p300, resulting in enhanced physical interaction with MyoD. Past work had demonstrated 
that p300 facilitates the formation of a trimeric complex with MyoD and the 
acetyltransferase PCAF, which directly acetylates MyoD to augment its DNA binding 
(Puri et al., 1997; Sartorelli et al., 1999). PI3K also appears to positively affect Mef2 via 
phosphorylation, although the actual kinase responsible has not been identified and does 
not appear to be Akt (Tamir and Bengal, 2000; Xu and Wu, 2000). Interestingly, IGF’s 
hypertrophic effects derive in part from its ability to counteract catabolic pathways via 
the phosphorylation and inactivation of Foxo transcription factors, known activators of 
atrophy-promoting E3 ligases (Sandri et al., 2004; Stitt et al., 2004). 
 While p38 and IGF are both pro-myogenic, they appear to act through 
independent pathways. Inhibition of PI3K does not affect the normal increase in 
phospho-p38 that accompanies differentiation, and inhibition of p38 does not influence 
Akt phosphorylation (Tamir and Bengal, 2000; Wu et al., 2000b). Nevertheless, recent 
evidence suggests that these signals may ultimately converge or integrate on the 
chromatin of myogenic target genes. Past work had demonstrated that p38 inhibition 
blocked chromatin remodeling at these promoters, apparently a consequence of impaired 
SWI/SNF recruitment (Simone et al., 2004). But interestingly, it has now been shown 
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that PI3K inhibition also results in compromised chromatin remodeling, despite normal 
recruitment of SWI/SNF (Serra et al., 2007). This finding suggests that PI3K activity, 
perhaps due to its requirement for histone acetylation via p300, appears essential for 
enabling the DNA-associated SWI/SNF enzyme to carry out its biological functions. 
 
Part 2: The Notch signaling pathway 
 
Notch: The core pathway 
 The Notch signaling cascade has emerged as another critical regulator of in vivo 
muscle development and regeneration. Notch derives its name from the phenotype of a 
mutant fly with notched wings, identified in the early 1900s by T. H. Morgan (Mohr, 
1919). Only decades later, in 1985, was the Notch locus cloned and characterized in 
Drosophila by Artavanis-Tsakonas and colleagues and shown to encode a single-pass 
transmembrane protein (Wharton et al., 1985). Two additional membrane-bound proteins, 
Delta and Serrate, were cloned shortly thereafter (Fleming et al., 1990; Vassin et al., 
1987) and found to physically interact with the Notch protein (Fehon et al., 1990; Rebay 
et al., 1991). It was quickly appreciated that Notch functions as a cell-surface receptor 
and mediates cell-cell communication by engaging with its ligands (Delta, Serrate) on 
neighboring cells to initiate an intracellular signaling cascade. 
 In mammals, there are four Notch receptors (Notch1-4) and five Notch ligands 
(Jagged1,2 and Delta-like-1,3,4). Notch exists as a heterodimer on the cell membrane, a 
result of a cleavage event (S1) mediated by a furin-like protease in the Golgi apparatus 
(Figure 1.6) (Blaumueller et al., 1997; Logeat et al., 1998). Structurally, the extracellular 
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Figure 1.6. Proteolytic cleavages of the Notch receptor. S1 cleavage is mediated 
by a furin-like protease in the Golgi apparatus to generate the Notch 
heterodimer. S2 cleavage by ADAM family metalloproteases occurs after 
engagement of receptor by ligand. S3 cleavage by the γ-secretase complex 
liberates the Notch intracellular domain (NICD). LNR, Lin12-Notch repeats; 
HD, heterodimerization domain. Adapted from Gordon et al. (2007).
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portion of the receptor is characterized by a series of Epidermal Growth Factor (EGF)-
like repeats and three Lin12-Notch repeats (LNR), followed by the heterodimerization 
(HD) domain. The Notch intracellular domain (NICD) contains two protein-protein 
interaction motifs (RAM” and ankyrin repeats), a nuclear localization signal, a 
transcriptional activation domain (in Notch1,2), and PEST motif. 
 One of the early challenges in the Notch field was to define the mechanism by 
which ligand-receptor engagement resulted in signal activation within the receptor-
expressing cell. It soon became apparent that proteolysis of the receptor itself was an 
essential aspect of signaling, resulting in the liberation of NICD and its subsequent 
translocation to the nucleus (Figures 1.6 & 1.7). Early studies that addressed how such 
proteolysis occurred were facilitated by the use of a truncated form of Notch lacking the 
extracellular domain, NotchΔΕ, which for reasons unknown at the time exhibited 
signaling activity in the absence of ligand stimulation. By transfecting cells with a doubly 
tagged NotchΔΕ construct, in which an HA epitope was fused to the N-terminus, and a 
Myc epitope was fused at the C-terminus, Kopan and colleagues demonstrated that HA 
reactivity was detectable on the cell surface, while Myc reactivity was localized to the 
nucleus (Kopan et al., 1996). Struhl and coworkers obtained evidence of NICD liberation 
and translocation via a different approach, showing that a Notch-Gal4-VP16 fusion 
construct elicited transcriptional activation only if Gal4-VP16 was placed in the 
intracellular domain of the receptor (Struhl and Adachi, 1998). Subsequent work used 
protein microsequencing on receptor fragments to ascertain that a cleavage event 
occurred at Valine 1744, which lies within the transmembrane domain. Strikingly, 
mutation of this specific residue of the truncated receptor compromised signaling activity 
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Figure 1.7. The Notch signaling pathway. Engagement of receptor by ligand (1) 
results in two proteolytic cleavages that liberate the Notch intracellular domain 
(NICD) and allow for its nuclear translocation (2). In the off state, Notch target 
genes are bound by the transcription factor CSL, complexed with corepressors. 
Upon association of NICD with CSL, corepressors are replaced by coactivators, 
and gene activation occurs (3). Adapted from Kadesch (2004).
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as evaluated by a Notch-responsive reporter construct (Schroeter et al., 1998). More 
significantly, knock-in mice carrying this single mutation in the endogenous Notch1 
locus exhibited comparable phenotypes as Notch1 knockout animals (Huppert et al., 
2000). While this result initially suggested that cleavage at Valine 1744 was essential for 
NICD generation, later work revealed that S3 proteolysis can also occur at Leucines 
1745-1746 and Serine 1747 (Tagami et al., 2008). The NICD molecules generated from 
these alternative cleavages, however, are far less stable than NICD-Valine 1744 and 
apparently cannot compensate for its absence in vivo. Genetic data from both Drosophila 
and mouse identified presinilin, a component of the γ-secretase complex, as the protease 
required for S3 proteolysis (De Strooper et al., 1999; Struhl and Greenwald, 1999). 
 While these studies explained the mechanics of NICD processing, it remained 
unclear why a truncated Notch receptor allowed for constitutive NICD generation, while 
the full-length receptor required ligand engagement for activation. Kopan and Israel 
provided an explanation by discovering an additional cleavage event, S2, that occurs 
within the extracellular juxtamembrane domain of Notch (Figure 1.6) (Brou et al., 2000; 
Mumm et al., 2000). Normally inhibited by the presence of the extracellular domain, S2 
cleavage only proceeds after a presumed conformational change following ligand-
receptor engagement (Gordon et al., 2007). Separate work has established that a critical 
event in Notch activation is the endocytosis of the Notch ligand (Delta) and trans-
endocytosis of the receptor extracellular domain into the signal-sending cell (Itoh et al., 
2003; Koo et al., 2005; Parks et al., 2000). It has been speculated that the mechanical 
force generated by these endocytotic movements may in fact drive the conformational 
transition that allows for S2 cleavage. Mediated by ADAM-family metalloproteases 
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(Brou et al., 2000), this processing step precedes and is required for the presinilin-
mediated cleavage (S3). Truncation of the receptor alleviates auto-inhibitory control over 
S2 cleavage, allowing for constitutive production of NICD. Interestingly, treatment of 
Notch-expressing cultured cells with the calcium chelator EDTA also results in 
unregulated S2 cleavage and NICD processing. It appears that stability of the Notch 
heterodimer on the membrane depends on calcium, and its depletion results in 
dissociation of the extracellular portion of the receptor (Rand et al., 2000). 
 Genetic studies from fly combined with biochemical assays in cultured cells 
helped define the molecular events that occur downstream of Notch proteolysis (Figure 
1.7) (Fortini and Artavanis-Tsakonas, 1994; Jarriault et al., 1995). Once translocated to 
the nucleus, NICD associates with the transcription factor CSL (CBF1, Suppressor of 
Hairless, Lag-1), which typically is constitutively bound to the promoters of Notch-
responsive genes. In the absence of ligand stimulation, CSL associates with corepressors. 
In mammals, these include N-CoR, SMRT, SHARP, and CtIP/CtBP (Kao et al., 1998; 
Oswald et al., 2002; Oswald et al., 2005), while in flies, the adaptor protein Hairless 
allows for indirect association with Groucho and CtBP (Barolo et al., 2002). It is thought 
that CSL-dependent recruitment of these corepressors may play a role in silencing the 
expression of Notch target genes in the absence of signaling activity. Binding of NICD 
results in the displacement of these corepressors and the recruitment of coactivators such 
as Mastermind-like (MAML) and p300 (Oswald et al., 2001; Wu et al., 2000a). Crystal 
structures of the CSL-NICD-MAML ternary complex revealed that association of the 
NICD RAM domain with CSL may result in a conformational change important for 
corepressor displacement, while binding of the NICD Ankyrin repeats to the CSL C-
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terminus creates a novel interface for MAML recruitment (Nam et al., 2006; Wilson and 
Kovall, 2006). Interestingly, recent work from Drosophila has added a new twist to the 
conventional view of Notch activation. Studies by Bray and colleagues in cultured insect 
cell lines have demonstrated that at least at a subset of Notch-responsive promoters, CSL 
DNA binding increases significantly but transiently following EDTA-mediated signal 
initiation (Krejci and Bray, 2007). While not yet confirmed in vertebrate or ligand-based 
systems, these results suggest the possibility that NICD may play a role in facilitating 
CSL recruitment to DNA at specific target promoters. 
 While much attention has focused on the mechanisms of Notch activation, an 
equally important question relates to how activity is terminated to ensure proper temporal 
control of signaling. The work of Jones and coworkers has contributed important insights 
into this problem by proposing a model in which activation and termination are 
intimately linked through regulation of NICD protein stability. An intriguing initial 
observation was that in cells transfected with NICD, CSL, and MAML, less NICD 
protein was detectable as compared to that seen in cells transfected with NICD and CSL 
alone (Fryer et al., 2002). Mutation of the NICD PEST domain, a motif known to 
regulate protein stability, eliminated this effect, as did truncation of the MAML C-
terminus. The implication was that MAML, a factor primarily thought of as a 
transcriptional coactivator, might also contribute to NICD turnover. Indeed, further 
studies revealed that MAML appears to recruit a specific kinase (CDK8) that 
phosphorylates the NICD PEST domain and marks it for subsequent ubiquitin-mediated 
proteasomal degradation (Fryer et al., 2004). These findings suggested a general 
mechanism also observed in yeast whereby inducible activators such as NICD may 
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participate in mediating their own destruction to finely limit the temporal widow of their 
transcriptional activity. 
 
In vivo functions of Notch 
 Since the cloning of the Notch receptor almost twenty-five years ago, Notch 
signaling has been shown to play vital roles in the control of cell fate determination in 
animals ranging from worms to mammals (Artavanis-Tsakonas et al., 1999). One of the 
first described and most iconic roles for Notch was in mediating a process called “lateral 
inhibition” in Drosophila (Cabrera, 1990; Chitnis, 1995; Heitzler and Simpson, 1991). In 
the developing central nervous system of the fly, an initially equivalent group of cells 
known as a proneural cluster ultimately gives rise to a single neuroblast surrounded by 
cells of the epidermal lineage. Loss of function mutations in a group of “neurogenic 
genes”, which includes Notch, disrupt this specification process and result in a phenotype 
of neural hypertrophy. Cells normally fated to the epidermal lineage instead convert to 
neuroblasts. The implication was that Notch signaling normally inhibits the adoption of 
the neural fate in the cluster of cells surrounding the single neurally-fated cell. A model 
of “lateral inhibition” was proposed, in which the single cell destined to become a 
neuroblast comes to express high levels of Notch ligands but low levels of receptor, 
rendering it capable of sending but not receiving a Notch signal. Conversely, its 
neighboring cells acquire the opposite expression profile and exhibit the ability to receive 
the signal but not initiate it. These expression disparities arise due to the amplification of 
very small initial differences in the original proneural cluster, resulting from 
transcriptional feedback effects of signaling on the expression of the receptor and ligands 
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themselves. Cells experiencing slightly higher initial signaling activity relative to a 
neighbor, for example, tend to downregulate expression of Notch ligands and upregulate 
the receptor, while cells with lower initial activity do the opposite. The net result is the 
eventual clustering of many signal-receiving cells around a single signal-sending cell. 
 In mammals, Notch signaling regulates the development of a vast array of cell 
lineages. Genetic knockouts of core Notch pathway components in the 1990s revealed 
that Notch plays critical early roles in somitogenesis and vascular remodeling during 
mouse embryonic development (Conlon et al., 1995; Hrabe de Angelis et al., 1997; Xue 
et al., 1999). Given that animals homozygous null for several of the individual Notch 
ligands or receptors exhibit early embryonic lethality, conditional deletion approaches 
have been employed to probe tissue-specific functions of the pathway at later 
developmental stages. In the immune system, such work demonstrated a genetic 
requirement for Notch signaling in the specification of T lymphocytes and the generation 
of Th2 helper T cells (Amsen et al., 2007; Radtke et al., 1999). The pathway’s effects on 
lymphocyte development were also revealed by a gain-of function approach in the case of 
T-cell commitment (Pui et al., 1999), or via the use of a lineage-specific dominant 
negative MAML transgenic mouse in the case of Th2 differentiation (Fang et al., 2007). 
In the skin, deletion of Notch1 results in epidermal hyperplasia, impaired differentiation, 
and the development of basal-cell carcinoma-like tumors, suggesting tumor suppressor 
functions (Nicolas et al., 2003; Rangarajan et al., 2001). By contrast, in the nervous 
system, conditional Notch1 ablation results in premature differentiation of neuroepithelial 
cells followed by their apoptotic elimination (Lutolf et al., 2002). These studies have 
highlighted the pathway’s functional versatility in different tissues. While in some 
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contexts, Notch primarily acts to inhibit cellular differentiation of one cell type and 
perhaps allow for progression down an alternative pathway, in others it actively helps 
specify or promote the differentiation of a particular lineage. A central challenge has been 
to understand the molecular circuitry downstream of Notch activation that underlies these 
diverse biological effects. 
 
Transcriptional effectors of Notch: Enhancer of split/Hes genes 
 Early genetic studies in Drosophila first illustrated the concept that Notch often 
controls cell fate decisions through the initiation of a transcriptional cascade, in which 
primary effectors themselves function as transcriptional repressors that target lineage-
determination genes. The inhibitory effects of Notch on the neural fate in the fly were 
shown to result from the transcriptional induction of a series of basic helix-loop-helix 
repressor proteins of the Enhancer of Split (E(spl)) locus (Bailey and Posakony, 1995; 
Jennings et al., 1994; Lecourtois and Schweisguth, 1995). These factors are present in the 
ectodermal cells surrounding neuroblasts. E(spl) expression is eliminated by loss-of-
function mutations in either Notch or Suppressor of Hairless (CSL), while it is expanded 
under conditions of ectopic Notch activation. The promoters of E(spl) genes contain CSL 
binding sites which are required for induction (Bailey and Posakony, 1995; Lecourtois 
and Schweisguth, 1995). Importantly, loss-of-function mutations in genes of the E(spl) 
locus recapitulate the Notch neural hypertrophy phenotype, with the severity of the 
hypertrophy dependent upon how many of the genes are mutated (Jennings et al., 1994). 
Together, these results provided strong evidence that Notch signals through inhibitory 
E(spl) proteins to restrict neural fate determination. 
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 Further studies suggested that the E(spl) factors and a closely related bHLH 
protein, hairy, primarily function by repressing the expression of achaete (ac), a proneural 
bHLH transcription factor. Hairy and E(spl) proteins associate with the Groucho 
corepressor via a C-terminal WRPW motif and are thought to repress ac transcription via 
direct DNA binding to an E-box within its promoter (Ohsako et al., 1994; Paroush et al., 
1994; Van Doren et al., 1994). This work was quickly extended to vertebrate systems, 
where a family of several Hairy and Enhancer of Split (Hes) homologues was identified 
(Sasai et al., 1992). In mammals, the bHLH repressors Hes1, Hes5, and Hes7 are all 
direct canonical targets of Notch (Figure 1.8) (Bessho et al., 2001; Jarriault et al., 1995; 
Nishimura et al., 1998). The role of E(spl) proteins in repressing neurogenesis appears to 
be conserved across species, as the Hes1 knockout mouse exhibits elevated levels of 
proneural bHLH proteins such as MASH1 (the ac orthologue) and accelerated 
neurogenesis before perinatal death (Ishibashi et al., 1995). Conversely, retroviral 
overexpression of Hes1 blocks neural differentiation in vitro and in vivo (Ishibashi et al., 
1994). Hes5 partially compensates for Hes1 function in repressing the neural fate, as the 
Hes1/Hes5 double knockout neural phenotype was more severe than the Hes1 single 
knockout. Furthermore, forced activation of Notch blocked the differentiation of single 
knockout, but not double knockout, neural precursors in culture (Ohtsuka et al., 1999). 
 
Transcriptional effectors of Notch: Hey genes 
 While Hes proteins appear to account for Notch’s primary phenotypic effects in 
the nervous system, these factors by no means represent the full range of Notch 
transcriptional output. The Hey/Hesr/HERP/CHF family of bHLH repressors (Hey1, 
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Figure 1.8. Canonical Notch target genes. Hes and Hey transcriptional 
repressors share a conserved basic helix-loop-helix (bHLH) motif that mediates 
DNA binding and dimerization, and an Orange domain implicated in protein-
protein interactions. Hes proteins contain a C-terminal WRPW tetrapeptide that 
facilitates recruitment of Groucho/TLE corepressors. Adapted from Iso et al. 
(2003).
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Hey2, HeyL) is another closely related group of transcription factors that are directly 
activated by Notch in a CSL-dependent fashion (Iso et al., 2002; Iso et al., 2001a; Maier 
and Gessler, 2000). Hey proteins, like Hes factors, dimerize with one another (and other 
bHLH proteins) via their HLH motif and bind to E-box or N-box elements within DNA 
via their basic domain (Figure 1.8) (Fischer et al., 2002; Iso et al., 2001b; Pichon et al., 
2004). Hes and Hey proteins also share a conserved Orange domain downstream of the 
bHLH motif, which is thought to mediate protein interactions and potentially serve as an 
extended dimerization interface (Taelman et al., 2004). In contrast to Hes family 
members, Hey factors lack the C-terminal WRPW interaction motif and associate with 
the corepressors mSin3A, N-CoR, and HDAC1 by way of their basic domain (Iso et al., 
2001b). 
 Gene knockout studies have shown that Hey factors play critical early roles in the 
developing heart and vasculature and likely represent the prime Notch effectors in these 
tissues (Fischer et al., 2004; Fischer et al., 2007; Gessler et al., 2002). As with Hes1 and 
Hes5 in the nervous system, functional redundancy exists among Hey proteins, as single 
knockout animals are either normal or display less severe phenotypes than double 
knockouts (Fischer et al., 2004; Fischer et al., 2007). The detailed molecular mechanisms 
by which Hey proteins function in specific biological contexts are not well defined. 
While Hey family members are capable of binding to DNA in-vitro, several reports have 
shown that binding to E-boxes within target promoters either does not occur or is not 
required for Hey-directed repression (Fischer et al., 2005; Holderfield et al., 2006; Huang 
et al., 2004; Nakagawa et al., 2000). Instead, Hey proteins often may physically associate 
with and antagonize the activity of other transcription factors. Hey family members are 
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capable of binding to GATA4/6 and inhibiting GATA-driven cardiac gene expression, 
which could partially account for important functions in the cardiovascular system 
(Fischer et al., 2005). In other contexts, inhibitory physical interactions between Hey 
proteins and Runx2 may explain Notch-mediated protection against aortic calcification 
(Garg et al., 2005), while associations between Hey factors and Ptf1-p48 may underlie 
Notch-directed inhibition of pancreatic exocrine differentiation (Ghosh and Leach, 2006). 
 Beyond the canonical Hes/Hey target genes, recent studies have revealed that 
Notch likely induces the expression of a much broader set of genes in various tissues. For 
example, in helper T-cell differentiation, direct induction of the transcription factor Gata3 
downstream of Notch is required for the pathway’s ability to promote Th2 specification 
(Amsen et al., 2007; Fang et al., 2007). In T-cell leukemia and mammary tumorigenesis, 
by contrast, Notch’s oncogenic effects have been linked to the direct induction of c-myc 
(Klinakis et al., 2006; Weng et al., 2006). And in skin, Notch-mediated upregulation of 
the cell cycle inhibitor p21 is required for the pathway’s growth suppressive effects 
(Rangarajan et al., 2001). The Notch-E(spl)-ac axis from Drosophila provides an 
appealingly simple illustration of how Notch influences cell fate, but clearly represents 
only one of many possible signaling modules employed by the pathway to bring about its 
diverse biological effects. 
 
Modulation of the Notch signal 
 A large number of regulatory controls have evolved to restrict and finely tune 
Notch activity and ensure a spatially and temporally appropriate signaling response. 
These modulators function at all levels of the pathway, from ligand-receptor engagement, 
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to receptor processing, to NICD stability and activity (Kadesch, 2004; Kopan and Ilagan, 
2009). Two of the earliest identified modulators were the glycosyltransferase enzyme 
Fringe and the cytoplasmic protein Numb. Work in Drosophila originally demonstrated 
that Fringe potentiates the response of Notch-expressing cells to the ligand Delta, but 
inhibits responsiveness to Serrate (Panin et al., 1997). This effect was only observed if 
Fringe was expressed in the cells expressing the Notch receptor. Later studies showed 
that Fringe acts in the Golgi as a glycosyltransferase to elongate O-linked fucose residues 
on the EGF repeats of Notch (Bruckner et al., 2000; Hicks et al., 2000; Moloney et al., 
2000). This post-translational modification of the receptor is thought to influence the 
efficiency with which different ligands can engage receptor and stimulate NICD 
proteolytic release. Three orthologues of this enzyme exist in mammals (lunatic fringe, 
radical fringe, and manic fringe), all of which exhibit similar glycosyltransferase activity 
(Moloney et al., 2000). 
 Numb was also characterized initially in the fly, where it was shown to be a 
membrane-associated protein that segregates asymmetrically into one daughter cell of a 
dividing sensory organ precursor in the peripheral nervous system (Rhyu et al., 1994). 
Numb+ cells were shown to adopt the neural fate, as would be expected of cells which 
turn off the inhibitory Notch pathway. It was later demonstrated that Numb physically 
associates with the intracellular domain of membrane-bound Notch and prevents NICD 
nuclear translocation (Wakamatsu et al., 1999). Ubiquitin-mediated degradation and 
receptor endocytosis have been proposed as potential mechanisms for Numb-dependent 
Notch downregulation (Berdnik et al., 2002; McGill and McGlade, 2003). Numb also 
functions in Drosophila myogenesis (Baylies et al., 1998). In this lineage, Notch first acts 
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via lateral inhibition in the singling out of a myogenic progenitor cell from a cluster of 
embryonic mesodermal cells. This progenitor then undergoes asymmetric cell division to 
generate two daughters, an adult muscle precursor (Numb−) and a founder myoblast 
(Numb+). Adult muscle precursors (AMPs) remain undifferentiated and can be thought of 
as the fly analogue of satellite cells. The asymmetric distribution of Numb in the muscle 
progenitor daughter cells is consistent with the known inhibitory functions of Notch on 
myogenic lineage progression. Furthermore, loss of Numb was shown to result in the 
formation of two AMPs and loss of muscle founders, while forced Numb expression led 
to the opposite phenotype (Ruiz Gomez and Bate, 1997). In mammals, whether Numb 
and its homologue Numb-like always function as antagonists of Notch in vivo has been 
more controversial. Knockout mice have yielded conflicting phenotypes in the 
developing central nervous system, with reports either of reduced neural differentiation 
(expected from increased Notch signaling) or premature neural differentiation (expected 
from decreased Notch activity) (Petersen et al., 2002; Zhong et al., 2000; Zilian et al., 
2001). 
 
Part 3: Regulation of skeletal myogenesis by Notch 
 
In vivo roles of Notch in muscle 
 Recent studies have revealed that the Notch signaling cascade plays critical roles 
in the regulation of embryonic and post-natal myogenesis. While it has been known for 
over a decade that forced activation of Notch in cultured myoblasts inhibits their 
differentiation (Kopan et al., 1994), newer work has demonstrated that this inhibitory 
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effect in vitro reflects similar functions during development and regeneration in vivo 
(Conboy et al., 2003; Conboy and Rando, 2002; Schuster-Gossler et al., 2007; Vasyutina 
et al., 2007). In post-natal myogenesis, Rando and colleagues first made the important 
observation that muscle injury results in activation of Notch signaling, as evidenced by 
increased levels of cleaved Notch1, and that this increased signaling may reflect 
induction of the Notch ligand Delta-like-1 (Dll1) (Conboy and Rando, 2002). 
Interestingly, experiments in muscle explants further demonstrated that the Notch 
pathway inhibitor Numb was asymmetrically segregated in dividing intermediate 
myogenic progenitors. Numb+ daughter cells were found to express lineage progression 
markers, such as Myf-5 and Desmin, but not the earlier pre-myoblast marker Pax3, while 
Numb− cells exhibited the opposite expression profile. These data suggested that 
cessation of Notch activity (Numb+) correlated with progression down the myogenic 
pathway, while sustained signaling (Numb−) correlated with a maintenance of the 
undifferentiated state. Additional studies showed that artificial activation of Notch via 
retrovirally expressed NICD in primary myoblast cultures resulted in enhanced 
proliferation, while siRNAs targeting the Notch1 receptor led to compromised 
proliferation. Together, these findings suggested that activation of Notch signaling 
following muscle injury promoted the expansion of satellite cells or myogenic precursors 
and prevented differentiation, while termination of Notch activity allowed for subsequent 
progression down the lineage pathway. 
 While this work revealed obvious parallels between vertebrate and Drosophila 
myogenesis with respect to asymmetric Numb segregation, a key limitation was that 
Rando and coworkers did not address whether Numb plays an actual causal role in 
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shutting off Notch activity and permitting differentiation in vivo. Since Numb knockout 
mice die early in gestation (Zhong et al., 2000), obtaining genetic proof of Numb’s 
importance in this process would require the generation of a conditional muscle-specific 
mutant. While the correlative evidence for Numb is compelling, other mechanisms could 
also account for the segregation of Notch activity to one daughter cell of a dividing 
satellite cell or progenitor. Indeed, the work of Rudnicki has revealed a potential role for 
asymmetric expression of the Notch ligand Dll1 (Kuang et al., 2007). Dll1 was only 
marginally detectable in the subset of satellite cells that are thought to exhibit true stem 
cell potential (permanently Myf-5 negative), but was highly expressed in neighboring 
sister satellite cells that at one point in their history expressed Myf-5. Notch receptors 
were expressed in both pools of cells, although Notch3 was enriched in the SC stem cell 
population. These findings suggest that elevated levels of Notch signaling in less 
committed satellite (stem) cells could result in part from restriction of ligand expression 
to neighboring sister cells. 
 Subsequent Notch gain- and loss-of-function studies in vivo built upon these 
initial observations (Conboy et al., 2003). Inhibition of Notch signaling via a soluble 
Jagged ligand was shown to impair regeneration following muscle injury, while 
conversely, enhanced Notch activation via an antibody specific for Notch1, facilitated the 
repair process. Intriguingly, the compromised regenerative ability of muscle from aged 
mice was associated with reduced induction of the Notch ligand Dll1, suggesting a 
potential defect in pathway activation. Consistent with this notion, forced induction of 
Notch signaling improved the repair response in these animals. Remarkably, subsequent 
studies in which the circulatory systems of old and young mice were united via parabiosis 
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suggested that circulating factors in the blood of young animals could help improve the 
ability of aged muscle to induce Dll1 and ultimately mount a regenerative response 
(Conboy et al., 2005). This result argued that compromised muscle regeneration in aged 
animals may primarily reflect an impaired signaling environment, rather than an intrinsic 
defect of the resident stem cell pool. Indeed, later work expanded on this notion and 
revealed that aged muscle also exhibits hyperactivation of the Wnt and TGFβ signaling 
pathways. Elevated Wnt signaling was postulated to account for increased fibrosis in old 
muscle, as Wnt activation biased myogenic progenitors towards adopting a fibrogenic 
fate (Brack et al., 2007). Increased levels of TGFβ, by contrast, were proposed to 
contribute to the defect in satellite cell proliferation, via Smad3-mediated induction of the 
cell cycle inhibitors p15, p16, p21, and p27 (Carlson et al., 2008). Interestingly, recent 
work has suggested that Wnt signaling also functions in later phases of a normal 
regenerative response to promote myogenic determination (Brack et al., 2008). The 
precise nature of the crosstalk between these multiple signaling pathways in muscle 
remains to be determined.  
 In addition to this work on post-natal myogenesis, other studies employed genetic 
loss-of-function approaches to demonstrate an important role for Notch in embryonic 
muscle development. Studies in different vertebrate model systems had shown previously 
that Notch affects the process of somitogenesis, whether by helping to specify somite 
borders or to impose anterior-posterior polarity (Lewis et al., 2009). It was not clear, 
however, whether the pathway also functioned downstream in the actual generation 
and/or maintenance of skeletal muscle. To circumvent the problem of early embryonic 
lethality caused by a null mutation in the Notch ligand Dll1, Gossler and colleagues 
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generated a Dll1 null/hypomorph heterozygote, which survived until birth but was found 
to exhibit striking defects in the skeletal muscle lineage (Schuster-Gossler et al., 2007). 
The central phenotype observed in this mouse, a dramatic hypotrophy of muscle tissue, 
appeared to reflect premature, accelerated muscle differentiation, accompanied by loss of 
the Pax3+/Pax7+ myogenic progenitor cell pool. A transient excess of myogenic cells was 
generated early on in the embryo, but myogenesis terminated too soon to allow for the 
ultimate generation of normal musculature. The conclusion was that Dll1-Notch signaling 
is essential for maintaining myogenic progenitors and preventing their precocious 
differentiation. Using a different approach, conditional CSL knockout mice, Birchmeier 
and coworkers reported similar findings (Vasyutina et al., 2007). Genetic deletion of CSL 
in either somitic or migrating myogenic precursors resulted in premature loss of these 
progenitors due to enhanced early differentiation. An absence of satellite cells as assessed 
by electron microscopy and Pax7 staining was also observed in these animals, consistent 
with previous proposals that the Pax3+/Pax7+ pool of progenitors represents the cellular 
origin of this stem cell population.  
 
Mechanisms of Notch-mediated inhibition of myogenesis 
 While Notch carries out important functions in embryonic and post-natal skeletal 
myogenesis, the molecular mechanisms by which Notch exerts its effects are not well 
understood. In the last fifteen years, the question of how Notch represses muscle 
differentiation has been tackled by a number of different studies but has remained 
controversial and resistant to solution. In 1994, it was first observed by Weintraub and 
colleagues that forced expression of NICD repressed myoblast differentiation and 
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fibroblast conversion in culture (Kopan et al., 1994). This inhibitory effect was also 
observed upon ligand-mediated activation of the pathway, in which myoblasts were co-
cultured with Jagged-expressing cells (Lindsell et al., 1995). The block to differentiation 
imposed by NICD could be overcome by expression of a MyoD-VP16 fusion protein but 
not a MyoD~E47 tethered dimer (Kopan et al., 1994). These initial results suggested that 
NICD might target the transcriptional activity of MyoD without affecting its dimerization 
or DNA-binding. Such conclusions, however, rested upon the use of an artificial MyoD 
fusion construct and did not directly assess MyoD occupancy at target gene promoters. 
Subsequent findings led to an alternative model of Notch action in muscle, whereby 
Notch would signal through the transcriptional repressor protein Hes1. NICD was shown 
to directly activate the Hes1 promoter via CSL (Jarriault et al., 1995), and forced 
expression of Hes1 phenocopied the inhibitory effects of NICD on fibroblast conversion 
(Sasai et al., 1992). It appeared that Hes1 functioned by disrupting the in vitro DNA 
binding of MyoD/E47 heterodimers, likely via inactive dimer formation with E47. While 
initially appealing, this model relied on the use of NICD overexpression and very high 
levels of transiently transfected Hes1. Indeed, later work by Weinmaster and colleagues 
demonstrated that Jagged1-mediated Notch signaling in C2C12 myoblasts repressed 
myogenesis without inducing Hes1 transcription (Shawber et al., 1996). Another study 
indicated that the Notch ligand Dll1 may in fact induce Hes1, albeit transiently and in an 
oscillating pattern of expression (Kuroda et al., 1999). Stable myoblast lines expressing 
Hes1, however, exhibited normal differentiation (Shawber et al., 1996), calling into 
question the significance of Hes1 induction. In vivo data also revealed that myogenesis 
was not perturbed in Hes1 knockout animals (Ishibashi et al., 1995). 
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 In parallel with their work on Hes1, Weinmaster and coworkers proposed an 
alternative theory for Notch-mediated inhibition, arguing for the existence of a CSL-
independent pathway. This idea was generated from the observation that mutant forms of 
NICD that were unable to interact with CSL or activate CSL-dependent gene expression 
were nevertheless capable of repressing myogenesis in C2C12 cells (Shawber et al., 
1996). Furthermore, forced expression of a dominant-negative CSL construct failed to 
rescue myogenic inhibition imposed by Notch ligands (Nofziger et al., 1999). This 
proposal was complicated, however, by the fact that residual CSL activity may have 
persisted in the presence of the dominant negative, and the mutant forms of NICD may 
still have retained a low-level ability to associate with and activate CSL (Kato et al., 
1997). Finally, the in vivo studies described previously revealed very similar phenotypes 
in the Dll1 null/hypomorph as compared to the conditional CSL knockout, indicating that 
CSL-dependent signaling accounts for the phenotypic effects of Notch activation, at least 
in embryonic muscle development (Schuster-Gossler et al., 2007; Vasyutina et al., 2007). 
 Other reports speculated that Notch may target the Mef2C transcription factor or 
the p38 signaling pathway, instead of directly antagonizing the muscle regulatory factors. 
In one study, a physical association was reported between the ankyrin repeats of NICD 
and Mef2C, which was proposed to account for NICD-mediated inhibition of Mef2C 
DNA binding and transcriptional activity in reporter assays (Wilson-Rawls et al., 1999). 
No attempts were made, however, to verify such an association downstream of ligand-
mediated signaling. Subsequent work reported that MAML can serve as a coactivator for 
Mef2C and hypothesized that Notch signaling, via NICD, could titrate MAML away 
from Mef2C to shut down myogenesis (Shen et al., 2006). While an intriguing idea, it 
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remains uncertain that MAML is limiting within the nucleus. MAML KO animals 
exhibited muscle defects and died within ten days of birth, but heterozygotes were 
phenotypically normal. Further, actual physical interaction between Mef2C and MAML 
was not demonstrated, and coIPs did not show disruption of NICD-MAML association 
by Mef2C. Finally, a third study revealed that forced expression of NICD induces 
expression of MKP-1, a phosphatase that targets p38 for inactivation (Kondoh et al., 
2007). While constitutive expression of MKP-1 was indeed shown to block 
differentiation and reduce phospho-p38, the effects of NICD itself on p-p38 were 
considerably more modest, and ligand-mediated signaling was not examined. 
 In summary, while much has been published on Notch and myogenesis, the 
mechanisms by which this important pathway inhibits myogenic differentiation remain 
controversial and require further elucidation. To this end, I have sought to define the key 
transcriptional targets activated by Notch in muscle and explore how these effectors 
function to inhibit the myogenic transcriptional program. In the first half of my work, I 
performed a gene expression screen to identify genes upregulated by ligand-mediated 
Notch activity in C2C12 myoblasts and carried out gain- and loss-of-function 
experiments to ascertain which of these genes are sufficient and/or necessary for 
myogenic repression. My results demonstrated that Notch induces the expression of over 
80 transcripts after six hours of stimulation. At least two of these genes, the canonical 
effector Hey1 and the novel responsive gene MyoR, were capable of recapitulating the 
block to myogenic differentiation when constitutively expressed. siRNA knockdown of 
these factors alone or in combination, however, did not alleviate repression by Notch, 
suggesting the existence of multiple, potentially redundant pathways. In the second half 
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of my studies, I focused my attention on the Notch effector Hey1 and employed a variety 
of biochemical and functional assays to help uncover the mechanism by which this 
protein interferes with myogenic transcription. My results indicated that Hey1 does not 
target the intrinsic transcriptional activity of the skeletal muscle master regulator MyoD, 
but rather associates with the promoter regions of two critical myogenic targets, 
Myogenin and Mef2C, to silence their expression.  
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Chapter II. Inhibition of Myogenesis by Notch: 
Evidence for Multiple Pathways1 
 
ABSTRACT 
 
 Notch signaling is critical for skeletal muscle development and regeneration, 
permitting the expansion of progenitor cells by preventing premature differentiation. I 
have interrogated the pathways through which ligand-mediated signaling inhibits 
myogenesis by identifying Notch-responsive genes and assessing their impact on 
differentiation in vitro. Notch activation led to the robust induction of the transcriptional 
repressors Hey1 and HeyL in myoblasts, but only constitutive expression of Hey1 
blocked myogenesis. siRNA-mediated knockdown of Hey1 had no effect on Notch’s 
ability to inhibit differentiation, suggesting the existence of additional, possibly 
redundant pathways. I identified 82 genes whose expression was activated when C2C12 
myoblasts were cultured in the presence of the Notch ligand Dll4. One of these, MyoR, is 
a novel Notch-responsive gene, whose protein product is known to repress myogenesis in 
vitro. siRNA-mediated knockdown of MyoR alone, or in combination with Hey1, was 
also ineffective at rescuing differentiation in the presence of Dll4. My data support a 
model in which Notch signaling inhibits myogenesis through multiple pathways, two of 
which are defined by the Notch-responsive genes Hey1 and MyoR. 
                                                 
1  Portions of this chapter are reprinted with permission from Buas, M.F., Kabak, S., and Kadesch, T.,  
J Cell Physiol 218, 84-93 (2009). 
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RESULTS 
 
 To study the mechanisms by which Notch signaling inhibits myogenic 
differentiation, I employed the myoblast cell line C2C12. This cell line was derived 
almost three decades ago by serial passaging of myoblasts isolated from an adult mouse 
hind limb muscle 70 hours following crush injury (Blau et al., 1985; Yaffe and Saxel, 
1977). C2C12 cells have long been used as an in vitro model system to investigate the 
molecular regulation of skeletal muscle differentiation. These cells proliferate as 
myoblasts in high serum, differentiate and fuse into multinucleated myotubes in low 
serum, and maintain a population of undifferentiated “reserve cells”, which have been 
likened to quiescent satellite cells (Yoshida et al., 1998).  
 
Ligand-induced Notch signaling blocks an early step in myogenesis 
 To obtain physiological levels of Notch signaling, I exposed cells to Notch 
ligands. Specifically, I grew cells in the presence of Fc-fusion proteins, containing either 
the extracellular domain of Delta-like4 (Fc-Dll4) or Jagged1 (Fc-Jag1), adhered to the 
surface of tissue culture dishes with an anti-Fc antibody (Varnum-Finney et al., 2000). 
Plating C2C12 myoblasts on Fc-Dll4, but not on a control Fc-fusion protein (Fc linked to 
a portion of the Trail receptor 4; dubbed “Fc-control” throughout), led to a robust 
generation of the Notch intracellular domain (NICD) (Figure 2.1A). When transferred 
from high serum (GM, growth medium) to low serum (DM, differentiation medium), 
cells grown on Fc-Dll4 were unable to form myotubes (data not shown) or to induce the 
expression of Myogenin, an early marker of myogenesis (Figure 2.1A). Similar results 
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were obtained using Fc-Jag1 as a Notch ligand. C2C12 cells whose differentiation is 
blocked by Notch signaling remain myoblasts since they retain the ability to form 
myotubes when transferred to normal culture dishes (data not shown). 
 Notch signaling also blocked the induction of RNAs encoding Mef2C and the 
splicing isoforms of Mef2A and Mef2D normally induced upon muscle differentiation 
(Figure 2.1B; (Zhu et al., 2005)). Expression of MyoD RNA was reduced in cells 
exposed to Notch ligand, but a significant level (30-40% of that observed in cells plated 
on Fc-control) still remained (Figure 2.2A). Additionally, Myf-5 RNA levels were 
induced by approximately three-fold in cells grown on Fc-Dll4 (Figure 2.2B). These data 
confirm the results of others that ligand-mediated Notch signaling blocks myogenesis 
(Lindsell et al., 1995), but challenge the notion that down-regulation of MyoD expression 
is the primary mechanism responsible for this inhibition (Kuroda et al., 1999). They also 
suggest that direct antagonism of MEF2C activity by NICD (Wilson-Rawls et al., 1999) 
is less likely to be important, as Notch signaling acts prior to the induction of Mef2C 
RNA. Our results indicate instead that Notch functions by repressing the ability of MyoD 
to induce Myogenin and Mef2C, two critical early mediators in the myogenic program 
(Cheng et al., 1993; Wang et al., 2001). 
 
Constitutive expression of Hey1 recapitulates the early block to myogenesis 
 I next determined if members of the Hey or Hes family of transcriptional 
repressors might mediate the effects of Notch in C2C12 cells. I found that while all three 
Hey family members (Hey1, Hey2 and HeyL) were induced as a consequence of Notch 
signaling, the overall level of Hey2 was extremely low (Figure 2.3), consistent with a 
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previous report (Iso et al., 2001a). Members of the Hes family regulated by Notch in 
other cell types (Hes1, Hes5, Hes7) were not appreciably induced (Shara Kabak, 
unpublished observation). To determine if constitutive expression of either Hey1 or HeyL 
could mimic the effect of Notch on differentiation, I used retroviral vectors to express 
FLAG-tagged versions of these repressors in C2C12 cells. Cells expressed comparable 
amounts of Hey1/HeyL RNAs; however, when I assessed differentiation, only Hey1 
blocked induction of Myogenin and Mef2C transcripts (Figure 2.4A) and reduced 
myoblast fusion (data not shown). Western analysis demonstrated that FLAG-Hey1 and 
FLAG-HeyL proteins were indeed expressed (the indicated bands migrated at the 
expected mobility of 40-45 kD), albeit at a low level in the case of Hey1 (Figure 2.4B). 
Induction of both Myogenin and Myosin heavy chain (MHC) proteins occurred normally 
in the presence of constitutively expressed HeyL, whereas in Hey1-expressing cells, these 
markers were completely repressed at early time-points and only became detectable by 
day 4. My results are consistent with a previous report implicating Hey1 as an inhibitor of 
myogenesis (Sun et al., 2001). While I also observed that a FLAG-tagged version of 
Hey2 exhibited the ability, like Hey1, to inhibit Myogenin induction (Figure 2.5), I do not 
consider Hey2 a major player in this system, given that ligand-mediated stimulation 
induces only a negligible amount of Hey2 transcription. Fc-Dll4 also induced Hey1 in 
primary human myoblasts, and this correlated with a block to Myogenin induction 
(Figure 2.6). I conclude that constitutive expression of Hey1 strongly inhibits early 
inductive events of myogenesis and ultimately delays the course of differentiation. 
  I next asked if Hey1 induction is necessary for Notch to inhibit myogenesis.  I 
reasoned that if I sufficiently reduced the level of Hey1 expression I might observe 
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normal Myogenin induction despite ongoing Notch signaling. Transfection of C2C12 
cells with siRNAs directed against Hey1, relative to control siRNAs, did not appreciably 
affect the low level of Hey1 RNA in cells plated on Fc-control (this was somewhat 
variable across multiple experiments; see Figure 2.19), but led to a significant reduction 
(~75 percent) in Hey1 expression when cells were plated on Fc-Dll4 (Figure 2.7, top). 
However, the induction of Myogenin (Figure 2.7, bottom) and two other myogenic 
markers, Mef2C and Myosin heavy polypeptide 3 (Myh3) (Figure 2.8), was still 
inhibited. This result argues that the high levels of Hey1 expression induced by Notch are 
not necessary for the inhibition of myogenesis, and that other, potentially redundant 
pathways may contribute. 
 
Identification of novel Notch-responsive genes in C2C12 cells 
 To identify additional effectors downstream of Notch, I performed a microarray-
based expression screen using C2C12 cells. Myoblasts were plated on either Fc-Dll4 or 
Fc-control ligand and maintained in growth medium (GM) for six hours prior to isolation 
of RNA for expression profiling. The six-hour time-point was chosen to bias the screen 
towards the detection of direct (early) targets of the pathway. Activation of Notch was 
verified by Western blot of protein lysates harvested from a parallel set of cultures using 
an antibody specific for cleaved Notch (data not shown). RNA was submitted to the Penn 
Microarray Core Facility for processing on Affymetrix MOE430v2.0 gene chips. 
 With a false discovery rate set to 0% and a fold change cutoff of two, the 
microarray identified 82 transcripts that were induced and five transcripts that were 
repressed by Notch ligand stimulation. The top 30 induced genes are shown in Table 1. 
57
10
8
6
4
2
0
R
el
at
iv
e
Le
ve
l
NS control Hey1-siRNA
Fc-control
Fc-Dll4
Hey1
1.5
1.0
0.5
0.0
R
el
at
iv
e
Le
ve
l
NS control Hey1-siRNA
Fc-control
Fc-Dll4
Myogenin
*p<0.02
*p<0.01
58
A3.0
2.0
1.0
0.0
R
el
at
iv
e
Le
ve
l
NS control Hey1-siRNA
Fc-control
Fc-Dll4
Mef2C
4.0
3.0
2.0
1.0
0.0
R
el
at
iv
e
Le
ve
l
NS control Hey1-siRNA
Myh3
Fc-control
Fc-Dll4
B
59
 
 
Table 1.  Genes induced by Notch in C2C12 myoblasts. 
 
 
 Gene Symbol Fold changea Description  
1 Nrarp 14.02   [C] Notch-regulated ankyrin repeat protein  
2 Heyl 10.86   [C] hairy/enhancer-of-split related with YRPW motif-like 
3 Hey1 7.818   [C] hairy/enhancer-of-split related with YRPW motif 1 
4 Il6 6.389   [C] interleukin 6  
5 Msc 5.204   [C] musculin [MyoR]  
6 Trib2 4.982   [C] expressed sequence AW319517 [Tribbles2] 
7 8430408G22Rik 4.743   [C] RIKEN cDNA 8430408G22 [G22]  
8 Ntn4 4.483   [C] netrin 4  
9 Dio2 4.324   [NT] deiodinase, iodothyronine, type II  
10 Jag1 4.066   [NT] jagged 1  
11 BC031353 3.979   [C] cDNA sequence BC031353  
12 Myf5 3.328   [C] myogenic factor 5  
13 BG143461 3.242   [NT] EST mab56d07.x1  
14 Mcf2l 3.151   [C] mcf.2 transforming sequence-like  
15 Sec14l2 3.122   [C] SEC14-like 2 (S. cerevisiae)  
16 Gata3 3.104   [C] GATA binding protein 3  
17 Adora2b 3.093   [NT] adenosine A2b receptor  
18 4832420M10 2.994   [C] hypothetical protein 4832420M10  
19 Tgfb2 2.954   [NC] transforming growth factor, beta 2  
20 Gpr30 2.927   [C] G protein-coupled receptor 30  
21 Egfr 2.923   [C] epidermal growth factor receptor  
22 4833422C13Rik 2.85     [NT] RIKEN cDNA 4833422C13  
23 Vav3 2.71     [C] vav 3 oncogene  
24 Cyp1b1 2.699   [NT] cytochrome P450, family 1, subfamily b, polypeptide 1 
25 A730054J21Rik 2.656   [NT] RIKEN cDNA A730054J21  
26 Kcnf1 2.618   [NT] potassium voltage-gated channel, subfamily F, member 1
27 Epha4 2.601   [NT] Eph receptor A4  
28 Calcrl 2.595   [NT] calcitonin receptor-like  
29 Id3 2.579   [C] inhibitor of DNA binding 3  
30 Ppp1r2 2.557   [NT] protein phosphatase 1, regulatory (inhibitor) subunit 2 
 
 
 
a Targets subsequently confirmed by RT-PCR are marked “C”, those not confirmed are 
marked “NC”, and those not tested are marked “NT”.  
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This observed skewing towards gene activation as opposed to repression suggests that our 
list may indeed contain a large number of direct targets of the pathway, since Notch is 
primarily thought to function as a transcriptional activator. Three known Notch targets—
Hey1, HeyL, and Nrarp—were at the top of the list of induced genes. Among the most 
highly induced were the cytokine interleukin-6 (IL-6), the transcription factor MyoR, the 
kinase-like protein Tribbles2 (Trib2), and the RIKEN cDNA 8430408G22 (G22). 
 I validated a subset of the Notch-responsive genes by RT-PCR. IL-6, MyoR, 
Trib2, G22, and the known targets Nrarp, Hey1, and HeyL, were all induced to varying 
extents in C2C12 cells exposed to Fc-Dll4 after six hours (Figure 2.9A). Quantitative RT-
PCR provided additional confirmation and revealed fold changes very similar to, or 
greater than, those reported by the array for Hey1, MyoR, IL-6, and an additional 
responsive gene, Id3 (Figure 2.9B). In total, 18 of the 30 most highly induced genes were 
confirmed by RT-PCR, one was not confirmed, and 11 were not tested (Table 1). Further 
studies demonstrated that the induction of three genes (MyoR, Trib2, and Hey1), was 
maintained upon serum withdrawal, while Nrarp and IL-6 expression was reduced 
(Figure 2.10). This result suggests that the expression of certain genes appears to require 
the combined actions of Notch and undefined factors present in serum. 
 
Expression of a subset of Notch-responsive genes inhibits C2C12 differentiation 
 I next asked if constitutive expression of any of our newly identified Notch-
responsive genes could inhibit myogenesis. I chose to focus initially on a subset of those 
most highly induced: Nrarp, Trib2, G22, and IL-6. Nrarp, Notch-regulated ankyrin repeat 
protein, has been shown to function as a feedback inhibitor of the pathway in Xenopus 
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and zebrafish, but was also reported to augment Notch-mediated transcriptional 
activation in cultured cells (Ishitani et al., 2005; Lamar et al., 2001). Trib2 is a kinase-like 
protein implicated in the pathogenesis of acute myelogenous leukemia and also reported 
to inhibit phosphorylation of Akt, a signaling molecule important in myogenesis (Du et 
al., 2003; Heron-Milhavet et al., 2007; Keeshan et al., 2006; Naiki et al., 2007; Wilson 
and Rotwein, 2007). Interleukin-6 is an inflammatory cytokine that is expressed in 
regenerating muscle and may promote satellite cell proliferation (Cantini et al., 1995; 
Kami and Senba, 1998). 
 cDNAs for Nrarp and Trib2 were cloned into the pBABE-puro retroviral 
expression vector, and individual viruses were used to infect C2C12 myoblasts. Resulting 
stable cell lines clearly expressed the specified transcripts, but exhibited normal induction 
of the early differentiation marker Myogenin when deprived of serum for 24 hours 
(Figure 2.11). Similar results were obtained when cells were infected with a retrovirus 
expressing the G22 cDNA (data not shown). C2C12 cells were also infected with 
retroviruses encoding FLAG-tagged Nrarp or Trib2, and protein expression was verified 
by Western blot (Figure 2.12A). Bands migrating at the appropriate mobility were 
detected in cells transduced with either of the two retroviruses, while the FLAG-Trib2 
signal ran at the same mobility as a non-specific background band (FLAG-Nrarp, ~20 kD 
(*), FLAG-Trib2, ~45 kD (**)). Induction of Myogenin and MHC proteins occurred 
normally in FLAG-Nrarp and FLAG-Trib2 cell lines over four days in DM (Figure 
2.12B). Fusion of myoblasts into myotubes after three days in differentiation medium 
was also unimpaired relative to that observed in the pBABE control cultures (Figure 
2.12C). Nrarp-transduced cells were also evaluated for their ability to induce Hey1 when 
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cultured on Fc-Dll4, testing the hypothesis that Nrarp is a feedback inhibitor of Notch 
signaling. While the induction of Hey1 was moderately reduced, this occurred at a level 
of Nrarp that exceeded that typically induced by ligand (data not shown). Thus, Nrarp 
does not appear to exert a significant effect on overall Notch signaling in our system. 
I also asked if IL-6 affects myogenesis. I observed a modest dose-dependent 
inhibition of Myogenin induction after serum withdrawal when cells were bathed in 
increasing concentrations of IL-6, with maximum inhibition of approximately two-fold 
occurring at a dose of 100 ng/ml (Figure 2.13). Given that this effect occurred only at 
high concentrations of the cytokine, which are likely to be supra-physiological, I am 
hesitant to ascribe a major role to IL-6 in mediating the effects of Notch in muscle, but do 
not rule out a potential contributory influence. 
 In contrast to the findings for Nrarp, Trib2, and G22, forced retroviral expression 
of MyoR resulted in a complete block to C2C12 myogenesis, consistent with a previous 
report that has implicated this bHLH protein as negative regulator of MyoD and of 
myogenic conversion of fibroblasts (Lu et al., 1999). MyoR-expressing myoblasts failed 
to induce Myogenin or Mef2C transcripts at 24 hours after serum withdrawal (Figure 
2.14A), showed no induction of Myogenin or MHC proteins over four days in 
differentiation medium (Figure 2.14B), and exhibited no evidence of fusion after three 
days in DM (Figure 2.14C). Expression of MyoR in these cells was verified by RT-PCR 
and Western blot analysis (Figure 2.14A-B). In parallel with these findings, I observed 
that ligand-mediated Notch signaling also induced expression of ABF-1, the human 
orthologue of MyoR, in primary human myoblasts (Figure 2.15). I conclude that Notch 
signaling strongly induces the expression of Nrarp, Trib2, G22, IL-6, and MyoR, but of 
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these, only constitutively expressed MyoR is sufficient to recapitulate the inhibition 
imposed by the pathway as a whole. 
 The precise manner by which MyoR expression is activated by Notch signaling 
remains an open question. Importantly, I have excluded the possibility that MyoR 
induction occurs downstream of Hey1, as MyoR RNA levels were essentially unchanged 
under conditions of Hey1 retroviral expression (data not shown). Bioinformatic analysis 
failed to reveal any conserved CSL binding sites within the MyoR 2kb proximal 
promoter, which was found to be unresponsive to NICD in luciferase reporter assays, but 
a far-upstream potential enhancer region containing three conserved CSL sites was 
responsive to NICD. However, mutation of these sites did not compromise NICD-
responsiveness (Figure 2.16). Accordingly, MyoR could well be an indirect target of 
Notch, but further studies will be needed to clearly define its mode of regulation. 
 
Knockdown of MyoR alone or in combination with Hey1 does not impair Notch 
activity 
 Given that constitutive expression of either Hey1 or MyoR mimicked the 
inhibitory effects of Notch in C2C12 cells, it appeared that Notch was acting through 
multiple pathways, and that perhaps no single gene target would be required for Notch to 
exert repression. To further test this notion, I performed an additional siRNA knockdown 
experiment to reduce the level of MyoR. Transfection of C2C12 cells with MyoR 
siRNAs, relative to control siRNAs, led to a significant reduction (>90 percent) in MyoR 
expression when cells were plated on Fc-Dll4 (Figure 2.17, top). In this experiment, a 
higher dose of Fc-Dll4 supernatant was employed relative to that depicted in Figure 2.7 
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to obtain robust induction of MyoR, a less sensitive Notch-responsive gene than Hey1. 
The reduced level of MyoR, however, did not compromise the ability of Notch to repress 
the induction of Myogenin (Figure 2.17, bottom), or of two additional markers, Mef2C 
and Myh3 (Figure 2.18). This result is consistent with our previous data indicating that 
Hey1 appears sufficient to account for the effects of Notch on early myogenesis; in the 
absence of MyoR, Hey1 would be expected to compensate. 
 To investigate the existence of any additional MyoR- and Hey1-independent 
pathways, I employed siRNAs to simultaneously knock-down both Hey1 and MyoR 
expression. Transfection of C2C12 cells with this mixture of siRNAs resulted in >85 
percent reduction of both Hey1 and MyoR RNA levels when cultures were plated on Fc-
Dll4 (Figure 2.19, top). Despite the drastically reduced levels of Hey1 and MyoR, 
exposure to Fc-Dll4 still effectively repressed induction of Myogenin at 24 hours in DM 
(Figure 2.19, bottom). Similar results were obtained when cultures were taken out to 
three days in DM and analyzed for Myh3 induction (Figure 2.20), with the caveat that 
knock-down efficiency had declined to ~65 percent. Myoblast fusion at four days in DM 
also continued to be repressed in cultures treated with Hey1/MyoR siRNAs and plated on 
Fc-Dll4 (Figure 2.21). While I cannot rule out the possibility that low levels of residual 
Hey1 or MyoR are sufficient to block myogenesis, our data suggest that Notch signaling 
inhibits myogenesis through multiple pathways, and that yet additional mediators beyond 
Hey1 and MyoR are likely to contribute to the pathway’s biological effects in our system. 
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DISCUSSION 
 
 Notch signaling was shown over a decade ago to inhibit myogenesis in cultured 
cells and more recently to prevent the premature differentiation of muscle progenitor cells 
and satellite cells in-vivo (Conboy and Rando, 2002; Kopan et al., 1994; Lindsell et al., 
1995; Schuster-Gossler et al., 2007; Vasyutina et al., 2007). However, the molecular 
pathways through which Notch exerts its inhibitory effects have not been clearly defined. 
My results provide evidence that Notch acts through multiple pathways to repress 
myogenesis. Notch induced the expression of a multitude of genes in cultured myoblasts, 
and individual constitutive expression of at least two of them, Hey1 and MyoR, was 
sufficient to block (or significantly delay) myogenesis. Consistent with a model in which 
no single factor downstream of Notch is required for myogenic inhibition, siRNA 
knockdown experiments directed against either Hey1 or MyoR revealed that significantly 
reducing the dosage of either of these factors had no appreciable effect on the ability of 
Notch to exert repression. Intriguingly, even simultaneous knockdown of both Hey1 and 
MyoR did not appear to rescue repression by Notch in any substantial fashion, suggesting 
the existence of additional contributory factors downstream of the pathway. 
 Notch affects myogenesis at an early step, inhibiting the induction of Myogenin 
and Mef2C. While MyoD expression levels were moderately reduced in cells exposed to 
Notch ligands, the extent of this down-regulation was not as severe as previously reported 
(Kuroda et al., 1999) and is unlikely to account for the complete block to myogenesis. 
Rather, it appears that Notch primarily functions to antagonize the ability of MyoD to 
activate downstream myogenic target genes. Since past work has shown that MyoD can 
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induce its own expression (Thayer et al., 1989), the observed reduction in MyoD RNA 
levels may reflect an indirect consequence of compromised MyoD transcriptional 
activity. Interestingly, Notch signaling led to a three-fold increase in Myf-5 transcripts. 
This induction could potentially reflect either the direct action of NICD on the Myf-5 
promoter, or an indirect effect of reduced MyoD expression, as Myf-5 levels are also 
elevated in the MyoD knockout mouse (Rudnicki et al., 1992). Whether the skewed 
expression pattern of increased Myf-5 (and reduced MyoD) has any functional 
significance in our system remains an open question. At least one report has argued that 
Myf-5 may be inherently less potent than MyoD as a driver of the differentiation program 
in vitro (Ishibashi et al., 2005), although apparently compensates adequately for MyoD in 
vivo (Rudnicki et al., 1992). Elevated Myf-5 expression levels alone do not appear to 
exert a negative impact on myogenesis, as forced retroviral expression of Myf-5 in 
C2C12 cells was compatible with normal differentiation (data not shown). 
 Members of both the Hes and Hey (HRT, HERP, CHF) families of bHLH 
repressors can be induced by Notch. In agreement with others (Shawber et al., 1996), 
Hes1 was expressed in C2C12 cells, but poorly induced, and was not effective at 
blocking myogenesis (Shara Kabak, unpublished observation). Other Hes family 
members were not appreciably induced. By contrast, all three members of the Hey 
family, Hey1, Hey2 and HeyL, were induced by Fc-Dll4, but the overall level of Hey2 
was very low. Constitutive expression of Hey1 repressed myogenesis while, surprisingly, 
HeyL had no effect. This argues that, despite a high level of structural similarity, the 
biological activities of the Hey proteins are distinct. Hey2, when expressed as a FLAG-
tagged construct, did exhibit the ability to repress myogenesis (Figure 2.5); however, 
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given the very low level of endogenous Hey2 transcript induced by Fc-Dll4, I do not 
consider Hey2 to be a significant player in the mediating the effects of Notch in this 
system. My results do, however, implicate Hey1 as a potentially important Notch effector 
in myoblasts. My data showing that a reduced level of Hey1 has no effect on the response 
of cells to Notch were therefore unexpected. This was true even at levels of Notch 
signaling that only partially induced Hey1 and partially restricted Myogenin induction. 
 In contrast to a simple model of Notch acting primarily to induce the transcription 
of Hes or Hey family members, my expression screen revealed over 82 transcripts that 
were upregulated after only six hours of ligand stimulation. Several strongly induced 
genes did not inhibit myogenesis when tested functionally by constitutive expression 
(Nrarp, Trib2, G22). However, whether or not these genes play any functional role in 
muscle remains to be determined. For example, it is possible that these genes exhibit little 
impact when expressed individually, but will affect myogenesis when expressed in 
combination. Despite this possibility, my screen suggests that Notch may generally 
induce a large number of genes, but employ only specific subsets of these to execute the 
pathway’s effects in different cell types. 
 Importantly, my work has identified MyoR as a novel Notch-responsive gene that 
appears to contribute to myogenic repression. MyoR was originally identified in a screen 
for cDNAs with homology to capsulin, another bHLH transcription factor (Lu et al., 
1999). MyoR exhibits a skeletal muscle-specific pattern of embryonic expression and has 
been shown to antagonize the activity of MyoD in reporter assays and bind to E-box 
DNA elements in vitro. Accordingly, it was suggested that this bHLH inhibitor functions 
to delay the progression of myogenesis during development. MyoR was also found to be 
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induced during muscle regeneration, arguing for an additional role in satellite cells (Zhao 
and Hoffman, 2006). ABF-1, the putative human orthologue of MyoR, was cloned 
concurrently from activated B-cells (Massari et al., 1998), suggesting muscle-
independent functions. 
 My data are consistent with a model in which Notch signaling acts through at 
least two myogenic inhibitors, Hey1 and MyoR, to repress myoblast differentiation in 
culture. It is tempting to speculate that these same proteins may also represent important 
arms of the Notch pathway during embryonic and/or post-natal myogenesis in-vivo. 
Impairment of Notch activity results in premature progenitor cell differentiation in the 
embryo and compromised satellite cell proliferation in the adult (Conboy et al., 2003; 
Schuster-Gossler et al., 2007; Vasyutina et al., 2007). While knockout mice deficient for 
either Hey1 or MyoR have been generated and do not exhibit overt embryonic muscle 
phenotypes (Fischer et al., 2004; Lu et al., 2002), the absence of such defects in single-
knockout animals is consistent with a model in which multiple factors downstream of 
Notch contribute to the pathway’s phenotypic effects. It has been observed that Hey1 and 
MyoR collaborate with related transcription factors, Hey2 and Capsulin, respectively.  
Hey1 and Hey2 act redundantly in the embryonic vasculature (Fischer et al., 2004), while 
MyoR and Capsulin function redundantly in the formation of the facial musculature (Lu 
et al., 2002). Preliminary in-situ hybridization studies have revealed a striking overlap in 
the expression patterns of Hey1 and MyoR in E10.5 embryos (Figure 2.22), a finding 
consistent with both distinct and coordinate regulation of these two genes. 
 In light of the results from my double knockdown experiment (Figures 2.19-2.21), 
it appears likely that additional factors beyond Hey1 and MyoR are important in 
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contributing to Notch-mediated inhibition of myogenesis. The large number of Notch-
responsive genes identified by my array is consistent with the notion that Notch activates 
an extensive gene network in order to execute its critical functions in muscle. My follow-
up studies have shown that at least two additional Notch-responsive genes, when 
constitutively expressed, can recapitulate the block to C2C12 differentiation. First, 
consistent with a previous report (Atherton et al., 1996), I demonstrated that forced 
expression of the HLH protein Id3 inhibited myogenesis (Figure 2.23). Id proteins, which 
lack a basic domain and cannot bind DNA, are thought to function by forming inactive 
heterodimers with E proteins or MyoD (Benezra et al., 1990; Jen et al., 1992). Notch 
activity has also been linked to Id3 induction in Xenopus (Reynaud-Deonauth et al., 
2002). Second, I later showed that another gene identified by the array, the transcription 
factor GATA3, was indeed induced by Notch in C2C12 cells (Figure 2.24) and also 
repressed differentiation (Figures 2.25 & 2.26). The work of others revealed that Notch 
can induce GATA3 in T cells (Amsen et al., 2007; Fang et al., 2007), but an inhibitory 
role for this protein in myogenesis has not been previously reported. Interestingly, 
GATA3 binding sites are present within the Myogenin and Mef2C promoters, but the 
mechanism by which this factor represses myogenic transcription remains to be 
determined. While the levels of Id3 and GATA3 induction observed in our system in 
response to Fc-Dll4 are relatively modest, these factors, in combination with other Notch-
responsive genes, such as IL-6, or even the negligible level of Hey2 induced by ligand 
stimulation, may indeed participate in myogenic repression. 
 The positioning of activated Notch as the hub of a transcriptional network 
containing multiple effectors, many of which may contribute functionally to the 
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pathway’s biological effects, is likely to be applicable to tissues other than muscle. 
Generally, such a framework may serve to render any one particular target of a signaling 
cascade dispensable for the overall phenotypic consequences of the pathway. In the 
mammalian nervous system, it appears that the transcriptional repressors Hes1 and Hes5 
represent the primary mediators of the pathway’s inhibitory effects on differentiation 
(Ohtsuka et al., 1999). By contrast, in the epidermis, Notch acts directly through both 
Hes1 and the cell cycle inhibitor p21 (Mammucari et al., 2005; Rangarajan et al., 2001). 
The specific targets (nodes) employed by Notch may differ from tissue to tissue, but the 
principle of functional redundancy could represent a general feature that ensures a robust 
signaling response. Redundancy and associated robustness are critical attributes of 
complex physiological systems that enhance their capacity to evolve (Kirschner and 
Gerhart, 1998). 
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Chapter III. The Notch Effector Hey1 Associates with 
Myogenic Target Genes to Repress Myogenesis 
 
ABSTRACT 
 
 Members of the Hey family of transcriptional repressors are basic helix-loop-helix 
proteins that are thought to act downstream of Notch in diverse tissues. While forced 
expression of Hey1, a target of Notch in myoblasts, is sufficient to recapitulate the 
pathway’s inhibitory effects on differentiation, how Hey1 interferes with myogenic 
transcription has not been fully elucidated. I provide multiple lines of evidence that Hey1 
does not target the intrinsic transcriptional activity of the skeletal muscle master regulator 
MyoD. My results indicate instead that Hey1 is recruited to the promoter regions of 
Myogenin and Mef2C, two genes whose induction is critical for myogenesis. Expression 
of Hey1 in C2C12 myoblasts correlates with reduced recruitment of MyoD to these 
promoters, arguing that Hey1 inhibits myogenesis by associating with and repressing 
expression of key myogenic targets.  
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RESULTS 
 
 My previous work suggested that ligand-mediated Notch signaling acts through 
multiple pathways to repress myogenesis (Chapter II). I next sought to determine how 
individual Notch effectors inhibit the myogenic transcriptional program. I focused my 
initial analysis on Hey1, as the molecular mechanisms by which Hey proteins function in 
specific biological contexts are not well understood. While induction of Hey1 was not 
required for Notch-mediated inhibition, this finding likely reflects the fact that Hey1 
functions together or in parallel with other repressors (eg. MyoR, Id3, or GATA3) to 
mediate the effects of Notch. In systems where functional redundancy may be a defining 
feature, it is only by unraveling the modes of action of individual effectors that we can 
reach a complete understanding of the pathway as a whole. 
 
Hey1 does not repress intrinsic MyoD transcriptional activity 
 Past studies have demonstrated that Hey1 inhibits MyoD-mediated myogenic 
conversion of cultured fibroblasts (Sun et al., 2001) and the differentiation of C2C12 
myoblasts (Chapter II). An important question relates to whether this inhibition reflects a 
generalized block to MyoD-driven transcription, or rather a selective targeting of 
individual myogenic promoters. To address this, I performed transfection assays in 
10T1/2 fibroblasts. When these cells are transfected with a vector expressing MyoD, they 
convert to a muscle phenotype and express a wide array of myogenic transcripts. I 
reasoned that if Hey1 were repressing the inherent ability of MyoD to activate gene 
expression, the induction of all targets downstream of MyoD should be compromised in 
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the presence of Hey1. Two of the earliest markers activated in this system are the cell 
adhesion molecule Cadherin-15 and the muscle regulatory factor Myogenin. While 
transfection of 10T1/2 cells with a MyoD-expression plasmid robustly induced both of 
these genes, as expected, co-expression of Hey1 inhibited the induction only of 
Myogenin, and not Cadherin-15 (Figure 3.1). This apparent specificity in Hey1-mediated 
repression was also observed in luciferase reporter assays. Two reporter constructs were 
employed, one consisting of the proximal 133-bp Myogenin promoter (G133-luciferase), 
and the other composed simply of four high-affinity MyoD consensus E-box elements 
linked to a minimal promoter (4RE-tk-luciferase). 4RE-tk-luciferase has been used 
previously as a readout of “pure” MyoD activity, as this construct does not contain 
binding sites for any MyoD cofactors, such as Mef2 (Lu et al., 2000). While MyoD 
robustly induced both reporters, Hey1 repressed the induction only of G133-luciferase, 
and not 4RE-tk-luciferase (Figure 3.2). Together, these results strongly suggest that 
Hey1’s inhibitory effects on myogenesis reflect promoter-specific repression of select 
myogenic targets, rather than generalized inhibition of MyoD activity.  
 
Hey1 does not form dimers with MyoD or E47 or disrupt endogenous MyoD:E47 
complexes 
 While the above functional data revealed that not all MyoD-responsive promoters 
are subject to repression by Hey1, a past report had proposed that Hey1 targets MyoD 
itself, by sequestering it into inactive heterodimers (Sun et al., 2001). To revisit this 
proposal, I evaluated whether Hey1 associates with MyoD or its binding partner E47 to 
repress myogenic transcription. I first performed co-immunoprecipitation assays in which 
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I overexpressed either MyoD in combination with E47 or Hey1 (Figure 3.3), or E47 in 
combination with MyoD or Hey1 (Figure 3.4). 293T cells were used for these 
experiments, as they allow for very high transfection efficiencies and levels of expressed 
proteins, raising the likelihood that even weak interactions can be detected. These studies 
confirmed the expected binding of MyoD to E47 (Figure 3.3, lane 5; Figure 3.4, lane 5) 
but failed to reveal any evidence of association between either of these factors and Hey1 
(Figure 3.3, lane 6; Figure 3.4, lane 6). The ability of Hey1 to dimerize with itself was 
verified independently using the Hey1 construct employed in these assays in combination 
with a Myc-tagged Hey1 (data not shown). 
 In parallel, I used electrophoretic mobility shift assays (EMSAs) to determine 
whether forced expression of Hey1 in C2C12 myoblasts would disrupt the formation of 
endogenous MyoD:E47 complexes. Nuclear extracts were prepared from C2C12 cells 
stably transduced with either the pBABE-puro or pBABE-FLAG-Hey1 retrovirus. As a 
control, I examined extracts of control 293T cells or 293T cells co-transfected with 
MyoD and E47 expression plasmids. When these 293T extracts were incubated with a 
radio-labeled probe containing a high-affinity E-box, complexes corresponding to 
MyoD:E47 heterodimers were readily observed (Figure 3.5A, compare lanes 2 and 3). A 
MyoD antibody shifted the mobility of the complexes, confirming that they contain 
MyoD (lane 4). Similar complexes were observed in the C2C12 cell extracts (Figure 
3.5A, lanes 5-8). Importantly, these complexes were not appreciably affected by the 
presence of Hey1 (compare lanes 5 and 6 to lanes 7 and 8). The complex migrating just 
below what I tentatively identify as MyoD homodimers in extracts from the pBABE-
transduced cells was not shifted by a MyoD antibody, but was shifted with a Myogenin 
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antibody (data not shown). As expected, this complex was not observed in extracts from 
Hey1-expressing cells, consistent with the lack of Myogenin protein (Figure 3.5B). Taken 
together, our results indicate that Hey1 does not disrupt MyoD:E47 heterodimers, a 
finding in agreement with our initial functional data demonstrating promoter-specific 
repression by Hey1. 
 
A role for Mef2C inhibition in Hey1-mediated repression of myogenesis 
 Our previous results (Figures 3.1 & 3.2) showed that Hey1 inhibits MyoD-
mediated induction of the endogenous Myogenin gene and a transfected Myogenin 
promoter, but not the endogenous Cadherin-15 gene or a transfected E-box-driven 
reporter. I sought to investigate the basis for this specificity. Past work in cultured 
fibroblasts by Tapscott and colleagues demonstrated that Cadherin-15, but not Myogenin, 
is transcriptionally induced by MyoD in the absence of new protein synthesis (Bergstrom 
et al., 2002). This finding suggested that MyoD must collaborate with a secondary 
mediator or coactivator to activate Myogenin transcription. Indeed, other studies revealed 
that Myogenin induction, which is absolutely required for myogenesis in vivo, requires 
both MyoD and Mef2 proteins (Edmondson et al., 1992; Hasty et al., 1993; Nabeshima et 
al., 1993). Mef2C is itself a target of MyoD (Dodou et al., 2003; Wang et al., 2001) and 
has been shown to be the only Mef2 family member transcriptionally upregulated upon 
differentiation in C2C12 cells (Figure 2.1B). I considered the possibility that Hey1 
represses myogenesis primarily by repressing Mef2C activity and/or Mef2C gene 
transcription, not the Myogenin promoter per se. To explore this possibility, I first 
confirmed that Mef2 is critical for Myogenin promoter activity. Indeed, mutation of the 
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single Mef2 element within the Myogenin proximal promoter dramatically reduced 
MyoD-stimulated reporter activity (Figure 3.6). I next asked if Hey1 affects Mef2C 
activity. I transfected 10T1/2 cells with a Mef2C expression vector along with a reporter 
consisting of three Mef2 DNA binding elements upstream of a minimal promoter driving 
luciferase. Induction of this reporter by Mef2C was unaffected by increasing amounts of 
Hey1, indicating that Hey1 does not inhibit Mef2C transcriptional activity per se (Figure 
3.7A). By contrast, transcriptional induction of the endogenous Mef2C gene by MyoD 
was significantly repressed by Hey1 (Figure 3.7B), a result consistent with those obtained 
with Hey1-transduced C1C12 cells (Figure 2.4A). 
 If Hey1 functions primarily by repressing Mef2C expression, then one would 
expect exogenous Mef2C to rescue Hey1-mediated repression of Myogenin. Reporter 
assays revealed that repression of the Myogenin promoter was reduced, but not 
eliminated by a Mef2C expression plasmid (Figure 3.8). These data suggest that 
inhibition of Mef2C expression likely contributes to Hey1-mediated repression of 
myogenesis, but that Hey1 may also function through additional inhibitory mechanisms. 
 
Evaluation of in-vitro DNA binding by Hey1 to myogenic promoter elements 
 I next asked if Hey1 inhibits transcription by binding DNA within target gene 
promoters. As a first step, I determined the ability of Hey1 to bind elements within the 
Myogenin and Mef2C proximal promoters in vitro. Prior studies employing SELEX 
approaches derived an optimum binding site for Hey1, which is the E-box CACGTG. 
Closely related variants of this sequence bind Hey1 less well (Fischer et al., 2002; Iso et 
al., 2001b; Pichon et al., 2004). The 133-bp Myogenin promoter contains a single E-box 
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(E1, CAGTTG), with an additional E-box (E2, CACATG) and N-box (N1, CACCAG) 
located within the 400bp proximal to the start site. The Mef2C minimum promoter 
contains a single E-box (2C, CAGGTG). I performed EMSAs using in vitro transcribed 
and translated (TNT) Hey1-V5 and a labeled probe containing the Hey1 consensus E-box 
(HCE). The Hey1 complex ran with the same mobility as a complex present in TNT 
lysates, so I evaluated Hey1 binding after shifting the complex to a slower mobility with 
an anti-V5 antibody (Figure 3.9, lanes 1-3). As expected, addition of cold HCE 
competitor, but not mutant HCE, completely eliminated the binding of Hey1 to labeled 
probe (lanes 4-5). Addition of competitor DNA containing the various E-boxes and N-
box found in the Myogenin and Mef2C promoters only marginally reduced formation of 
the Hey1 complex, despite a 50X molar excess of cold DNA (Figure 3.9, lanes 6-9). 
Other reports have also failed to show association of Hey1 with the high-affinity MyoD 
E-box (CAGGTG) (Fischer et al., 2002; Pichon et al., 2004). These data argue against 
robust DNA binding by Hey1 to known control elements within these myogenic 
promoters. Consistent with this conclusion, when I mutated the E1 site within the 
Myogenin promoter and carried out reporter assays in 10T1/2 cells, Hey1 still repressed 
MyoD-induced activity, indicating that inhibition is independent of this particular E-box 
(Figure 3.10). Efforts to map Hey1-responsive elements in the Myogenin promoter 
distinct from those necessary for induced activity were unsuccessful (data not shown). 
 
Evidence for association of Hey1 with the Myogenin and Mef2C promoters in vivo 
 Despite the above findings in vitro, I sought to determine if Hey1 associates with 
the Myogenin and Mef2C promoters in vivo. Chromatin immunoprecipitation (ChIP) 
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assays yielded inconsistent and variable results; accordingly, I turned to DamID, an assay 
that is better suited for detecting potentially weak or indirect interactions with DNA in 
vivo (van Steensel and Henikoff, 2000, 2003). In this assay, a protein of interest is fused 
with the bacterial DNA adenine methyltransferase (Dam) and then expressed at low 
levels in mammalian cells. If the chimeric protein associates with particular regions of 
DNA, then only the targeted DNA becomes methylated since mammalian cells lack Dam. 
Methylated regions are revealed on the basis of cutting by the methylation-specific 
restriction enzyme DpnI and subsequent amplification of digested fragments (Reddy et 
al., 2008; Vogel et al., 2007). This assay is capable of detecting even transient and weak 
interactions between the chimeric proteins and their target DNA. 
 I generated lentiviruses that express MyoD-Dam and Hey1-Dam. Expression and 
activity of the fusion proteins were confirmed with Western immunoblots and reporter 
assays, respectively (Figure 3.11). When transiently transfected, the pLgw-based 
lentiviral vectors employ a strong CMV promoter to drive high-level expression. This 
promoter is deleted following infection and integration, and subsequent low-level 
expression from the virus DNA is controlled by an un-induced heat shock promoter. I 
infected C2C12 cells with individual lentiviruses, and genomic DNA was isolated and 
processed (see Materials and Methods). Amplified (i.e. methylated) DNA was 
interrogated for genes of interest using quantitative PCR. Cells infected with a Dam-only 
virus were used to control for background methylation. As expected, cells infected with 
the MyoD-Dam virus gave rise to a ~3 fold relative increase in methylation in the vicinity 
of the Myogenin and Mef2C promoters, but not in the vicinity of the GAPDH promoter 
or immunoglobulin heavy-chain (IgH) enhancer (Figure 3.12A). Importantly, cells 
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infected with the Hey1-Dam virus also generated significantly increased relative 
methylation (~12 fold) in the vicinity of the Myogenin and Mef2C promoters (Figure 
3.12B). These data indicate that Hey1 associates specifically with the Myogenin and 
Mef2C genes, and this likely leads to their transcriptional repression. 
 I next asked if targeting of Hey1 has consequences for the recruitment of MyoD. I 
transduced C2C12 cells with either a pBABE-puro or a pBABE-FLAG-Hey1 retrovirus 
and switched the cultures from growth medium to differentiation medium for 40 hours. I 
then used ChIP to evaluate the recruitment of MyoD to the Myogenin and Mef2C 
promoters in each group of cells. I observed a reduction in MyoD recruitment in cells 
transduced with FLAG-Hey1 relative to those harboring the parental virus (Figure 3.13). 
As expected, Pol II recruitment was also reduced at the Myogenin promoter (Pol II was 
not detected at the Mef2C promoter for unknown reasons). Only negligible recruitment of 
either factor was observed at the silent immunoglobulin heavy-chain enhancer, which 
was used to normalize the data. Reduced MyoD recruitment in vivo is not likely to result 
from the downregulation of MyoD expression by Hey1, as MyoD RNA levels were only 
marginally reduced (Figure 3.14), and MyoD:E47 heterodimers were still observed in 
Hey1-expressing C2C12 cells (Figure 3.5). I conclude that forced expression of Hey1 
results in compromised recruitment of the master regulator MyoD to its target gene 
promoters. 
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DISCUSSION 
 
 Hey1 is one of several transcription factors downstream of Notch activation 
which may contribute to the pathway’s inhibitory effects in muscle. In this portion of my 
thesis, I sought to determine the mechanism by which this canonical Notch effector 
mediates transcriptional repression. My studies on Hey1 support a model in which this 
bHLH inhibitor primarily functions by binding in the vicinity of the Myogenin and 
Mef2C promoters to shut off target gene expression. I present three independent and 
complementary lines of evidence that are consistent with this model and argue against a 
proposal that Hey1 sequesters MyoD into inactive heterodimers (Sun et al., 2001). First, 
MyoD-mediated induction of a direct MyoD target gene (Cadherin-15) or of an E-box-
driven reporter (4RE-tk-luc) was resistant to repression by Hey1. Second, MyoD did not 
form heterodimers with Hey1 under the conditions of my co-immunoprecipitation assays, 
yet readily formed heterodimers with E47 as expected. Importantly, Hey1 did form 
homodimers. Third, MyoD:E47 heterodimers were unaffected in cells expressing Hey1, 
despite the inability of these cells to differentiate. While the basis for the discrepancy 
with a previous study (Sun et al., 2001) is currently unknown, my combination of 
functional and biochemical data strongly argue that Hey1 does not repress the intrinsic 
ability of MyoD to activate transcription. 
 Since Hey1 repressed the induction of Myogenin but not Cadherin-15, I sought to 
determine the basis for this promoter specificity. Past work had implicated the Mef2 
family of transcription factors as critical mediators of Myogenin induction, in particular 
Mef2C (Dodou et al., 2003; Edmondson et al., 1992; Wang et al., 2001). While Hey1 did 
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not inhibit Mef2C activity, it did repress Mef2C expression, suggesting that repression of 
Myogenin might be due to the lack of Mef2C protein. However, forced expression of 
Mef2C only partially restored Myogenin promoter activity in the presence of Hey1, 
suggesting additional mechanisms. Indeed, DamID assays showed that Hey1 associates 
with both the Mef2C and Myogenin promoter regions, indicating that its ability to inhibit 
myogenesis may be due to the repression of multiple myogenic loci. 
 The work presented here raises several additional mechanistic questions of 
interest. If Hey1 associates with DNA in proximity to the Myogenin and Mef2C 
transcriptional start sites, where exactly does this binding occur, through what 
intermediates if any, and how does Hey1’s presence translate into transcriptional 
silencing? The resolution of DamID has been reported to be ~1 kb at best (Greil et al., 
2006) and thus cannot be used to identify specific binding sites occupied by Hey1 within 
these target promoters. My EMSA data argue that Hey1 is not likely to bind directly to E-
boxes or N-boxes at these loci, leaving open the possibility that Hey1 may associate 
instead through distinct DNA-bound regulatory proteins. Aside from MyoD and Mef2, 
additional transcription factors such as Pbx1/Meis, MSY-3, Six1/4, and Ski also 
participate in the complex transcriptional control of the Myogenin locus (Berghella et al., 
2008; Berkes et al., 2004; Spitz et al., 1998; Zhang and Stavnezer, 2009). Hypothetically, 
Hey1 could interact with any of these or other factors present at the Myogenin promoter. 
An intriguing possibility is that Hey1 functions in conjunction with GATA proteins, 
specifically GATA3. As noted previously, GATA3 is induced by Notch in C2C12 cells 
and inhibits differentiation when constitutively expressed. Past work in other systems has 
demonstrated physical interactions between Hey1 and GATA proteins (Elagib et al., 
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2004; Fischer et al., 2005; Kathiriya et al., 2004). If GATA3 is found to associate with 
GATA binding sites in the Myogenin and/or Mef2C promoters, this factor could 
potentially serve as an adaptor protein for Hey1 recruitment. 
 Hey1’s presence at these loci appears linked to a reduction in MyoD recruitment, 
but how this occurs remains to be determined. Importantly, expression of Hey1 in C2C12 
cells did not significantly reduce expression of MyoD or its inherent ability to bind a 
target E-box in-vitro. Under one scenario, Hey1 could alter local chromatin structure by 
recruiting histone modifying enzymes such as HDACs, and thereby impede MyoD 
recruitment. Hey proteins have been shown to bind HDACs in vitro (Iso et al., 2001b), 
but many studies have indicated Hey-mediated repression is insensitive to trichostatin A 
(Elagib et al., 2004; Fischer et al., 2005; Garg et al., 2005; Nakagawa et al., 2000), 
calling into question the relevance of such associations. Furthermore, I found that Hey1 
failed to significantly repress a reporter construct in which the 133-bp Myogenin 
proximal promoter fragment was fused to a strong basal thymidine kinase promoter (data 
not shown). Repression of the nearby TK promoter would be expected if Hey1 were 
binding to this DNA and recruiting HDACs. Under a different scenario, by associating 
with myogenic promoters, Hey1 might sterically occlude access of MyoD to its target E-
box or interfere with its binding to Pbx1/Meis, homeodomain proteins postulated to 
facilitate initial (weak) recruitment of MyoD to the Myogenin locus (Berkes et al., 2004). 
 While these questions require additional investigation, my data provide strong 
evidence that Hey1 functions by physically associating with the promoter regions of two 
critical myogenic genes, Myogenin and Mef2C. Previous reports have often proposed 
that Hey family proteins silence transcription via protein-protein interactions with 
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transcriptional activators, but seldom demonstrated association with target gene 
promoters (Fischer and Gessler, 2007). My results using the sensitive DamID technique 
imply that such protein-protein interactions may often serve to tether Hey proteins to 
promoter regions rather than simply to sequester transcription factors away from DNA. 
Given that Mef2C is required for Myogenin induction, I initially explored the possibility 
that the Mef2C promoter alone may be the primary target of Hey1-mediated repression. 
Instead, my results indicate that Hey1 acts on both promoters, perhaps as a means to 
reinforce or lock in the repressed state through redundant mechanisms. It remains to be 
seen whether Hey1 also directly targets a much broader set of myogenic promoters, or 
whether specific features of the Myogenin and Mef2C loci render them uniquely 
receptive to Hey1 recruitment. 
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Chapter IV. Perspective and Future Directions 
 
 In total, my work has revealed an unanticipated level of complexity in the 
molecular regulation of skeletal myogenesis by the Notch signaling pathway. Contrary to 
past proposals that Notch functions simply by inducing the expression of the canonical 
targets Hes1 or Hey1, my results suggest that multiple effectors downstream of Notch 
activation likely contribute to myogenic repression. Some of these, like Hey1, appear to 
target specific critical promoters rather than silencing generalized MyoD transcriptional 
activity. The apparent redundancy of multiple mediators and the potential diversity of 
inhibitory mechanisms underscore the critical role that the Notch pathway plays in the 
developmental and regenerative biology of skeletal muscle. 
 When considered in the context of the Notch transcriptional network in muscle, 
my results on Hey1 suggest that individual Notch effectors may function through distinct 
yet complementary mechanisms to shut down myogenic gene expression. In contrast to 
Hey1, which appears to exert promoter-specific repression of myogenesis via association 
with key target loci, past studies on MyoR and Id3 have demonstrated that these factors 
directly repress the inherent activity of MyoD, the master regulator. As mentioned 
previously, Id3 likely acts by sequestering MyoD or E2A proteins into inactive 
heterodimers (Benezra et al., 1990; Jen et al., 1992). MyoR has similarly been reported to 
titrate E2A away from MyoD, but also directly binds E-box DNA elements in vitro (Lu et 
al., 1999). My own data on MyoR were largely consistent with these past findings 
(Figures 4.1-4.3). I found that MyoR dimerizes with E47 but not MyoD, binds to an E-
box probe in vitro, and represses MyoD-mediated induction of both the Myogenin 
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promoter and a pure E-box-driven reporter. Whether ligand-induced levels of MyoR and 
Id3 are sufficient to bring about these effects on MyoD remains an open question. 
Interestingly, formation of endogenous MyoD:E47 complexes in C2C12 cells was not 
significantly affected by ligand stimulation (Figure 4.4). This finding suggests that 
endogenous levels of MyoR and Id3, if important for myogenic inhibition, may 
potentially act through mechanisms different from those described for the constitutively 
expressed proteins. 
 In light of the above results, one general limitation of my work relates to the use 
of constitutive overexpression in the functional analysis of Notch-responsive genes. 
While my studies revealed that at least four such genes (Hey1, MyoR, Id3, Gata3) can 
mimic the inhibitory effects of the pathway in muscle, my stably transduced cell lines 
expressed these genes at levels substantially higher than those observed following ligand-
based stimulation. Just as past work has revealed that NICD overexpression can result in 
the activation of target genes not induced by Notch ligands (Iso et al., 2001a), so the use 
of overexpressed effectors could result in artifactual functional effects on differentiation. 
To address this concern, future studies will invoke an inducible system, in which 
expression levels of stably integrated transgenes can be finely tuned to more faithfully 
recapitulate ligand-mediated signaling. This approach will enable me to determine if 
expression of a given individual target at physiological levels is indeed sufficient to 
mimic Notch activation. 
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Functional studies in primary myoblast cultures and mice 
 A central future endeavor will be to extend my results in C2C12 cells to primary 
myoblast cultures and in vivo mouse models. While C2C12 cells exhibit many of the core 
properties of myoblasts in vivo, this cell line has undoubtedly undergone changes as a 
consequence of immortalization and extended culturing over three decades, and cannot be 
assumed to recapitulate all aspects of myoblast or satellite cell biology. Indeed, one 
important observation made by Rando and colleagues was that Notch activation in 
cultured primary myoblasts resulted in increased cellular proliferation (Conboy and 
Rando, 2002). Work from our own lab, by contrast, has failed to detect a significant 
effect of ligand-mediated stimulation on cell number or cell cycle exit in C2C12 cells; 
furthermore, forced cell cycle exit via p21 adenoviral infection failed to rescue the block 
to myogenesis (Shara Kabak, unpublished observations). If the proliferative effect of 
NICD reported by Rando can be validated with ligand-based Notch signaling in primary 
myoblasts, it would be interesting to revisit the possibility that Notch may function in 
part by promoting the cell cycle to inhibit differentiation. 
 Along these lines, an intriguing feature of my array list of Notch-induced genes 
was the presence of three growth factor receptors: epidermal growth factor receptor 
(EGFR), leukemia inhibitory factor receptor (LIFR), and platelet-derived growth factor 
receptor β (PDGFRβ). Furthermore, the cytoplasmic protein MIG6, a known inhibitor of 
EGFR (Zhang et al., 2007), was one of the few genes that was downregulated by ligand-
mediated signaling. Induction of these cell-surface receptors by Notch (and repression of 
receptor inhibitors) might sensitize dividing satellite cells or myogenic progenitors to 
locally circulating growth cues and help maintain the proliferative, undifferentiated state. 
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In C2C12 cells, I validated EGFR and MIG6 as Notch-responsive genes by RT-PCR 
(Figure 4.5). I found that forced expression of EGFR is not sufficient to recapitulate the 
Notch-mediated block to differentiation observed in low serum medium (DM), although 
EGFR did sensitize cells to EGF-mediated inhibition (Figure 4.6). Given that 
immortalized C2C12 cells do not exhibit a proliferative response to Notch, a top priority 
will be to determine if constitutive expression of these growth factor receptors in primary 
myoblasts, preferably at levels induced by Notch ligands, phenocopies the effects of 
Notch activation; conversely, I will examine if siRNA knockdown of these receptors or 
their pharmacological inhibition impairs Notch-mediated responses. Interestingly, two 
studies in the past year have also reported EGFR as a target of Notch in different settings. 
Fine and colleagues demonstrated that Notch upregulates EGFR expression in human 
gliomas, potentially contributing to the pathway’s oncogenic effects (Purow et al., 2008). 
Bray and colleagues, by contrast, showed that Notch directly induces EGFR in the 
Drosophila muscle cell line DmD8 (Krejci et al., 2009). Consistent with the growth factor 
model proposed above, further studies demonstrated that antagonism of EGFR signaling 
or loss of Notch function both result in premature differentiation of adult muscle 
progenitors in the fly (Krejci et al., 2009). 
 Beyond EGFR, the cytokine interleukin-6 (IL-6) is another validated Notch-
responsive gene on my array list that deserves reexamination. While exposure of C2C12 
cells to high levels of IL-6 had only modest inhibitory effects on differentiation (Figure 
2.13), recent work has established a genetic requirement for IL-6 in satellite cell 
proliferation in vivo (Serrano et al., 2008). Interestingly, past reports have demonstrated 
that CSL associates with the IL-6 promoter in vitro (Kannabiran et al., 1997; Palmieri et 
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al., 1999; Vales and Friedl, 2002), suggesting that this gene could be directly activated by 
Notch. It will be important to assess whether IL-6 levels increase upon muscle injury in a 
Notch-dependent fashion, as induction of this cytokine may represent yet another 
mechanism by which Notch could enhance the proliferative response of satellite cells. 
This could be tested by injecting a Notch inhibitor into injured muscle, as Rando and 
colleagues have described (Conboy et al., 2003), and examining local IL-6 production.  
 It remains to be determined whether the same Notch-responsive genes shown to 
repress myogenesis in our in vitro system also account for key functions of Notch during 
in vivo muscle development and regeneration. Single knockout animals for Hey1, MyoR, 
and Id3 exhibit no overt skeletal muscle defects (Fischer et al., 2004; Lu et al., 2002; Pan 
et al., 1999), suggesting that these effectors either play no role in myogenic development, 
or function redundantly with each other or additional factors. GATA3 null mice die 
during gestation (Pandolfi et al., 1995), necessitating the generation of a muscle-specific 
conditional mutant. One approach would be to cross the normal single knockouts above 
to generate double or triple knockout animals, and assess the formation of embryonic 
skeletal muscle. If these effectors are critical for Notch function, the expected phenotype 
would mirror that observed in the conditional CSL knockout or Dll1 null/hypomorph 
heterozygote—premature progenitor cell differentiation and ultimate muscle hypotrophy 
(Schuster-Gossler et al., 2007; Vasyutina et al., 2007). If the animals survive post-natally, 
muscle regenerative capacity could be evaluated following injury, with the expectation of 
compromised repair due to reduced satellite cell activation. Before initiating such studies, 
however, I would first opt for functional analyses of these and other Notch-responsive 
genes in primary myoblast cultures, as described above. If, for example, the EGF 
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receptor, alone or in combination with other effectors is shown to be critical for enhanced 
myoblast proliferation and impaired differentiation downstream of Notch activation, this 
gene and its partners would instead become the new focus for future in vivo explorations. 
 
Expression profiling of the temporal response to Notch activation 
 While my array list of Notch-responsive genes in C2C12 myoblasts provided a 
solid starting point to probe the transcriptional output of the pathway in muscle, it 
remains possible that important targets were missed due to the selection of an early 6-
hour time point. I chose this time point to bias the list of genes towards direct targets of 
the pathway and indeed captured several known CSL-dependent primary Notch effectors 
(Nrarp, Hey1, HeyL). To fully flesh out the broader scope of transcriptional changes 
downstream of ligand-mediated signaling, however, the gene profiling analysis should be 
extended to a time-course over 12-48 hours. Notch typically functions as a transcriptional 
cascade, in which primary targets like Hes/Hey proteins act as repressors to shut off 
expression of a set of secondary targets. However, in some cases, secondary or indirect 
targets may also be induced, perhaps as a consequence of “feed-forward” collaboration 
between NICD and one of its primary effectors. For example, in Th2 cells, Notch 
activates expression of GATA3, which then synergizes with NICD to induce the 
transcription of the cytokine IL-4 (Fang et al., 2007). In muscle, MyoR induction may 
reflect an analogous mode of regulation, as its expression is delayed relative to that of 
Hey1 and HeyL (Figure 4.7). By examining an extended temporal window following 
ligand stimulation, I would gain a clearer sense of secondary expression changes in 
muscle, whether positive or negative, which could offer important functional insights into 
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the mechanisms of myogenic inhibition. My current list revealed only five genes, mostly 
not well characterized, whose expression declined after 6 hours, suggesting that this time 
point was too early to detect most secondarily repressed targets. Another interpretation, 
however, is that some genes targeted for repression by primary effectors may be silent by 
default in myoblasts, prior to differentiation, and hence would not be detected by my 
arrays (eg. Myogenin or Mef2C). One way to circumvent this problem would be to 
activate Notch signaling in cultures that had already initiated differentiation, and identify 
the specific transcripts that decline in abundance after a short duration (whether Notch 
activity can in fact reverse or impair the myogenic transcriptional program once initiated 
must first be verified). 
 
Further functional analysis of Notch-responsive genes 
 One of the strategic questions I faced in my thesis project was how to functionally 
evaluate the list of genes obtained from my array experiment. The straightforward path 
that I chose was first to determine which individual genes out of a restricted subset were 
sufficient, when constitutively expressed in C2C12 cells, to phenocopy Notch-mediated 
repression of differentiation. Subsequently, I employed siRNAs against one or more 
genes capable of inhibition, in an attempt to define the set of effectors essential for the 
pathway’s function. This approach had two main limitations, beyond the use of 
constitutive retroviral overexpression. First, cloning individual cDNAs into a retroviral 
construct and generating stable cell lines was a time- and labor-intensive process that 
severely limited the number of genes I could realistically test for function. Second, my 
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functional screening evaluated only single genes in parallel, without addressing potential 
combinatorial, collaborative actions of multiple targets. 
 In the future evaluation of this array data set or subsequent ones, I would consider 
alternative approaches. To address the above concerns, I would seek out higher-
throughput strategies to functionally screen through the induced genes on my list. The 
cost of purchasing cDNA clones ready for use in expression plasmids has dropped 
significantly, which would facilitate the quick acquisition of a much larger pool of 
cDNAs. As a first pass, rather than relying on stable cell line creation, I would likely 
perform luciferase reporter assays in cultured myoblasts to screen for the ability of 
individual or multiple Notch-responsive genes to inhibit MyoD-mediated activation of a 
Myogenin reporter construct (G133-luciferase), a robust readout of the combined 
activities of MyoD and Mef2. Use of this readout should capture most potential inhibitors 
of the myogenic transcriptional program, as MyoD and Mef2 represent the central drivers 
of transcription in muscle. While results from this initial screen would rely on transient 
transfections and consequently on high levels of expressed gene products, I would then 
move to a system of stable inducible expression in C2C12 myoblasts. A subset of genes 
that exhibited the strongest inhibitory activity would be expressed under the control of a 
TET-inducible retroviral promoter, to dial down expression to ligand-induced levels. 
Ideally, this strategy would even allow for the assessment of potential synergistic or 
collaborative effects between a pair of effectors expressed off vector backbones with 
different selectable markers. 
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Examination of potential post-transcriptional effects of Notch 
 Notch activates a transcriptional cascade, and hence most of my efforts have been 
focused on identifying and investigating the function of genes upregulated in response to 
ligand-mediated signaling. Past work, however, has revealed that Notch signaling can 
also orchestrate the ubiquitin-mediated proteasomal degradation of various transcription 
factors, such as E2A and Tal1/SCL (Nie et al., 2008; Nie et al., 2003). Exactly how 
Notch facilitates the destruction of these proteins has not been elucidated, but such post-
transcriptional effects may represent indirect consequences of Notch-mediated 
transcription. Indeed, reduced protein stability of E2A and Tal1/SCL was shown to 
depend on CSL function, suggesting that Notch may directly activate genes involved in 
the ubiquitination pathway. While transcription downstream of Notch likely remains the 
common denominator, these studies suggest that phenotypic consequences of Notch 
activity in some instances reflect alterations in protein stability. In future work, I would 
like to test the hypothesis that Notch signaling in muscle functions in part to promote (or 
inhibit) the protein turnover of selected targets. My own work has shown that the effect 
of Notch on E2A reported in lymphocytes appears to be tissue-specific, as ligand-
mediated signaling in C2C12 myoblasts did not affect E47 protein levels (Figure 4.8). 
Nevertheless, other components of the myogenic program could potentially be targeted 
post-transcriptionally. 
 To determine if Notch alters the stability of cellular proteins in proliferating 
myoblasts, I would invoke a recently described high-throughput system devised by 
Elledge and colleagues, called global protein stability profiling (Yen et al., 2008). This 
approach relies on the use of fluorescence-activated cell sorting (FACS) and microarray 
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analysis to infer the stability of a vast number of proteins simultaneously. In basic terms, 
the system employs a retroviral reporter construct that expresses a bicistronic message 
with an internal ribosome entry site (IRES). This message codes for two fluorescent 
proteins, a control protein DsRed, and a fusion protein between EGFP and a protein of 
interest (X). Since these proteins are expressed off the same RNA, they should be 
produced at the same ratio in transduced cells, and the EGFP/DsRed ratio reflects the 
stability of protein X. A cDNA library in this retroviral vector is employed to generate 
viruses and infect cells at low multiplicity of infection to make reporter cell collections. 
The cell library is fractionated by FACS into several pools based on increasing 
EGFP/DsRed ratios. Stability of a given protein “X” is inferred based on the distribution 
of cells expressing the protein X-EGFP fusion within the different pools (cells expressing 
a high-stability protein would be most concentrated in the pool with the highest ratio). 
High-throughput determinations are made possible by PCR-amplification of integrated 
virus-ORF identifier sequences from genomic DNA of sorted sub-pools and the total cell 
library; microarrays are then used to quantify the representation of each cDNA in a given 
sub-pool relative to the total cell population. 
 To apply this technology to my specific question, I would generate a C2C12 
reporter cell library. One pool of library cells would be propagated on Fc-control ligands, 
and another on Fc-Dll4. Clone distribution profiles for each condition would be 
determined following cell library fractionation by FACS and microarray analysis. If a 
particular protein exhibited altered stability in the presence of an active Notch signal, this 
change would be reflected in a modified distribution of cells expressing that fusion 
protein in the fractionated pools. Assuming I am able to identify such targets, I would 
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first validate a subset of them by ascertaining the stability of the endogenous proteins via 
more traditional methods, such as pulse-chase experiments. Additional studies would be 
guided by several questions: Are these proteins functionally important in myogenesis? Is 
altered stability mediated through the ubiquitin-proteasome pathway? Does the effect 
depend on CSL-directed transcription? 
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Chapter V. Materials and Methods 
 
Plasmids 
Plasmids expressing the extracellular domains of Dll4 and Trail Receptor4 as Fc-fusion 
proteins were provided by Dr. Marion Dorsch (Millennium Pharmaceuticals, Cambridge, 
MA).  Retroviral vectors encoding FLAG-tagged Hey1, Hey2, and HeyL were generated 
by sub-cloning the murine cDNAs, provided by Dr. Eric Olson (University of Texas), 
into the EcoRI site of the multiple cloning site of pBABE-puro-FLAG. Retroviral vectors 
for Nrarp, Trib2, and MyoR were generated by PCR amplification of the respective 
cDNAs from Notch ligand-stimulated C2C12 myoblasts followed by insertion into 
pBABE-puro at the BamHI/SalI sites (Nrarp) or the BamHI/EcoRI sites (Trib2, MyoR). 
The MyoR cDNA was also subcloned into the BamH1/EcoR1 sites of the expression 
vectors pcDNA-6X-Myc and pcDNA3.1-V5/HisA (Invitrogen, Carlsbad, CA). FLAG-
tagged Nrarp and Trib2 were generated by PCR-subcloning the respective cDNAs into 
the SalI site (Nrarp) or EcoRI site (Trib2) of pBABE-puro-FLAG. G22Riken cDNA was 
obtained from Invitrogen (Carlsbad, CA) (clone 2649431) and sub-cloned by PCR into 
the BamHI/EcoRI sites of pBABE-puro. pBABE-HA-Id3 was generated by sub-cloning 
the HA-Id3 cDNA from RSV-HA-Id3 into the EcoRI site of pBABE-puro. The GATA3 
retroviral vector was generated by PCR-subcloning the murine GATA3 cDNA, provided 
by Dr. Steve Reiner, into the EcoRI site of pBABE-puro-FLAG. The human EGFR 
cDNA, provided by Dr. Mark Lemmon, was excised from pcDNA3.1-EGFR using the 
PmeI and XhoI restriction sites and ligated into the SnaBI and SalI sites of pBABE-puro. 
MyoR reporter constructs were generated by PCR amplification of the indicated elements 
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from BAC RP23-398C14 (Invitrogen, Carlsbad, CA) followed by ligation into the 
KpnI/BglII sites of pGL3-basic (CR1), the KpnI/BglII sites of pGL2-promoter (CR2), or 
the KpnI site of pGL2-promoter (CR3). Three CSL sites present within CR3 were 
mutated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) as 
follows: CSL site #1 was changed from “TTCCCACA” to “GGTACCCA”; CSL site #2 
was changed from “TTCCCACG” to “GGTACCCG”; CSL site #3 was changed from 
“TTCCCA” to “TGTACA”. CMV-NICD has been described previously (Ross and 
Kadesch, 2001). 
 G133-luciferase was provided by Vittorio Sartorelli (National Institutes of Health) 
and contains the 133-bp Myogenin proximal promoter fused to luciferase (Xu and Wu, 
2000). pcDNA3.1-Mef2C (α1ß splice isoform) and 3x-Mef2-tk-luciferase were provided 
by Tod Gulick (Harvard Medical School). 3x-Mef2-tk-luciferase contains three copies of 
a Mef2 binding element fused to a minimal thymidine kinase (tk) promoter driving firefly 
luciferase (Zhu and Gulick, 2004). pEMSV-MyoD and 4RE-tk-luciferase were provided 
by Eric Olson (University of Texas). 4RE-tk-luciferase contains 4 copies of the MCK 
enhancer right E-box fused to a minimal tk promoter driving firefly luciferase (Lu et al., 
2000). pcDNA3.1-TOPO-Hey1-V5 was generated by inserting the Hey1 cDNA 
(provided by Eric Olson) into the TOPO recognition site of pcDNA3.1D/V5-His-TOPO 
(Invitrogen, Carlsbad, CA). pcDNA3.1-Hey1-V5 was generated by PCR sub-cloning the 
Hey1 cDNA into the BamHI/EcoR1 sites of pcDNA3.1-V5/HisA (Invitrogen). G133-
mutMef2-luciferase and G133-mutE1-luciferase were generated by QuikChange-
mediated mutagenesis of the G133-luciferase Mef2 element (from [CTATATTTAT] to 
[CTATACTTTAT] (Edmondson et al., 1992)) or E1 element (from [CAGTTG] to 
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[AATTCG]), respectively. CMV-E47 has been described (Shen and Kadesch, 1995). 
DamID lentiviral vectors pLgw-RFC1-V5-EcoDam and pLgw-V5-EcoDam (Vogel et al., 
2007) were provided by Bas Van Steensel (Netherlands Cancer Institute). pLgw-MyoD-
V5-EcoDam and pLgw-Hey1-V5-EcoDam were generated via the Gateway 
recombination system (Invitrogen, Carlsbad, CA). The MyoD and Hey1 cDNAs were 
first sub-cloned by PCR into the Gateway entry vector pENTR-3C. Resulting entry 
clones were then recombined using LR Clonase II with the lentiviral destination vector 
pLgw-RFC1-V5-EcoDam. pVSVG, pGag/Pol, and pRSV-REV were provided by Carl 
June (University of Pennsylvania). All plasmids generated by PCR were verified by 
sequencing. 
 
Cell culture 
C2C12 myoblasts, C3H 10T1/2 fibroblasts, and 293T cells were cultured in Dulbecco’s 
modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) 
supplemented with L-glutamine and penicillin-streptomycin (growth medium, GM). 
Human skeletal muscle myoblasts (SkMC and HSMM) were purchased from Cambrex 
(East Rutherford, NJ) and maintained as directed by the manufacturer. For differentiation 
of myoblasts, cells were grown to near confluence and then shifted to DMEM containing 
0.5% FBS (differentiation medium, DM). 
 Notch signaling was induced by exposing the cells to immobilized ligand. 
Conditioned medium was first prepared from 293T cells transfected with plasmids coding 
for fusion proteins between Fcγ of human IgG and either the extracellular domain of 
Notch ligand Delta-like-4 (Fc-Dll4) or that of Trail Receptor 4 (Fc-control). Culture 
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plates were initially coated for 1 hour at room temperature with 10 µg/ml anti-Fc 
antibody (Jackson Immunoresearch, West Grove, PA). The anti-Fc PBS solution was 
then aspirated and replaced by filtered conditioned medium described above. Following 1 
hour incubation, supernatant was aspirated and cells were plated.   
 
Transfections and luciferase assays 
10T1/2 cells were transfected according to the FuGENE 6 protocol (Roche Diagnostics,  
Indianapolis, IN). For quantitative RT-PCR experiments, cells were seeded at a density of 
5x104 cells per well in 6-well plates and transfected with a total of 1.5 µg of DNA per 
well (pcDNA3.1/V5-HisA empty vector was used to keep the total amount of DNA 
constant). Cultures were maintained in growth medium (GM) for 1 day post-transfection 
and then switched to differentiation medium (DM) for 24 hours prior to isolation of 
RNA. For luciferase assays, cells were seeded at a density of 1x104 cells per well in 24-
well plates and transfected with a total of 300 ng DNA. Cultures were maintained for 1 
day in GM post-transfection and then switched to DM for 24 hours prior to harvesting of 
lysates. Luciferase activity was determined using the Dual-Luciferase Reporter Assay 
System (Promega, Madison, WI). Transfections were normalized to Renilla luciferase 
(pRL-TK; Promega). 
 
Microarray expression screen 
2.5x106 C2C12 cells were plated on 10-cm dishes coated with either Fc-Dll4 or Fc-
control ligand (2.5 ml per dish) and grown in GM for 6 hours. RNA was harvested with 
the RNeasy Kit (Qiagen, Valencia, CA). Three replicates were included for each 
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condition. RNA was submitted to the University of Pennsylvania Microarray Core 
Facility for subsequent transcript profiling analysis on Affymetrix MOE430v2.0 
GeneChip arrays. Raw data was processed at the Penn Bioinformatics Core Facility using 
Array Assist Lite (Stratagene, La Jolla, CA), Spotfire (Tibco, 
Somerville, MA), and Significance Analysis of Microarrays (Stanford University). 
 
Retroviral infections 
Infections were performed as previously described (Pear et al., 1993) with minor 
modifications. Briefly, retroviral supernatants were harvested from 293T cells two days 
following FuGENE6 (Roche Diagnostics, Indianapolis, IN)-mediated transfection with 8 
µg of the indicated pBABE vector and 2 µg of gag/pol and env helper plasmids. 
Supernatants were filtered (0.4 µm) to remove non-adherent 293T cells prior to direct use 
or storage at –80ºC. 18-24 hours prior to infection, C2C12 cells were plated on 6-well 
plates at a density of ~1x105 cells/well. Each well was incubated for 4-6 hours with 1.5 
ml viral supernatant supplemented with 8 µg/ml polybrene. 24-48 hours following 
infection and subsequent re-plating on 10-cm dishes, selection was initiated with 2 µg/ml 
puromycin and continued for 3-5 days to obtain stable lines. 
 
siRNA knockdown 
C2C12 cells were transfected with 100-150 nM of the indicated SMARTpool siRNA 
oligonucleotides purchased from Dharmacon (Lafayette, CO). Transfections were 
performed as specified by the manufacturer using the Dharmafect#3 reagent. Briefly, 
myoblasts were plated on 12-well dishes at a density of ~1x104 cells per well the day 
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prior to transfection. One day post-transfection, cells were trypsinized and re-plated on 
ligand-coated 12-well plates. Wells were coated with 400 µl of Fc-control supernatant 
and either 15 µl (Figures 2.7 & 2.8), 100 µl (Figures 2.17 & 2.18), or 80 µl (Figures 2.19-
2.21) of Fc-Dll4 supernatant; the total ligand volume on Fc-Dll4-coated wells was kept 
constant (400 µl) by mixing Fc-control supernatant as required. Cultures were switched 
from GM to DM one day following re-plating and harvested for RNA after an additional 
24-72 hours as indicated. For the double knockdown, a mixture of 110 nM Hey1 siRNA 
and 40 nM MyoR siRNA was employed. 
 
Semi-quantitative and quantitative RT-PCR 
Total RNA was isolated from C2C12 cultures using the RNeasy kit (Qiagen, Valencia, 
CA). 0.125 to 2 µg of RNA was used to generate cDNA with the High Capacity cDNA 
Archive Kit (Applied Biosystems, Foster City, CA). For semi-quantitative RT-PCR, 5% 
of the cDNA was included in each PCR reaction. Products were run out on 1.5% agarose 
gels and visualized by ethidium bromide staining. For quantitative PCR, TaqMan gene 
expression assays were employed for MyoD, Myf-5, Myogenin, Mef2C, Myh3, Hey1, 
Hey2, HeyL, MyoR, IL-6, Id3, ABF-1, Cadherin-15, GATA3, EGFR, MIG6, and 18S as 
an endogenous control (Applied Biosystems). 1-4% of a given cDNA reaction, 10 µl of 
2X Taq Universal Mastermix, and 1 µl of the indicated 20X TaqMan assay were included 
in a 20 µl reaction volume per well. All reactions were performed in triplicate. Results 
were analyzed using the SDS2.2 Software (Applied Biosystems). Primer sequences used 
for SQ-RT-PCR are as follows:  
HPRT 5’-GTTGGATACAGGCCAGACTTTGTTG-3’ and 
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 5’-TGGGGACGCAGCAACTGACATTTCT-3’;   
Myogenin 5'-GCGGACTGAGCTCAGCTTAAG-3' and 
 5'- GCTGTCCACGATGGACGTAAG-3';  
MEF2A, 5'-TTGGAATGAACAGTCGGAAAC-3' and 5'-
CTAGTCCCTGTGGAGGCAAG-3’;  
MEF2C, 5'-GAGAAGCAGAAAGGCACTGG-3' and 5'-
ATCTCACAGTCGCACAGCAC-3’;  
MEF2D, 5'-AGCTCTCTGGTCACTCCTTCC-3' and 5'-
GCCCTGGCTGAGTAAACTTG-3'; 
GAPDH, 5'-AACGGATTTGGTCGTATTGGG-3' and 
 5'-TGGAAGGATGGTGATGGGATTTC-3'; 
Hey1 5’- GAAGCGCCGACGAGACCGAATCAA-3’ and 
 5’-CAGGGCGTGCGCGTCAAAATAACC-3’; 
Hey2 5'-CGACGTGGGGAGCGAGAACAAT-3’ and 
5'-GGCAAGAGCATGGGCATCAAAGTA-3'; 
HeyL 5’- GGTCCCCACTGCCTTTGAGA-3’ and 
 5’- TAGCTGACTGCTCAGGGAAGGCAA-3’;  
Nrarp 5’- TGGTGAAGCTGTTGGTCAAG-3’ and 5’- 
GTAGTTGGCGGGAAGGTACA-3’;  
IL-6 5’- CCGGAGAGGAGACTTCACAG-3’ and 5’- 
GGAAATTGGGGTAGGAAGGA-3’; 
Trib2 5’- GCAACATCAACCAAATCACG-3’ and 5’- 
GCGTCTTCCAAACTCTCCAG-3’; 8430408G22Rik 5’-CTCCTGCCACCCTGACTG-
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3’ and 5’- TGGGCTGTGACCTTGTCC-3’; MyoR (Figures 2.9 & 2.10) 5’-
GCTACGAGGACAGCTATGTGC-3’ and 
 5’-AGGAGGGCAAACAACACTTG-3’;  
MyoR (Figure 2.14) 5’-GGGAGGATGCAAGAGGAAG-3’ and 
 5’-CGTCCAGAGACCACGAATG-3’; 
Id3 5’-GCCTCTTGGACGACATGAA-3’ and 5’-GGCGTTGAGTTCAGGGTAAG-3’. 
 
Western immunoblot analysis 
Protein lysates for Western blots were prepared from cultured cells using RIPA lysis 
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS) or a modified lysis buffer (10 mM Tris pH 7.3, 150 mM NaCl, 1% NP-40) 
supplemented with freshly added protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, IN), 10 mM sodium fluoride, and 400 µM sodium orthovanadate. Lysates 
were incubated on ice for 15 minutes and cleared by centrifugation. Protein 
concentrations were determined using the DC Assay (Bio-Rad, Hercules, CA). 25-50 µg 
of lysate was added to 2X or 6X SDS sample buffer and boiled for 5 minutes prior to 
analysis by SDS-PAGE. Proteins were transferred to nitrocellulose and blotted with the 
following antibodies at the indicated dilutions: 1:1000 ß-tubulin (Sigma T-5293, St. 
Louis, MO), 1:500 Myogenin (Santa Cruz M-225, Santa Cruz, CA), 1:20 MHC (MF20, 
Developmental Studies Hybridoma Bank), 1:2000 cleaved Notch1 (Cell Signaling 2421, 
Danvers, MA), 1:500 FLAG (Abcam ab6711-200, Cambridge, MA) or 1:1000 FLAG 
(Sigma M2), 1:500 MyoR (Santa Cruz M-20), 1:5000 anti-Mre11 (Novus NB 100-
142G1, Littleton, CO), 1:500 anti-GFP (Santa Cruz sc-8334), 1:1000 anti-E47 
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(BD/Pharmingen G127-32, San Jose, CA). After incubation with 1:2000 dilutions of 
HRP-conjugated anti-rabbit, anti-mouse, or anti-goat secondary antibodies (Amersham, 
Piscataway, NJ), bands were visualized via the LumiLight or LumiLight-plus detection 
system (Roche, Indianapolis, IN). 
 
Co-immunoprecipitation assays 
For immunoprecipitations, 293T cells were harvested ~48 hours post-transfection by 
scraping into lysis buffer (20 mM Tris-HCl pH 8.0, 100 mM KCl, 0.1% NP-40, 5 mM 
MgCl2, 10% glycerol) supplemented with freshly added protease inhibitor cocktail 
(Roche Diagnostics, Indianapolis, IN), 10 mM sodium fluoride, and 400 µM sodium 
orthovanadate (Iso et al., 2001b). Lysates were incubated on ice for 15 minutes and 
cleared by centrifugation. Protein concentrations were determined using the DC Assay 
(Bio-Rad Laboratories, Hercules, CA). Lysates were pre-cleared in lysis buffer 
supplemented with 50 µl proteinA/G PLUS-agarose and 4 µg normal rabbit IgG (Santa 
Cruz Biotechnology sc-2027, Santa Cruz, CA) for 2 hours at 4°C. 500 µg of pre-cleared 
lysate was incubated with 2 µg of anti-MyoD (Novocastra 5.8A, Newcastle upon Tyne, 
United Kingdom), anti-E47 (BD/Pharmingen G127-32, San Jose, CA), or anti-Myc 
(Santa Cruz Biotechnology sc-40 9E10, Santa Cruz, CA) antibody and 15 µl of protein 
A/G PLUS-agarose at 4°C overnight. Immune complexes were washed 4X with lysis 
buffer, eluted in 2X SDS sample buffer, and boiled for 5 minutes prior to resolution by 
SDS-PAGE. Proteins were transferred to nitrocellulose and blotted with the following 
antibodies at the indicated dilutions: 1:5000 anti-V5 (Invitrogen, Carlsbad, CA), 1:1000 
anti-E47 (BD/Pharmingen), 1:500 anti-MyoD (Novocastra 5.8A), 1:1000 anti-Myc 
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(Santa Cruz 9E10). After incubation with a 1:2000 dilution of HRP-conjugated anti-
mouse secondary antibody (Amersham, Piscataway, NJ), bands were visualized via the 
LumiLight or LumiLight-plus detection system (Roche Diagnostics, Indianapolis, IN). 
 
Electrophoretic mobility shift assays (EMSAs) 
Nuclear extracts for EMSAs were prepared from 293T or C2C12 cells using the 
NXTRACT CelLytic NuCLEAR Extraction Kit (Sigma, St. Louis, MO). 293T cells were 
transiently transfected with either 2 µg EMSV-MyoD and 2 µg CMV-E47, or 4 µg 
pcDNA3.1/Myc-HisC (Invitrogen, Carlsbad, CA), 48 hours prior to harvesting of 
extracts. C2C12 cells seeded on Fc-control or Fc-Dll4 ligands or stably transduced with 
pBABE-puro or pBABE-FLAG-Hey1 were maintained in 0.5% serum for 24 hours prior 
to extract isolation. Hey1-V5 was transcribed and translated in-vitro using the TNT T7 
Coupled Reticulocyte Lysate System (Promega, Madison, WI). 32P-labeled 
oligonucleotide probes containing the Mef2C E-box (Wang et al., 2001) or the Hey1 
consensus target E-box (Fischer et al., 2002; Pichon et al., 2004) were prepared by end-
labeling annealed oligonucleotides with [γ-32P] ATP using T4 polynucleotide kinase 
(New England Biolabs, Ipswich, MA). Labeled probes were purified through G-25 Quick 
Spin Sephadex Columns (Roche Diagnostics, Indianapolis, IN) as specified by the 
manufacturer. 8 µg of nuclear extract or 8 µl of TNT lysate was incubated for 15 minutes 
at room temperature with 100,000 cpm of probe in a 15 µl binding reaction consisting of 
0.2-1.0 µg poly dI:dC, 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, and 
5.4% glycerol. Prior to addition of probe, extract was pre-incubated in binding buffer at 
room temperature for ten minutes. Where indicated, 50X excess of cold competitor probe 
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was added to the reaction. For supershifts, 1 µg of anti-MyoD (Novocastra 5.8A, 
Newcastle upon Tyne, United Kingdom) or 1 µg of anti-V5 (Invitrogen) antibody was 
added to the sample and incubated for an additional 15 minutes. Binding reactions were 
run out on 5% non-denaturing polyacrylamide TBE Ready Gels (Bio-Rad Laboratories, 
Hercules, CA) in 0.5X TBE. Gels were dried and visualized by autoradiography. 
Oligonucleotide sequences used for the generation of labeled probes and cold competitors 
are as follows, with E-boxes or N-boxes underlined: MEF2C.F 
GAGTGACATGAACAGGTGCACCCTGGCCT; MEF2C.R 
AGGCCAGGGTGCACCTGTTCATGTCACTC; HCE.F 
TCCAATGGCACGTGCCACTGCC; HCE.R GGCAGTGGCACGTGCCATTGGA; 
ΔHCE.F TCCAATGGGCCGTACCACTGCC; ΔHCE.R 
GGCAGTGGTACGGCCCATTGGA; E1.F CACCCAGCAGTTGGTGTGAG; E1.R 
CTCACACCAACTGCTGGGTG; N1.F TGCCCTGTCCACCAGCTGCCTTG; N1.R 
CAAGGCAGCTGGTGGACAGGGCA; E2.F 
GAAGGGGAATCACATGTAATCCACTG; E2.R 
CAGTGGATTACATGTGATTCCCCTTC. 
 
DamID 
DamID assays were carried out essentially as described (Vogel et al., 2007), with minor 
modifications. Briefly, lentiviral supernatants were harvested from 10-cm dishes of 293T 
cells on three consecutive days, two days following FuGENE6 (Roche Diagnostics, 
Indianapolis, IN)-mediated transfection with 10 µg of the indicated pLgw lentiviral 
vector, 3.5 µg of pVSVG, 6.5 µg of pGag/Pol, and 2.5 µg of pRSV-REV. Supernatants 
146
 90
were filtered (0.4 µm) to remove non-adherent 293T cells prior to storage at –80ºC. ~18 
hours prior to infection, C2C12 cells were plated on 6-well plates at a density of 1x105 
cells/well. Each well was incubated overnight with 1.5 ml viral supernatant, diluted ~2:1 
in growth medium. After removal of virus, cultures were maintained for two days in GM 
and then switched to DM for an additional 24 hours. Genomic DNA was isolated with the 
DNeasy Tissue Kit (Qiagen, Valencia, CA). Following ethanol precipitation of gDNA, 
DpnI digestion, ligation of adaptors, DpnII digestion, and ligation-mediated PCR (11 
cycles of amplification in the final stage of PCR), samples were purified with Qiagen 
columns and diluted 1:60 in buffer EB prior to Q-PCR analysis (Reddy et al., 2008). 8 µl 
of a diluted sample was mixed with 10 µl 2X Power-SYBR green mastermix (Applied 
Biosystems, Foster City, CA), 1 µl of 2 µM forward primer, and 1 µl of 2 µM reverse 
primer. PCR primers were first tested on genomic DNA via semi-quantitative PCR to 
verify amplification of a single product of the expected size. Q-PCR reactions were also 
subjected to dissociation curve analysis. Primer sequences are as follows: Myog.F 
GTGGACTGGCACAGGAGAAC; Myog.R GTGGACTTGGGACAAAGCAG; 
Mef2C.F GAGAAGCAGAAAGGCACTGG; Mef2C.R 
CATTTCCAGCTCACTCATCATC; IgH.F GTCATGTGGCAAGGCTATTTG; IgH.R 
TTTGCTCAGCCTGGACTTTC; GAPDH.F CTCACGTCCCAACTCTCCAC; 
GAPDH.R GGCCTCCTATAGTATCCCTCCTC.  
Primers for GAPDH and IgH are located directly within the proximal promoter and 
enhancer, respectively. Primers for Mef2C and Myogenin are located ~200 bp and ~700 
bp downstream of the transcriptional start sites, respectively, due to the unfavorable 
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distribution of DpnI sites within the promoter regions; DpnI-generated fragments larger 
than 2 kb are not efficiently amplified in the ligation-mediated PCR step.  
 
Chromatin immunoprecipitation assays 
chIP was performed as previously described (Caretti et al., 2004), with minor 
modifications. C2C12 cells stably transduced with pBABE-puro or pBABE-FLAG-Hey1 
were seeded on 15-cm dishes at a density of 1.25-1.4 x 106 cells per plate, maintained in 
GM for 2 days, and then switched to DM for 40 hours. Cultures were fixed in 1% 
formaldehyde for 10 minutes at room temperature, incubated for 5 minutes in 0.125 M 
glycine, washed twice in cold PBS, and scraped into 3 ml PBS. Following brief 
centrifugation, cell pellets were resuspended in 500 µl cell lysis buffer (5 mM Pipes pH 
8.0, 85 mM KCl, 0.5% NP-40) supplemented with 1 mM PMSF and protease inhibitor 
cocktail (Roche Diagnostics, Indianapolis, IN), incubated on ice for 10 minutes, and 
dounced 15X to facilitate nuclei release. After a 5-minute centrifugation at 5000 rpm, 
nuclei were resuspended in 300 µl nuclei lysis buffer (50 mM Tris-Cl pH 8.1, 10 mM 
EDTA, 1% SDS, 1 mM PMSF, protease inhibitor cocktail) and incubated on ice for 10 
minutes. Samples were sonicated in ice water using a Misonix 3000 sonicator for three 
10-second intervals interrupted by 1 minute rests, followed by a 10-minute centrifugation 
at 14,000 rpm at 4°C. Supernatants were transferred to clean tubes, diluted 1:10 with 
dilution buffer (0.5% Trition X-100, 2 mM EDTA, 20 mM Tris-Cl pH 8.1, 150 mM 
NaCl), and pre-cleared with protein A/G agarose-ssDNA (Upstate Biotechnology, 
Billerica, MA) for 2 hours. 250 µg pre-cleared chromatin was incubated with 4 µg of 
normal rabbit IgG (Santa Cruz sc-2027, Santa Cruz, CA), 4 µg of anti-MyoD (Santa Cruz 
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M-318X), or 4 µg anti-RNA-Pol II (Santa Cruz H-224X) antibody overnight with 
rotation at 4°C. Immune complexes were collected with BSA-blocked protein A/G 
agarose-ssDNA for 2 hours. Beads were washed eight times as follows: 2X buffer 1 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, pH 8.1, 150 mM NaCl), 2X 
buffer 2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, pH 8.1, 500 mM 
NaCl), 2X buffer 1, 1X buffer 3 (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM 
EDTA, 10 mM Tris, pH 8.1), 1X TE. Washed beads were incubated twice in 150 µl 
elution buffer (1% SDS, 100 mM NaHC03) for 15 minutes at 65°C. Pooled eluates were 
treated with DNase-free RNase (Roche Diagnostics, Indianapolis, IN) and incubated at 
65°C overnight to reverse crosslinks. Following proteinase K treatment, 
phenol:chloroform extraction, and ethanol precipitation, samples were analyzed by Q-
PCR. 2 µl of a 50 µl sample was mixed with 10 µl 2X Power-SYBR green mastermix 
(Applied Biosystems, Foster City, CA), 6 µl water, 1 µl of 2 µM forward primer, and 1 µl 
of 2 µM reverse primer. PCR primer sequences for the Myogenin promoter and IgH 
enhancer have been published (Bergstrom et al., 2002; Mal and Harter, 2003). Primers 
for the Mef2C promoter are as follows:  Mef2C.F2 GAGCAGTTCTGTGTTCTTTTGC; 
Mef2C.R2 ATCCCTCTGCACAAGTGTCTG. 
(Iso et al., 2003) 
 
149
 93
Chapter VI. References 
 
Amsen, D., Antov, A., Jankovic, D., Sher, A., Radtke, F., Souabni, A., Busslinger, M., 
McCright, B., Gridley, T., and Flavell, R.A. (2007). Direct regulation of Gata3 
expression determines the T helper differentiation potential of Notch. Immunity 27, 89-
99. 
Andres, V., and Walsh, K. (1996). Myogenin expression, cell cycle withdrawal, and 
phenotypic differentiation are temporally separable events that precede cell fusion upon 
myogenesis. J Cell Biol 132, 657-666. 
Artavanis-Tsakonas, S., Rand, M.D., and Lake, R.J. (1999). Notch signaling: cell fate 
control and signal integration in development. Science 284, 770-776. 
Atherton, G.T., Travers, H., Deed, R., and Norton, J.D. (1996). Regulation of cell 
differentiation in C2C12 myoblasts by the Id3 helix-loop-helix protein. Cell Growth 
Differ 7, 1059-1066. 
Bae, G.U., Kim, B.G., Lee, H.J., Oh, J.E., Lee, S.J., Zhang, W., Krauss, R.S., and Kang, 
J.S. (2009). Cdo binds Abl to promote p38alpha/beta mitogen-activated protein kinase 
activity and myogenic differentiation. Mol Cell Biol 29, 4130-4143. 
Bailey, A.M., and Posakony, J.W. (1995). Suppressor of hairless directly activates 
transcription of enhancer of split complex genes in response to Notch receptor activity. 
Genes Dev 9, 2609-2622. 
Barolo, S., Stone, T., Bang, A.G., and Posakony, J.W. (2002). Default repression and 
Notch signaling: Hairless acts as an adaptor to recruit the corepressors Groucho and 
dCtBP to Suppressor of Hairless. Genes Dev 16, 1964-1976. 
Barton-Davis, E.R., Shoturma, D.I., Musaro, A., Rosenthal, N., and Sweeney, H.L. 
(1998). Viral mediated expression of insulin-like growth factor I blocks the aging-related 
loss of skeletal muscle function. Proc Natl Acad Sci U S A 95, 15603-15607. 
Baylies, M.K., Bate, M., and Ruiz Gomez, M. (1998). Myogenesis: a view from 
Drosophila. Cell 93, 921-927. 
Benezra, R., Davis, R.L., Lockshon, D., Turner, D.L., and Weintraub, H. (1990). The 
protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59. 
150
 94
Berdnik, D., Torok, T., Gonzalez-Gaitan, M., and Knoblich, J.A. (2002). The endocytic 
protein alpha-Adaptin is required for numb-mediated asymmetric cell division in 
Drosophila. Dev Cell 3, 221-231. 
Berghella, L., De Angelis, L., De Buysscher, T., Mortazavi, A., Biressi, S., Forcales, 
S.V., Sirabella, D., Cossu, G., and Wold, B.J. (2008). A highly conserved molecular 
switch binds MSY-3 to regulate myogenin repression in postnatal muscle. Genes Dev 22, 
2125-2138. 
Bergstrom, D.A., Penn, B.H., Strand, A., Perry, R.L., Rudnicki, M.A., and Tapscott, S.J. 
(2002). Promoter-specific regulation of MyoD binding and signal transduction cooperate 
to pattern gene expression. Mol Cell 9, 587-600. 
Bergstrom, D.A., and Tapscott, S.J. (2001). Molecular distinction between specification 
and differentiation in the myogenic basic helix-loop-helix transcription factor family. 
Mol Cell Biol 21, 2404-2412. 
Berkes, C.A., Bergstrom, D.A., Penn, B.H., Seaver, K.J., Knoepfler, P.S., and Tapscott, 
S.J. (2004). Pbx marks genes for activation by MyoD indicating a role for a 
homeodomain protein in establishing myogenic potential. Mol Cell 14, 465-477. 
Bessho, Y., Miyoshi, G., Sakata, R., and Kageyama, R. (2001). Hes7: a bHLH-type 
repressor gene regulated by Notch and expressed in the presomitic mesoderm. Genes 
Cells 6, 175-185. 
Black, B.L., and Olson, E.N. (1998). Transcriptional control of muscle development by 
myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 14, 167-196. 
Blau, H.M., Pavlath, G.K., Hardeman, E.C., Chiu, C.P., Silberstein, L., Webster, S.G., 
Miller, S.C., and Webster, C. (1985). Plasticity of the differentiated state. Science 230, 
758-766. 
Blaumueller, C.M., Qi, H., Zagouras, P., and Artavanis-Tsakonas, S. (1997). Intracellular 
cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 90, 
281-291. 
Bober, E., Franz, T., Arnold, H.H., Gruss, P., and Tremblay, P. (1994). Pax-3 is required 
for the development of limb muscles: a possible role for the migration of dermomyotomal 
muscle progenitor cells. Development 120, 603-612. 
151
 95
Brack, A.S., Conboy, I.M., Conboy, M.J., Shen, J., and Rando, T.A. (2008). A temporal 
switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult 
myogenesis. Cell Stem Cell 2, 50-59. 
Brack, A.S., Conboy, M.J., Roy, S., Lee, M., Kuo, C.J., Keller, C., and Rando, T.A. 
(2007). Increased Wnt signaling during aging alters muscle stem cell fate and increases 
fibrosis. Science 317, 807-810. 
Braun, T., Bober, E., Winter, B., Rosenthal, N., and Arnold, H.H. (1990). Myf-6, a new 
member of the human gene family of myogenic determination factors: evidence for a 
gene cluster on chromosome 12. EMBO J 9, 821-831. 
Braun, T., Buschhausen-Denker, G., Bober, E., Tannich, E., and Arnold, H.H. (1989). A 
novel human muscle factor related to but distinct from MyoD1 induces myogenic 
conversion in 10T1/2 fibroblasts. EMBO J 8, 701-709. 
Braun, T., Rudnicki, M.A., Arnold, H.H., and Jaenisch, R. (1992). Targeted inactivation 
of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal 
death. Cell 71, 369-382. 
Briata, P., Forcales, S.V., Ponassi, M., Corte, G., Chen, C.Y., Karin, M., Puri, P.L., and 
Gherzi, R. (2005). p38-dependent phosphorylation of the mRNA decay-promoting factor 
KSRP controls the stability of select myogenic transcripts. Mol Cell 20, 891-903. 
Brou, C., Logeat, F., Gupta, N., Bessia, C., LeBail, O., Doedens, J.R., Cumano, A., Roux, 
P., Black, R.A., and Israel, A. (2000). A novel proteolytic cleavage involved in Notch 
signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5, 207-216. 
Bruckner, K., Perez, L., Clausen, H., and Cohen, S. (2000). Glycosyltransferase activity 
of Fringe modulates Notch-Delta interactions. Nature 406, 411-415. 
Cabrera, C.V. (1990). Lateral inhibition and cell fate during neurogenesis in Drosophila: 
the interactions between scute, Notch and Delta. Development 110, 733-742. 
Cantini, M., Massimino, M.L., Rapizzi, E., Rossini, K., Catani, C., Dalla Libera, L., and 
Carraro, U. (1995). Human satellite cell proliferation in vitro is regulated by autocrine 
secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes. 
Biochem Biophys Res Commun 216, 49-53. 
Caretti, G., Di Padova, M., Micales, B., Lyons, G.E., and Sartorelli, V. (2004). The 
Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle 
differentiation. Genes Dev 18, 2627-2638. 
152
 96
Carlson, B.M. (1973). The regeneration of skeletal muscle. A review. Am J Anat 137, 
119-149. 
Carlson, M.E., Hsu, M., and Conboy, I.M. (2008). Imbalance between pSmad3 and 
Notch induces CDK inhibitors in old muscle stem cells. Nature 454, 528-532. 
Cerletti, M., Jurga, S., Witczak, C.A., Hirshman, M.F., Shadrach, J.L., Goodyear, L.J., 
and Wagers, A.J. (2008). Highly efficient, functional engraftment of skeletal muscle stem 
cells in dystrophic muscles. Cell 134, 37-47. 
Cheng, T.C., Wallace, M.C., Merlie, J.P., and Olson, E.N. (1993). Separable regulatory 
elements governing myogenin transcription in mouse embryogenesis. Science 261, 215-
218. 
Chitnis, A.B. (1995). The role of Notch in lateral inhibition and cell fate specification. 
Mol Cell Neurosci 6, 311-321. 
Cole, F., Zhang, W., Geyra, A., Kang, J.S., and Krauss, R.S. (2004). Positive regulation 
of myogenic bHLH factors and skeletal muscle development by the cell surface receptor 
CDO. Dev Cell 7, 843-854. 
Collins, C.A., Olsen, I., Zammit, P.S., Heslop, L., Petrie, A., Partridge, T.A., and 
Morgan, J.E. (2005). Stem cell function, self-renewal, and behavioral heterogeneity of 
cells from the adult muscle satellite cell niche. Cell 122, 289-301. 
Conboy, I.M., Conboy, M.J., Smythe, G.M., and Rando, T.A. (2003). Notch-mediated 
restoration of regenerative potential to aged muscle. Science 302, 1575-1577. 
Conboy, I.M., Conboy, M.J., Wagers, A.J., Girma, E.R., Weissman, I.L., and Rando, 
T.A. (2005). Rejuvenation of aged progenitor cells by exposure to a young systemic 
environment. Nature 433, 760-764. 
Conboy, I.M., and Rando, T.A. (2002). The regulation of Notch signaling controls 
satellite cell activation and cell fate determination in postnatal myogenesis. Dev Cell 3, 
397-409. 
Conlon, R.A., Reaume, A.G., and Rossant, J. (1995). Notch1 is required for the 
coordinate segmentation of somites. Development 121, 1533-1545. 
Coolican, S.A., Samuel, D.S., Ewton, D.Z., McWade, F.J., and Florini, J.R. (1997). The 
mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling 
pathways. J Biol Chem 272, 6653-6662. 
153
 97
Cooper, R.N., Tajbakhsh, S., Mouly, V., Cossu, G., Buckingham, M., and Butler-
Browne, G.S. (1999). In vivo satellite cell activation via Myf5 and MyoD in regenerating 
mouse skeletal muscle. J Cell Sci 112 ( Pt 17), 2895-2901. 
Cornelison, D.D., and Wold, B.J. (1997). Single-cell analysis of regulatory gene 
expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol 191, 
270-283. 
Davis, R.L., and Weintraub, H. (1992). Acquisition of myogenic specificity by 
replacement of three amino acid residues from MyoD into E12. Science 256, 1027-1030. 
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single transfected 
cDNA converts fibroblasts to myoblasts. Cell 51, 987-1000. 
de Angelis, L., Zhao, J., Andreucci, J.J., Olson, E.N., Cossu, G., and McDermott, J.C. 
(2005). Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 
signaling pathway. Dev Biol 283, 171-179. 
de la Serna, I.L., Carlson, K.A., and Imbalzano, A.N. (2001). Mammalian SWI/SNF 
complexes promote MyoD-mediated muscle differentiation. Nat Genet 27, 187-190. 
de la Serna, I.L., Ohkawa, Y., Berkes, C.A., Bergstrom, D.A., Dacwag, C.S., Tapscott, 
S.J., and Imbalzano, A.N. (2005). MyoD targets chromatin remodeling complexes to the 
myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol 25, 3997-
4009. 
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J.S., 
Schroeter, E.H., Schrijvers, V., Wolfe, M.S., Ray, W.J., et al. (1999). A presenilin-1-
dependent gamma-secretase-like protease mediates release of Notch intracellular domain. 
Nature 398, 518-522. 
Dodou, E., Xu, S.M., and Black, B.L. (2003). mef2c is activated directly by myogenic 
basic helix-loop-helix proteins during skeletal muscle development in vivo. Mech Dev 
120, 1021-1032. 
Du, K., Herzig, S., Kulkarni, R.N., and Montminy, M. (2003). TRB3: a tribbles homolog 
that inhibits Akt/PKB activation by insulin in liver. Science 300, 1574-1577. 
Edmondson, D.G., Cheng, T.C., Cserjesi, P., Chakraborty, T., and Olson, E.N. (1992). 
Analysis of the myogenin promoter reveals an indirect pathway for positive 
autoregulation mediated by the muscle-specific enhancer factor MEF-2. Mol Cell Biol 
12, 3665-3677. 
154
 98
Elagib, K.E., Xiao, M., Hussaini, I.M., Delehanty, L.L., Palmer, L.A., Racke, F.K., 
Birrer, M.J., Shanmugasundaram, G., McDevitt, M.A., and Goldfarb, A.N. (2004). Jun 
blockade of erythropoiesis: role for repression of GATA-1 by HERP2. Mol Cell Biol 24, 
7779-7794. 
Epstein, J.A., Shapiro, D.N., Cheng, J., Lam, P.Y., and Maas, R.L. (1996). Pax3 
modulates expression of the c-Met receptor during limb muscle development. Proc Natl 
Acad Sci U S A 93, 4213-4218. 
Fang, T.C., Yashiro-Ohtani, Y., Del Bianco, C., Knoblock, D.M., Blacklow, S.C., and 
Pear, W.S. (2007). Notch directly regulates Gata3 expression during T helper 2 cell 
differentiation. Immunity 27, 100-110. 
Fehon, R.G., Kooh, P.J., Rebay, I., Regan, C.L., Xu, T., Muskavitch, M.A., and 
Artavanis-Tsakonas, S. (1990). Molecular interactions between the protein products of 
the neurogenic loci Notch and Delta, two EGF-homologous genes in Drosophila. Cell 61, 
523-534. 
Ferrari, G., Cusella-De Angelis, G., Coletta, M., Paolucci, E., Stornaiuolo, A., Cossu, G., 
and Mavilio, F. (1998). Muscle regeneration by bone marrow-derived myogenic 
progenitors. Science 279, 1528-1530. 
Fischer, A., and Gessler, M. (2007). Delta-Notch--and then? Protein interactions and 
proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 35, 
4583-4596. 
Fischer, A., Klattig, J., Kneitz, B., Diez, H., Maier, M., Holtmann, B., Englert, C., and 
Gessler, M. (2005). Hey basic helix-loop-helix transcription factors are repressors of 
GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal 
hearts. Mol Cell Biol 25, 8960-8970. 
Fischer, A., Leimeister, C., Winkler, C., Schumacher, N., Klamt, B., Elmasri, H., Steidl, 
C., Maier, M., Knobeloch, K.P., Amann, K., et al. (2002). Hey bHLH factors in 
cardiovascular development. Cold Spring Harb Symp Quant Biol 67, 63-70. 
Fischer, A., Schumacher, N., Maier, M., Sendtner, M., and Gessler, M. (2004). The 
Notch target genes Hey1 and Hey2 are required for embryonic vascular development. 
Genes Dev 18, 901-911. 
Fischer, A., Steidl, C., Wagner, T.U., Lang, E., Jakob, P.M., Friedl, P., Knobeloch, K.P., 
and Gessler, M. (2007). Combined loss of Hey1 and HeyL causes congenital heart 
defects because of impaired epithelial to mesenchymal transition. Circ Res 100, 856-863. 
155
 99
Fleming, R.J., Scottgale, T.N., Diederich, R.J., and Artavanis-Tsakonas, S. (1990). The 
gene Serrate encodes a putative EGF-like transmembrane protein essential for proper 
ectodermal development in Drosophila melanogaster. Genes Dev 4, 2188-2201. 
Fortini, M.E., and Artavanis-Tsakonas, S. (1994). The suppressor of hairless protein 
participates in notch receptor signaling. Cell 79, 273-282. 
Fryer, C.J., Lamar, E., Turbachova, I., Kintner, C., and Jones, K.A. (2002). Mastermind 
mediates chromatin-specific transcription and turnover of the Notch enhancer complex. 
Genes Dev 16, 1397-1411. 
Fryer, C.J., White, J.B., and Jones, K.A. (2004). Mastermind recruits CycC:CDK8 to 
phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 16, 509-
520. 
Garg, V., Muth, A.N., Ransom, J.F., Schluterman, M.K., Barnes, R., King, I.N., 
Grossfeld, P.D., and Srivastava, D. (2005). Mutations in NOTCH1 cause aortic valve 
disease. Nature 437, 270-274. 
Gerber, A.N., Klesert, T.R., Bergstrom, D.A., and Tapscott, S.J. (1997). Two domains of 
MyoD mediate transcriptional activation of genes in repressive chromatin: a mechanism 
for lineage determination in myogenesis. Genes Dev 11, 436-450. 
Gessler, M., Knobeloch, K.P., Helisch, A., Amann, K., Schumacher, N., Rohde, E., 
Fischer, A., and Leimeister, C. (2002). Mouse gridlock: no aortic coarctation or 
deficiency, but fatal cardiac defects in Hey2 -/- mice. Curr Biol 12, 1601-1604. 
Ghosh, B., and Leach, S.D. (2006). Interactions between hairy/enhancer of split-related 
proteins and the pancreatic transcription factor Ptf1-p48 modulate function of the PTF1 
transcriptional complex. Biochem J 393, 679-685. 
Gordon, W.R., Vardar-Ulu, D., Histen, G., Sanchez-Irizarry, C., Aster, J.C., and 
Blacklow, S.C. (2007). Structural basis for autoinhibition of Notch. Nat Struct Mol Biol 
14, 295-300. 
Goulding, M., Lumsden, A., and Paquette, A.J. (1994). Regulation of Pax-3 expression in 
the dermomyotome and its role in muscle development. Development 120, 957-971. 
Greil, F., Moorman, C., and van Steensel, B. (2006). DamID: mapping of in vivo protein-
genome interactions using tethered DNA adenine methyltransferase. Methods Enzymol 
410, 342-359. 
156
 100
Gros, J., Manceau, M., Thome, V., and Marcelle, C. (2005). A common somitic origin for 
embryonic muscle progenitors and satellite cells. Nature 435, 954-958. 
Gussoni, E., Soneoka, Y., Strickland, C.D., Buzney, E.A., Khan, M.K., Flint, A.F., 
Kunkel, L.M., and Mulligan, R.C. (1999). Dystrophin expression in the mdx mouse 
restored by stem cell transplantation. Nature 401, 390-394. 
Hasty, P., Bradley, A., Morris, J.H., Edmondson, D.G., Venuti, J.M., Olson, E.N., and 
Klein, W.H. (1993). Muscle deficiency and neonatal death in mice with a targeted 
mutation in the myogenin gene. Nature 364, 501-506. 
Heitzler, P., and Simpson, P. (1991). The choice of cell fate in the epidermis of 
Drosophila. Cell 64, 1083-1092. 
Heron-Milhavet, L., Mamaeva, D., Rochat, A., Lamb, N.J., and Fernandez, A. (2007). 
Akt2 is implicated in skeletal muscle differentiation and specifically binds 
Prohibitin2/REA. J Cell Physiol 214, 158-165. 
Hicks, C., Johnston, S.H., diSibio, G., Collazo, A., Vogt, T.F., and Weinmaster, G. 
(2000). Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 
and Notch2. Nat Cell Biol 2, 515-520. 
Holderfield, M.T., Henderson Anderson, A.M., Kokubo, H., Chin, M.T., Johnson, R.L., 
and Hughes, C.C. (2006). HESR1/CHF2 suppresses VEGFR2 transcription independent 
of binding to E-boxes. Biochem Biophys Res Commun 346, 637-648. 
Hrabe de Angelis, M., McIntyre, J., 2nd, and Gossler, A. (1997). Maintenance of somite 
borders in mice requires the Delta homologue DII1. Nature 386, 717-721. 
Huang, Q., Raya, A., DeJesus, P., Chao, S.H., Quon, K.C., Caldwell, J.S., Chanda, S.K., 
Izpisua-Belmonte, J.C., and Schultz, P.G. (2004). Identification of p53 regulators by 
genome-wide functional analysis. Proc Natl Acad Sci U S A 101, 3456-3461. 
Huppert, S.S., Le, A., Schroeter, E.H., Mumm, J.S., Saxena, M.T., Milner, L.A., and 
Kopan, R. (2000). Embryonic lethality in mice homozygous for a processing-deficient 
allele of Notch1. Nature 405, 966-970. 
Ishibashi, J., Perry, R.L., Asakura, A., and Rudnicki, M.A. (2005). MyoD induces 
myogenic differentiation through cooperation of its NH2- and COOH-terminal regions. J 
Cell Biol 171, 471-482. 
157
 101
Ishibashi, M., Ang, S.L., Shiota, K., Nakanishi, S., Kageyama, R., and Guillemot, F. 
(1995). Targeted disruption of mammalian hairy and Enhancer of split homolog-1 (HES-
1) leads to up-regulation of neural helix-loop-helix factors, premature neurogenesis, and 
severe neural tube defects. Genes Dev 9, 3136-3148. 
Ishibashi, M., Moriyoshi, K., Sasai, Y., Shiota, K., Nakanishi, S., and Kageyama, R. 
(1994). Persistent expression of helix-loop-helix factor HES-1 prevents mammalian 
neural differentiation in the central nervous system. EMBO J 13, 1799-1805. 
Ishitani, T., Matsumoto, K., Chitnis, A.B., and Itoh, M. (2005). Nrarp functions to 
modulate neural-crest-cell differentiation by regulating LEF1 protein stability. Nat Cell 
Biol 7, 1106-1112. 
Iso, T., Chung, G., Hamamori, Y., and Kedes, L. (2002). HERP1 is a cell type-specific 
primary target of Notch. J Biol Chem 277, 6598-6607. 
Iso, T., Kedes, L., and Hamamori, Y. (2003). HES and HERP families: multiple effectors 
of the Notch signaling pathway. J Cell Physiol 194, 237-255. 
Iso, T., Sartorelli, V., Chung, G., Shichinohe, T., Kedes, L., and Hamamori, Y. (2001a). 
HERP, a new primary target of Notch regulated by ligand binding. Mol Cell Biol 21, 
6071-6079. 
Iso, T., Sartorelli, V., Poizat, C., Iezzi, S., Wu, H.Y., Chung, G., Kedes, L., and 
Hamamori, Y. (2001b). HERP, a novel heterodimer partner of HES/E(spl) in Notch 
signaling. Mol Cell Biol 21, 6080-6089. 
Itoh, M., Kim, C.H., Palardy, G., Oda, T., Jiang, Y.J., Maust, D., Yeo, S.Y., Lorick, K., 
Wright, G.J., Ariza-McNaughton, L., et al. (2003). Mind bomb is a ubiquitin ligase that is 
essential for efficient activation of Notch signaling by Delta. Dev Cell 4, 67-82. 
Jarriault, S., Brou, C., Logeat, F., Schroeter, E.H., Kopan, R., and Israel, A. (1995). 
Signalling downstream of activated mammalian Notch. Nature 377, 355-358. 
Jen, Y., Weintraub, H., and Benezra, R. (1992). Overexpression of Id protein inhibits the 
muscle differentiation program: in vivo association of Id with E2A proteins. Genes Dev 
6, 1466-1479. 
Jennings, B., Preiss, A., Delidakis, C., and Bray, S. (1994). The Notch signalling pathway 
is required for Enhancer of split bHLH protein expression during neurogenesis in the 
Drosophila embryo. Development 120, 3537-3548. 
158
 102
Jones, N.C., Tyner, K.J., Nibarger, L., Stanley, H.M., Cornelison, D.D., Fedorov, Y.V., 
and Olwin, B.B. (2005). The p38alpha/beta MAPK functions as a molecular switch to 
activate the quiescent satellite cell. J Cell Biol 169, 105-116. 
Kadesch, T. (2004). Notch signaling: the demise of elegant simplicity. Curr Opin Genet 
Dev 14, 506-512. 
Kami, K., and Senba, E. (1998). Localization of leukemia inhibitory factor and 
interleukin-6 messenger ribonucleic acids in regenerating rat skeletal muscle. Muscle 
Nerve 21, 819-822. 
Kang, J.S., Bae, G.U., Yi, M.J., Yang, Y.J., Oh, J.E., Takaesu, G., Zhou, Y.T., Low, 
B.C., and Krauss, R.S. (2008). A Cdo-Bnip-2-Cdc42 signaling pathway regulates 
p38alpha/beta MAPK activity and myogenic differentiation. J Cell Biol 182, 497-507. 
Kannabiran, C., Zeng, X., and Vales, L.D. (1997). The mammalian transcriptional 
repressor RBP (CBF1) regulates interleukin-6 gene expression. Mol Cell Biol 17, 1-9. 
Kao, H.Y., Ordentlich, P., Koyano-Nakagawa, N., Tang, Z., Downes, M., Kintner, C.R., 
Evans, R.M., and Kadesch, T. (1998). A histone deacetylase corepressor complex 
regulates the Notch signal transduction pathway. Genes Dev 12, 2269-2277. 
Kassar-Duchossoy, L., Gayraud-Morel, B., Gomes, D., Rocancourt, D., Buckingham, M., 
Shinin, V., and Tajbakhsh, S. (2004). Mrf4 determines skeletal muscle identity in 
Myf5:Myod double-mutant mice. Nature 431, 466-471. 
Kassar-Duchossoy, L., Giacone, E., Gayraud-Morel, B., Jory, A., Gomes, D., and 
Tajbakhsh, S. (2005). Pax3/Pax7 mark a novel population of primitive myogenic cells 
during development. Genes Dev 19, 1426-1431. 
Kathiriya, I.S., King, I.N., Murakami, M., Nakagawa, M., Astle, J.M., Gardner, K.A., 
Gerard, R.D., Olson, E.N., Srivastava, D., and Nakagawa, O. (2004). Hairy-related 
transcription factors inhibit GATA-dependent cardiac gene expression through a signal-
responsive mechanism. J Biol Chem 279, 54937-54943. 
Kato, H., Taniguchi, Y., Kurooka, H., Minoguchi, S., Sakai, T., Nomura-Okazaki, S., 
Tamura, K., and Honjo, T. (1997). Involvement of RBP-J in biological functions of 
mouse Notch1 and its derivatives. Development 124, 4133-4141. 
Keeshan, K., He, Y., Wouters, B.J., Shestova, O., Xu, L., Sai, H., Rodriguez, C.G., 
Maillard, I., Tobias, J.W., Valk, P., et al. (2006). Tribbles homolog 2 inactivates 
C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 10, 401-411. 
159
 103
Kelly, A.M., and Zacks, S.I. (1969). The histogenesis of rat intercostal muscle. J Cell 
Biol 42, 135-153. 
Kirschner, M., and Gerhart, J. (1998). Evolvability. Proc Natl Acad Sci U S A 95, 8420-
8427. 
Klinakis, A., Szabolcs, M., Politi, K., Kiaris, H., Artavanis-Tsakonas, S., and Efstratiadis, 
A. (2006). Myc is a Notch1 transcriptional target and a requisite for Notch1-induced 
mammary tumorigenesis in mice. Proc Natl Acad Sci U S A 103, 9262-9267. 
Kondoh, K., Sunadome, K., and Nishida, E. (2007). Notch signaling suppresses p38 
MAPK activity via induction of MKP-1 in myogenesis. J Biol Chem 282, 3058-3065. 
Koo, B.K., Lim, H.S., Song, R., Yoon, M.J., Yoon, K.J., Moon, J.S., Kim, Y.W., Kwon, 
M.C., Yoo, K.W., Kong, M.P., et al. (2005). Mind bomb 1 is essential for generating 
functional Notch ligands to activate Notch. Development 132, 3459-3470. 
Kopan, R., and Ilagan, M.X. (2009). The canonical Notch signaling pathway: unfolding 
the activation mechanism. Cell 137, 216-233. 
Kopan, R., Nye, J.S., and Weintraub, H. (1994). The intracellular domain of mouse 
Notch: a constitutively activated repressor of myogenesis directed at the basic helix-loop-
helix region of MyoD. Development 120, 2385-2396. 
Kopan, R., Schroeter, E.H., Weintraub, H., and Nye, J.S. (1996). Signal transduction by 
activated mNotch: importance of proteolytic processing and its regulation by the 
extracellular domain. Proc Natl Acad Sci U S A 93, 1683-1688. 
Krejci, A., Bernard, F., Housden, B.E., Collins, S., and Bray, S.J. (2009). Direct response 
to Notch activation: signaling crosstalk and incoherent logic. Sci Signal 2, ra1. 
Krejci, A., and Bray, S. (2007). Notch activation stimulates transient and selective 
binding of Su(H)/CSL to target enhancers. Genes Dev 21, 1322-1327. 
Kuang, S., Kuroda, K., Le Grand, F., and Rudnicki, M.A. (2007). Asymmetric self-
renewal and commitment of satellite stem cells in muscle. Cell 129, 999-1010. 
Kuroda, K., Tani, S., Tamura, K., Minoguchi, S., Kurooka, H., and Honjo, T. (1999). 
Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and 
myogenesis. J Biol Chem 274, 7238-7244. 
160
 104
Lamar, E., Deblandre, G., Wettstein, D., Gawantka, V., Pollet, N., Niehrs, C., and 
Kintner, C. (2001). Nrarp is a novel intracellular component of the Notch signaling 
pathway. Genes Dev 15, 1885-1899. 
Lassar, A.B., Davis, R.L., Wright, W.E., Kadesch, T., Murre, C., Voronova, A., 
Baltimore, D., and Weintraub, H. (1991). Functional activity of myogenic HLH proteins 
requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66, 305-315. 
Lassar, A.B., Paterson, B.M., and Weintraub, H. (1986). Transfection of a DNA locus 
that mediates the conversion of 10T1/2 fibroblasts to myoblasts. Cell 47, 649-656. 
Le Grand, F., Jones, A.E., Seale, V., Scime, A., and Rudnicki, M.A. (2009). Wnt7a 
activates the planar cell polarity pathway to drive the symmetric expansion of satellite 
stem cells. Cell Stem Cell 4, 535-547. 
Lecourtois, M., and Schweisguth, F. (1995). The neurogenic suppressor of hairless DNA-
binding protein mediates the transcriptional activation of the enhancer of split complex 
genes triggered by Notch signaling. Genes Dev 9, 2598-2608. 
Lepper, C., Conway, S.J., and Fan, C.M. (2009). Adult satellite cells and embryonic 
muscle progenitors have distinct genetic requirements. Nature 460, 627-631. 
Lewis, J., Hanisch, A., and Holder, M. (2009). Notch signaling, the segmentation clock, 
and the patterning of vertebrate somites. J Biol 8, 44. 
Lindsell, C.E., Shawber, C.J., Boulter, J., and Weinmaster, G. (1995). Jagged: a 
mammalian ligand that activates Notch1. Cell 80, 909-917. 
Liu, J.P., Baker, J., Perkins, A.S., Robertson, E.J., and Efstratiadis, A. (1993). Mice 
carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 
1 IGF receptor (Igf1r). Cell 75, 59-72. 
Lluis, F., Ballestar, E., Suelves, M., Esteller, M., and Munoz-Canoves, P. (2005). E47 
phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle-specific 
gene transcription. EMBO J 24, 974-984. 
Logeat, F., Bessia, C., Brou, C., LeBail, O., Jarriault, S., Seidah, N.G., and Israel, A. 
(1998). The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc 
Natl Acad Sci U S A 95, 8108-8112. 
161
 105
Lu, J., McKinsey, T.A., Zhang, C.L., and Olson, E.N. (2000). Regulation of skeletal 
myogenesis by association of the MEF2 transcription factor with class II histone 
deacetylases. Mol Cell 6, 233-244. 
Lu, J., Webb, R., Richardson, J.A., and Olson, E.N. (1999). MyoR: a muscle-restricted 
basic helix-loop-helix transcription factor that antagonizes the actions of MyoD. Proc 
Natl Acad Sci U S A 96, 552-557. 
Lu, J.R., Bassel-Duby, R., Hawkins, A., Chang, P., Valdez, R., Wu, H., Gan, L., Shelton, 
J.M., Richardson, J.A., and Olson, E.N. (2002). Control of facial muscle development by 
MyoR and capsulin. Science 298, 2378-2381. 
Lutolf, S., Radtke, F., Aguet, M., Suter, U., and Taylor, V. (2002). Notch1 is required for 
neuronal and glial differentiation in the cerebellum. Development 129, 373-385. 
Maier, M.M., and Gessler, M. (2000). Comparative analysis of the human and mouse 
Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun 
275, 652-660. 
Mal, A., and Harter, M.L. (2003). MyoD is functionally linked to the silencing of a 
muscle-specific regulatory gene prior to skeletal myogenesis. Proc Natl Acad Sci U S A 
100, 1735-1739. 
Mal, A., Sturniolo, M., Schiltz, R.L., Ghosh, M.K., and Harter, M.L. (2001). A role for 
histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: 
inhibition of the myogenic program. EMBO J 20, 1739-1753. 
Mal, A.K. (2006). Histone methyltransferase Suv39h1 represses MyoD-stimulated 
myogenic differentiation. EMBO J 25, 3323-3334. 
Mammucari, C., Tommasi di Vignano, A., Sharov, A.A., Neilson, J., Havrda, M.C., 
Roop, D.R., Botchkarev, V.A., Crabtree, G.R., and Dotto, G.P. (2005). Integration of 
Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and 
differentiation control. Dev Cell 8, 665-676. 
Maroto, M., Reshef, R., Munsterberg, A.E., Koester, S., Goulding, M., and Lassar, A.B. 
(1997). Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm 
and neural tissue. Cell 89, 139-148. 
Massari, M.E., Rivera, R.R., Voland, J.R., Quong, M.W., Breit, T.M., van Dongen, J.J., 
de Smit, O., and Murre, C. (1998). Characterization of ABF-1, a novel basic helix-loop-
162
 106
helix transcription factor expressed in activated B lymphocytes. Mol Cell Biol 18, 3130-
3139. 
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9, 
493-495. 
McGill, M.A., and McGlade, C.J. (2003). Mammalian numb proteins promote Notch1 
receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem 
278, 23196-23203. 
Megeney, L.A., Kablar, B., Garrett, K., Anderson, J.E., and Rudnicki, M.A. (1996). 
MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev 
10, 1173-1183. 
Mohr, O.L. (1919). Character Changes Caused by Mutation of an Entire Region of a 
Chromosome in Drosophila. Genetics 4, 275-282. 
Molkentin, J.D., Black, B.L., Martin, J.F., and Olson, E.N. (1995). Cooperative activation 
of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell 83, 1125-1136. 
Moloney, D.J., Panin, V.M., Johnston, S.H., Chen, J., Shao, L., Wilson, R., Wang, Y., 
Stanley, P., Irvine, K.D., Haltiwanger, R.S., et al. (2000). Fringe is a glycosyltransferase 
that modifies Notch. Nature 406, 369-375. 
Montarras, D., Morgan, J., Collins, C., Relaix, F., Zaffran, S., Cumano, A., Partridge, T., 
and Buckingham, M. (2005). Direct isolation of satellite cells for skeletal muscle 
regeneration. Science 309, 2064-2067. 
Mumm, J.S., Schroeter, E.H., Saxena, M.T., Griesemer, A., Tian, X., Pan, D.J., Ray, 
W.J., and Kopan, R. (2000). A ligand-induced extracellular cleavage regulates gamma-
secretase-like proteolytic activation of Notch1. Mol Cell 5, 197-206. 
Munsterberg, A.E., Kitajewski, J., Bumcrot, D.A., McMahon, A.P., and Lassar, A.B. 
(1995). Combinatorial signaling by Sonic hedgehog and Wnt family members induces 
myogenic bHLH gene expression in the somite. Genes Dev 9, 2911-2922. 
Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., 
Barton, E.R., Sweeney, H.L., and Rosenthal, N. (2001). Localized Igf-1 transgene 
expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 
27, 195-200. 
1 3
 107
Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S., and Nonaka, I. (1993). 
Myogenin gene disruption results in perinatal lethality because of severe muscle defect. 
Nature 364, 532-535. 
Naiki, T., Saijou, E., Miyaoka, Y., Sekine, K., and Miyajima, A. (2007). TRB2, a mouse 
Tribbles ortholog, suppresses adipocyte differentiation by inhibiting AKT and 
C/EBPbeta. J Biol Chem 282, 24075-24082. 
Nakagawa, O., McFadden, D.G., Nakagawa, M., Yanagisawa, H., Hu, T., Srivastava, D., 
and Olson, E.N. (2000). Members of the HRT family of basic helix-loop-helix proteins 
act as transcriptional repressors downstream of Notch signaling. Proc Natl Acad Sci U S 
A 97, 13655-13660. 
Nam, Y., Sliz, P., Song, L., Aster, J.C., and Blacklow, S.C. (2006). Structural basis for 
cooperativity in recruitment of MAML coactivators to Notch transcription complexes. 
Cell 124, 973-983. 
Nicolas, M., Wolfer, A., Raj, K., Kummer, J.A., Mill, P., van Noort, M., Hui, C.C., 
Clevers, H., Dotto, G.P., and Radtke, F. (2003). Notch1 functions as a tumor suppressor 
in mouse skin. Nat Genet 33, 416-421. 
Nie, L., Wu, H., and Sun, X.H. (2008). Ubiquitination and degradation of Tal1/SCL are 
induced by notch signaling and depend on Skp2 and CHIP. J Biol Chem 283, 684-692. 
Nie, L., Xu, M., Vladimirova, A., and Sun, X.H. (2003). Notch-induced E2A 
ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 22, 
5780-5792. 
Nishimura, M., Isaka, F., Ishibashi, M., Tomita, K., Tsuda, H., Nakanishi, S., and 
Kageyama, R. (1998). Structure, chromosomal locus, and promoter of mouse Hes2 gene, 
a homologue of Drosophila hairy and Enhancer of split. Genomics 49, 69-75. 
Nofziger, D., Miyamoto, A., Lyons, K.M., and Weinmaster, G. (1999). Notch signaling 
imposes two distinct blocks in the differentiation of C2C12 myoblasts. Development 126, 
1689-1702. 
Ohsako, S., Hyer, J., Panganiban, G., Oliver, I., and Caudy, M. (1994). Hairy function as 
a DNA-binding helix-loop-helix repressor of Drosophila sensory organ formation. Genes 
Dev 8, 2743-2755. 
164
 108
Ohtsuka, T., Ishibashi, M., Gradwohl, G., Nakanishi, S., Guillemot, F., and Kageyama, 
R. (1999). Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. 
EMBO J 18, 2196-2207. 
Oswald, F., Kostezka, U., Astrahantseff, K., Bourteele, S., Dillinger, K., Zechner, U., 
Ludwig, L., Wilda, M., Hameister, H., Knochel, W., et al. (2002). SHARP is a novel 
component of the Notch/RBP-Jkappa signalling pathway. EMBO J 21, 5417-5426. 
Oswald, F., Tauber, B., Dobner, T., Bourteele, S., Kostezka, U., Adler, G., Liptay, S., and 
Schmid, R.M. (2001). p300 acts as a transcriptional coactivator for mammalian Notch-1. 
Mol Cell Biol 21, 7761-7774. 
Oswald, F., Winkler, M., Cao, Y., Astrahantseff, K., Bourteele, S., Knochel, W., and 
Borggrefe, T. (2005). RBP-Jkappa/SHARP recruits CtIP/CtBP corepressors to silence 
Notch target genes. Mol Cell Biol 25, 10379-10390. 
Ott, M.O., Bober, E., Lyons, G., Arnold, H., and Buckingham, M. (1991). Early 
expression of the myogenic regulatory gene, myf-5, in precursor cells of skeletal muscle 
in the mouse embryo. Development 111, 1097-1107. 
Oustanina, S., Hause, G., and Braun, T. (2004). Pax7 directs postnatal renewal and 
propagation of myogenic satellite cells but not their specification. EMBO J 23, 3430-
3439. 
Palmieri, M., Sasso, M.P., Monese, R., Merola, M., Faggioli, L., Tovey, M., and Furia, 
A. (1999). Interaction of the nuclear protein CBF1 with the kappaB site of the IL-6 gene 
promoter. Nucleic Acids Res 27, 2785-2791. 
Pan, L., Sato, S., Frederick, J.P., Sun, X.H., and Zhuang, Y. (1999). Impaired immune 
responses and B-cell proliferation in mice lacking the Id3 gene. Mol Cell Biol 19, 5969-
5980. 
Pandolfi, P.P., Roth, M.E., Karis, A., Leonard, M.W., Dzierzak, E., Grosveld, F.G., 
Engel, J.D., and Lindenbaum, M.H. (1995). Targeted disruption of the GATA3 gene 
causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat 
Genet 11, 40-44. 
Panin, V.M., Papayannopoulos, V., Wilson, R., and Irvine, K.D. (1997). Fringe 
modulates Notch-ligand interactions. Nature 387, 908-912. 
165
 109
Parks, A.L., Klueg, K.M., Stout, J.R., and Muskavitch, M.A. (2000). Ligand endocytosis 
drives receptor dissociation and activation in the Notch pathway. Development 127, 
1373-1385. 
Paroush, Z., Finley, R.L., Jr., Kidd, T., Wainwright, S.M., Ingham, P.W., Brent, R., and 
Ish-Horowicz, D. (1994). Groucho is required for Drosophila neurogenesis, 
segmentation, and sex determination and interacts directly with hairy-related bHLH 
proteins. Cell 79, 805-815. 
Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. (1993). Production of high-titer 
helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90, 8392-
8396. 
Penn, B.H., Bergstrom, D.A., Dilworth, F.J., Bengal, E., and Tapscott, S.J. (2004). A 
MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal 
muscle differentiation. Genes Dev 18, 2348-2353. 
Petersen, P.H., Zou, K., Hwang, J.K., Jan, Y.N., and Zhong, W. (2002). Progenitor cell 
maintenance requires numb and numblike during mouse neurogenesis. Nature 419, 929-
934. 
Pichon, B., Taelman, V., Bellefroid, E.J., and Christophe, D. (2004). Transcriptional 
repression by the bHLH-Orange factor XHRT1 does not involve the C-terminal YRPW 
motif. Biochim Biophys Acta 1680, 46-52. 
Polesskaya, A., Seale, P., and Rudnicki, M.A. (2003). Wnt signaling induces the 
myogenic specification of resident CD45+ adult stem cells during muscle regeneration. 
Cell 113, 841-852. 
Pui, J.C., Allman, D., Xu, L., DeRocco, S., Karnell, F.G., Bakkour, S., Lee, J.Y., 
Kadesch, T., Hardy, R.R., Aster, J.C., et al. (1999). Notch1 expression in early 
lymphopoiesis influences B versus T lineage determination. Immunity 11, 299-308. 
Puri, P.L., Iezzi, S., Stiegler, P., Chen, T.T., Schiltz, R.L., Muscat, G.E., Giordano, A., 
Kedes, L., Wang, J.Y., and Sartorelli, V. (2001). Class I histone deacetylases sequentially 
interact with MyoD and pRb during skeletal myogenesis. Mol Cell 8, 885-897. 
Puri, P.L., Sartorelli, V., Yang, X.J., Hamamori, Y., Ogryzko, V.V., Howard, B.H., 
Kedes, L., Wang, J.Y., Graessmann, A., Nakatani, Y., et al. (1997). Differential roles of 
p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1, 35-45. 
166
 110
Purow, B.W., Sundaresan, T.K., Burdick, M.J., Kefas, B.A., Comeau, L.D., Hawkinson, 
M.P., Su, Q., Kotliarov, Y., Lee, J., Zhang, W., et al. (2008). Notch-1 regulates 
transcription of the epidermal growth factor receptor through p53. Carcinogenesis 29, 
918-925. 
Radtke, F., Wilson, A., Stark, G., Bauer, M., van Meerwijk, J., MacDonald, H.R., and 
Aguet, M. (1999). Deficient T cell fate specification in mice with an induced inactivation 
of Notch1. Immunity 10, 547-558. 
Rand, M.D., Grimm, L.M., Artavanis-Tsakonas, S., Patriub, V., Blacklow, S.C., Sklar, J., 
and Aster, J.C. (2000). Calcium depletion dissociates and activates heterodimeric notch 
receptors. Mol Cell Biol 20, 1825-1835. 
Rangarajan, A., Talora, C., Okuyama, R., Nicolas, M., Mammucari, C., Oh, H., Aster, 
J.C., Krishna, S., Metzger, D., Chambon, P., et al. (2001). Notch signaling is a direct 
determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 20, 
3427-3436. 
Rebay, I., Fleming, R.J., Fehon, R.G., Cherbas, L., Cherbas, P., and Artavanis-Tsakonas, 
S. (1991). Specific EGF repeats of Notch mediate interactions with Delta and Serrate: 
implications for Notch as a multifunctional receptor. Cell 67, 687-699. 
Reddy, K.L., Zullo, J.M., Bertolino, E., and Singh, H. (2008). Transcriptional repression 
mediated by repositioning of genes to the nuclear lamina. Nature 452, 243-247. 
Relaix, F., Montarras, D., Zaffran, S., Gayraud-Morel, B., Rocancourt, D., Tajbakhsh, S., 
Mansouri, A., Cumano, A., and Buckingham, M. (2006). Pax3 and Pax7 have distinct and 
overlapping functions in adult muscle progenitor cells. J Cell Biol 172, 91-102. 
Relaix, F., Rocancourt, D., Mansouri, A., and Buckingham, M. (2005). A Pax3/Pax7-
dependent population of skeletal muscle progenitor cells. Nature 435, 948-953. 
Reshef, R., Maroto, M., and Lassar, A.B. (1998). Regulation of dorsal somitic cell fates: 
BMPs and Noggin control the timing and pattern of myogenic regulator expression. 
Genes Dev 12, 290-303. 
Reynaud-Deonauth, S., Zhang, H., Afouda, A., Taillefert, S., Beatus, P., Kloc, M., Etkin, 
L.D., Fischer-Lougheed, J., and Spohr, G. (2002). Notch signaling is involved in the 
regulation of Id3 gene transcription during Xenopus embryogenesis. Differentiation 69, 
198-208. 
67
 111
Rhyu, M.S., Jan, L.Y., and Jan, Y.N. (1994). Asymmetric distribution of numb protein 
during division of the sensory organ precursor cell confers distinct fates to daughter cells. 
Cell 76, 477-491. 
Ridgeway, A.G., Wilton, S., and Skerjanc, I.S. (2000). Myocyte enhancer factor 2C and 
myogenin up-regulate each other's expression and induce the development of skeletal 
muscle in P19 cells. J Biol Chem 275, 41-46. 
Ross, D.A., and Kadesch, T. (2001). The notch intracellular domain can function as a 
coactivator for LEF-1. Mol Cell Biol 21, 7537-7544. 
Rudnicki, M.A., Braun, T., Hinuma, S., and Jaenisch, R. (1992). Inactivation of MyoD in 
mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently 
normal muscle development. Cell 71, 383-390. 
Rudnicki, M.A., Schnegelsberg, P.N., Stead, R.H., Braun, T., Arnold, H.H., and Jaenisch, 
R. (1993). MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 75, 
1351-1359. 
Ruiz Gomez, M., and Bate, M. (1997). Segregation of myogenic lineages in Drosophila 
requires numb. Development 124, 4857-4866. 
Sacco, A., Doyonnas, R., Kraft, P., Vitorovic, S., and Blau, H.M. (2008). Self-renewal 
and expansion of single transplanted muscle stem cells. Nature 456, 502-506. 
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., 
Schiaffino, S., Lecker, S.H., and Goldberg, A.L. (2004). Foxo transcription factors induce 
the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 
399-412. 
Sartorelli, V., Huang, J., Hamamori, Y., and Kedes, L. (1997). Molecular mechanisms of 
myogenic coactivation by p300: direct interaction with the activation domain of MyoD 
and with the MADS box of MEF2C. Mol Cell Biol 17, 1010-1026. 
Sartorelli, V., Puri, P.L., Hamamori, Y., Ogryzko, V., Chung, G., Nakatani, Y., Wang, 
J.Y., and Kedes, L. (1999). Acetylation of MyoD directed by PCAF is necessary for the 
execution of the muscle program. Mol Cell 4, 725-734. 
Sasai, Y., Kageyama, R., Tagawa, Y., Shigemoto, R., and Nakanishi, S. (1992). Two 
mammalian helix-loop-helix factors structurally related to Drosophila hairy and Enhancer 
of split. Genes Dev 6, 2620-2634. 
68
 112
Sassoon, D., Lyons, G., Wright, W.E., Lin, V., Lassar, A., Weintraub, H., and 
Buckingham, M. (1989). Expression of two myogenic regulatory factors myogenin and 
MyoD1 during mouse embryogenesis. Nature 341, 303-307. 
Schroeter, E.H., Kisslinger, J.A., and Kopan, R. (1998). Notch-1 signalling requires 
ligand-induced proteolytic release of intracellular domain. Nature 393, 382-386. 
Schuster-Gossler, K., Cordes, R., and Gossler, A. (2007). Premature myogenic 
differentiation and depletion of progenitor cells cause severe muscle hypotrophy in 
Delta1 mutants. Proc Natl Acad Sci U S A 104, 537-542. 
Seale, P., Sabourin, L.A., Girgis-Gabardo, A., Mansouri, A., Gruss, P., and Rudnicki, 
M.A. (2000). Pax7 is required for the specification of myogenic satellite cells. Cell 102, 
777-786. 
Serra, C., Palacios, D., Mozzetta, C., Forcales, S.V., Morantte, I., Ripani, M., Jones, 
D.R., Du, K., Jhala, U.S., Simone, C., et al. (2007). Functional interdependence at the 
chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle 
differentiation. Mol Cell 28, 200-213. 
Serrano, A.L., Baeza-Raja, B., Perdiguero, E., Jardi, M., and Munoz-Canoves, P. (2008). 
Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle 
hypertrophy. Cell Metab 7, 33-44. 
Shawber, C., Nofziger, D., Hsieh, J.J., Lindsell, C., Bogler, O., Hayward, D., and 
Weinmaster, G. (1996). Notch signaling inhibits muscle cell differentiation through a 
CBF1-independent pathway. Development 122, 3765-3773. 
Shen, C.P., and Kadesch, T. (1995). B-cell-specific DNA binding by an E47 homodimer. 
Mol Cell Biol 15, 4518-4524. 
Shen, H., McElhinny, A.S., Cao, Y., Gao, P., Liu, J., Bronson, R., Griffin, J.D., and Wu, 
L. (2006). The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-
mediated transcription and is required for normal myogenesis. Genes Dev 20, 675-688. 
Sherwood, R.I., Christensen, J.L., Conboy, I.M., Conboy, M.J., Rando, T.A., Weissman, 
I.L., and Wagers, A.J. (2004). Isolation of adult mouse myogenic progenitors: functional 
heterogeneity of cells within and engrafting skeletal muscle. Cell 119, 543-554. 
Simone, C., Forcales, S.V., Hill, D.A., Imbalzano, A.N., Latella, L., and Puri, P.L. 
(2004). p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific 
loci. Nat Genet 36, 738-743. 
69
 113
Skapek, S.X., Rhee, J., Spicer, D.B., and Lassar, A.B. (1995). Inhibition of myogenic 
differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267, 
1022-1024. 
Spitz, F., Demignon, J., Porteu, A., Kahn, A., Concordet, J.P., Daegelen, D., and Maire, 
P. (1998). Expression of myogenin during embryogenesis is controlled by Six/sine oculis 
homeoproteins through a conserved MEF3 binding site. Proc Natl Acad Sci U S A 95, 
14220-14225. 
Stitt, T.N., Drujan, D., Clarke, B.A., Panaro, F., Timofeyva, Y., Kline, W.O., Gonzalez, 
M., Yancopoulos, G.D., and Glass, D.J. (2004). The IGF-1/PI3K/Akt pathway prevents 
expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription 
factors. Mol Cell 14, 395-403. 
Struhl, G., and Adachi, A. (1998). Nuclear access and action of notch in vivo. Cell 93, 
649-660. 
Struhl, G., and Greenwald, I. (1999). Presenilin is required for activity and nuclear access 
of Notch in Drosophila. Nature 398, 522-525. 
Sun, J., Kamei, C.N., Layne, M.D., Jain, M.K., Liao, J.K., Lee, M.E., and Chin, M.T. 
(2001). Regulation of myogenic terminal differentiation by the hairy-related transcription 
factor CHF2. J Biol Chem 276, 18591-18596. 
Taelman, V., Van Wayenbergh, R., Solter, M., Pichon, B., Pieler, T., Christophe, D., and 
Bellefroid, E.J. (2004). Sequences downstream of the bHLH domain of the Xenopus 
hairy-related transcription factor-1 act as an extended dimerization domain that 
contributes to the selection of the partners. Dev Biol 276, 47-63. 
Tagami, S., Okochi, M., Yanagida, K., Ikuta, A., Fukumori, A., Matsumoto, N., Ishizuka-
Katsura, Y., Nakayama, T., Itoh, N., Jiang, J., et al. (2008). Regulation of Notch 
signaling by dynamic changes in the precision of S3 cleavage of Notch-1. Mol Cell Biol 
28, 165-176. 
Tajbakhsh, S., Rocancourt, D., Cossu, G., and Buckingham, M. (1997). Redefining the 
genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of 
MyoD. Cell 89, 127-138. 
Tamir, Y., and Bengal, E. (2000). Phosphoinositide 3-kinase induces the transcriptional 
activity of MEF2 proteins during muscle differentiation. J Biol Chem 275, 34424-34432. 
70
 114
Tapscott, S.J. (2005). The circuitry of a master switch: Myod and the regulation of 
skeletal muscle gene transcription. Development 132, 2685-2695. 
Thayer, M.J., Tapscott, S.J., Davis, R.L., Wright, W.E., Lassar, A.B., and Weintraub, H. 
(1989). Positive autoregulation of the myogenic determination gene MyoD1. Cell 58, 
241-248. 
Vales, L.D., and Friedl, E.M. (2002). Binding of C/EBP and RBP (CBF1) to overlapping 
sites regulates interleukin-6 gene expression. J Biol Chem 277, 42438-42446. 
Van Doren, M., Bailey, A.M., Esnayra, J., Ede, K., and Posakony, J.W. (1994). Negative 
regulation of proneural gene activity: hairy is a direct transcriptional repressor of achaete. 
Genes Dev 8, 2729-2742. 
van Steensel, B., and Henikoff, S. (2000). Identification of in vivo DNA targets of 
chromatin proteins using tethered dam methyltransferase. Nat Biotechnol 18, 424-428. 
van Steensel, B., and Henikoff, S. (2003). Epigenomic profiling using microarrays. 
Biotechniques 35, 346-350, 352-344, 356-347. 
Varnum-Finney, B., Wu, L., Yu, M., Brashem-Stein, C., Staats, S., Flowers, D., Griffin, 
J.D., and Bernstein, I.D. (2000). Immobilization of Notch ligand, Delta-1, is required for 
induction of notch signaling. J Cell Sci 113 Pt 23, 4313-4318. 
Vassin, H., Bremer, K.A., Knust, E., and Campos-Ortega, J.A. (1987). The neurogenic 
gene Delta of Drosophila melanogaster is expressed in neurogenic territories and encodes 
a putative transmembrane protein with EGF-like repeats. EMBO J 6, 3431-3440. 
Vasyutina, E., Lenhard, D.C., Wende, H., Erdmann, B., Epstein, J.A., and Birchmeier, C. 
(2007). RBP-J (Rbpsuh) is essential to maintain muscle progenitor cells and to generate 
satellite cells. Proc Natl Acad Sci U S A 104, 4443-4448. 
Vogel, M.J., Peric-Hupkes, D., and van Steensel, B. (2007). Detection of in vivo protein-
DNA interactions using DamID in mammalian cells. Nat Protoc 2, 1467-1478. 
Wakamatsu, Y., Maynard, T.M., Jones, S.U., and Weston, J.A. (1999). NUMB localizes 
in the basal cortex of mitotic avian neuroepithelial cells and modulates neuronal 
differentiation by binding to NOTCH-1. Neuron 23, 71-81. 
Wang, D.Z., Valdez, M.R., McAnally, J., Richardson, J., and Olson, E.N. (2001). The 
Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins 
during skeletal muscle development. Development 128, 4623-4633. 
71
 115
Wang, Y., and Jaenisch, R. (1997). Myogenin can substitute for Myf5 in promoting 
myogenesis but less efficiently. Development 124, 2507-2513. 
Weintraub, H., Dwarki, V.J., Verma, I., Davis, R., Hollenberg, S., Snider, L., Lassar, A., 
and Tapscott, S.J. (1991). Muscle-specific transcriptional activation by MyoD. Genes 
Dev 5, 1377-1386. 
Weintraub, H., Genetta, T., and Kadesch, T. (1994). Tissue-specific gene activation by 
MyoD: determination of specificity by cis-acting repression elements. Genes Dev 8, 
2203-2211. 
Weintraub, H., Tapscott, S.J., Davis, R.L., Thayer, M.J., Adam, M.A., Lassar, A.B., and 
Miller, A.D. (1989). Activation of muscle-specific genes in pigment, nerve, fat, liver, and 
fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci U S A 86, 5434-
5438. 
Weng, A.P., Millholland, J.M., Yashiro-Ohtani, Y., Arcangeli, M.L., Lau, A., Wai, C., 
Del Bianco, C., Rodriguez, C.G., Sai, H., Tobias, J., et al. (2006). c-Myc is an important 
direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20, 
2096-2109. 
Wharton, K.A., Johansen, K.M., Xu, T., and Artavanis-Tsakonas, S. (1985). Nucleotide 
sequence from the neurogenic locus notch implies a gene product that shares homology 
with proteins containing EGF-like repeats. Cell 43, 567-581. 
Wilson-Rawls, J., Molkentin, J.D., Black, B.L., and Olson, E.N. (1999). Activated notch 
inhibits myogenic activity of the MADS-Box transcription factor myocyte enhancer 
factor 2C. Mol Cell Biol 19, 2853-2862. 
Wilson, E.M., and Rotwein, P. (2007). Selective control of skeletal muscle differentiation 
by Akt1. J Biol Chem 282, 5106-5110. 
Wilson, J.J., and Kovall, R.A. (2006). Crystal structure of the CSL-Notch-Mastermind 
ternary complex bound to DNA. Cell 124, 985-996. 
Wright, W.E., Sassoon, D.A., and Lin, V.K. (1989). Myogenin, a factor regulating 
myogenesis, has a domain homologous to MyoD. Cell 56, 607-617. 
Wu, L., Aster, J.C., Blacklow, S.C., Lake, R., Artavanis-Tsakonas, S., and Griffin, J.D. 
(2000a). MAML1, a human homologue of Drosophila mastermind, is a transcriptional 
co-activator for NOTCH receptors. Nat Genet 26, 484-489. 
72
 116
Wu, Z., Woodring, P.J., Bhakta, K.S., Tamura, K., Wen, F., Feramisco, J.R., Karin, M., 
Wang, J.Y., and Puri, P.L. (2000b). p38 and extracellular signal-regulated kinases 
regulate the myogenic program at multiple steps. Mol Cell Biol 20, 3951-3964. 
Xu, Q., and Wu, Z. (2000). The insulin-like growth factor-phosphatidylinositol 3-kinase-
Akt signaling pathway regulates myogenin expression in normal myogenic cells but not 
in rhabdomyosarcoma-derived RD cells. J Biol Chem 275, 36750-36757. 
Xue, Y., Gao, X., Lindsell, C.E., Norton, C.R., Chang, B., Hicks, C., Gendron-Maguire, 
M., Rand, E.B., Weinmaster, G., and Gridley, T. (1999). Embryonic lethality and 
vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet 8, 723-730. 
Yaffe, D., and Saxel, O. (1977). Serial passaging and differentiation of myogenic cells 
isolated from dystrophic mouse muscle. Nature 270, 725-727. 
Yang, X.M., Vogan, K., Gros, P., and Park, M. (1996). Expression of the met receptor 
tyrosine kinase in muscle progenitor cells in somites and limbs is absent in Splotch mice. 
Development 122, 2163-2171. 
Yee, S.P., and Rigby, P.W. (1993). The regulation of myogenin gene expression during 
the embryonic development of the mouse. Genes Dev 7, 1277-1289. 
Yen, H.C., Xu, Q., Chou, D.M., Zhao, Z., and Elledge, S.J. (2008). Global protein 
stability profiling in mammalian cells. Science 322, 918-923. 
Yoshida, N., Yoshida, S., Koishi, K., Masuda, K., and Nabeshima, Y. (1998). Cell 
heterogeneity upon myogenic differentiation: down-regulation of MyoD and Myf-5 
generates 'reserve cells'. J Cell Sci 111 ( Pt 6), 769-779. 
Zammit, P.S., Golding, J.P., Nagata, Y., Hudon, V., Partridge, T.A., and Beauchamp, J.R. 
(2004). Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell 
Biol 166, 347-357. 
Zammit, P.S., Relaix, F., Nagata, Y., Ruiz, A.P., Collins, C.A., Partridge, T.A., and 
Beauchamp, J.R. (2006). Pax7 and myogenic progression in skeletal muscle satellite 
cells. J Cell Sci 119, 1824-1832. 
Zhang, H., and Stavnezer, E. (2009). Ski regulates muscle terminal differentiation by 
transcriptional activation of Myog in a complex with Six1 and Eya3. J Biol Chem 284, 
2867-2879. 
73
 117
Zhang, W., Behringer, R.R., and Olson, E.N. (1995). Inactivation of the myogenic bHLH 
gene MRF4 results in up-regulation of myogenin and rib anomalies. Genes Dev 9, 1388-
1399. 
Zhang, X., Pickin, K.A., Bose, R., Jura, N., Cole, P.A., and Kuriyan, J. (2007). Inhibition 
of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 
450, 741-744. 
Zhao, P., and Hoffman, E.P. (2006). Musculin isoforms and repression of MyoD in 
muscle regeneration. Biochem Biophys Res Commun 342, 835-842. 
Zhong, W., Jiang, M.M., Schonemann, M.D., Meneses, J.J., Pedersen, R.A., Jan, L.Y., 
and Jan, Y.N. (2000). Mouse numb is an essential gene involved in cortical neurogenesis. 
Proc Natl Acad Sci U S A 97, 6844-6849. 
Zhu, B., and Gulick, T. (2004). Phosphorylation and alternative pre-mRNA splicing 
converge to regulate myocyte enhancer factor 2C activity. Mol Cell Biol 24, 8264-8275. 
Zhu, B., Ramachandran, B., and Gulick, T. (2005). Alternative pre-mRNA splicing 
governs expression of a conserved acidic transactivation domain in myocyte enhancer 
factor 2 factors of striated muscle and brain. J Biol Chem 280, 28749-28760. 
Zilian, O., Saner, C., Hagedorn, L., Lee, H.Y., Sauberli, E., Suter, U., Sommer, L., and 
Aguet, M. (2001). Multiple roles of mouse Numb in tuning developmental cell fates. Curr 
Biol 11, 494-501. 
 
 
4
